"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We'll begin by turning the conferen",48,"Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",587,"Good morning, everyone, and thank you for joining today's call. I am will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. 
In our remarks today, David and Tom will cover a number of topics, including Cigna's full year 2014 financial results, as well as our financial outlook for 2015. 
As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled adjusted income from operations and earnings per share on the same basis as the principal measures of performance for Cigna and our business segments.  A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com. 
In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. 
Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. First, please note that when we discuss the number of covered lives for our global medical customers, we will be doing so on a basis that excludes those individuals that were previously covered under Limited Benefits plans. As a reminder, we exited the Limited Benefits business as of December 31, 2013, as required by the Affordable Care Act regulation. 
Second, please note that our definition of adjusted income from operations will change for 2015 reporting in that we will now exclude acquisition-related amortization expense from this operating measure. When we discuss our earnings outlook for 2015 today, it will be on the basis of adjusted income from operations that excludes acquisition-related amortization expense. This is a change compared to the basis on which 2014 results are reported and how we have previously provided our 2014 outlook. 
In 2015, the impact of excluding acquisition-related amortization expense is approximately $100 million after-tax or $0.40 per share. 
Third, beginning in 2015, we have simplified our guidance and disclosures for our Medicare ratios, or MCRs, by reporting them on a basis of total commercial and total government. The total commercial ratio encompasses all of our commercial risk products, including Medical, Pharmacy, Dental, Stop Loss and Behavioral Products provided through Guaranteed Cost or experience-rated funding arrangements in both the United States and internationally. The total government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses. To lead the transition, we have provided historical Medicare ratios on these bases within our quarterly financial supplement that was posted in the Investor Relations section of cigna.com this morning. 
Lastly, consistent with past practices we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or prior-year development of medical cost. Our outlook also exclude the impact from our recently announced acquisition of Walkure, which we do not expect will have a material impact to our financial results in 2015. 
And with that, I will turn the call over to David."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks,  Will. Good morning, everyone, and thank you for joining our call today. To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers clie",1717,"Thanks,  Will. Good morning, everyone, and thank you for joining our call today. To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers clients and shareholders in the future. I'll also illustrate more specifically how we are creating value in our Seniors business and leveraging our experience and success of that business to drive long-term growth.  Then Tom will address our Fourth Quarter and Full Year 2014 financial performance in more detail, as well as provide specifics for our outlook in 2015 before we take your questions. And following the Q&A session, I'll wrap up the call with a few closing remarks. We'll start with some highlights in the year. 
Cigna's strong 2014 performance represents the fifth consecutive year of competitively attractive financial results. This outstanding track record of results is driven by the disciplined execution of our growth strategy. All, while we continue to invest in capabilities, expand our offerings and our geographic footprint. Over the past several years in the face of a particularly challenging and dynamic environment, we have been focused and disciplined with targeted yet meaningful investments to drive innovation, including new clinical programs, aligned incentives for customers, expanded technologies and programs for Health Care professionals. We have done all these while delivering competitively differentiated results year in and year out. 
The full year 2014 consolidated revenues increased 8% to $35 billion, with each business segment delivering strong growth over 2013. We reported adjusted income from operations for the full year of $2 billion or $7.43 per share, which represents a per share increase of 9% over 2013. 
Our revenue and earnings performance reflect growth all of our businesses over the course of the year, the year in which we also grew to more than 85 million customer relationships worldwide and where we continue to generate strong margins and significant free cash flow for the benefit of shareholders. These results position us to once again deliver competitively attractive revenue and earnings growth in 2015. 
For 2015, our outlook of 8% to 10% revenue growth and 5% to 10% EPS growth, excluding reserve development recognized in 2014, as well as future capital deployment reflect the focused and clarity of our strategy and continued strong performance of our team around the world. Tom will walk you through more specifics regarding outlook later on the call. 
Now, I' like to talk about how our guiding framework of the global strategy and multiple avenues for growth have enabled our long track record of success and will drive ongoing future value creation. Across our business, we operate in ever-changing market landscape with diverse needs across customers, employers, health care professionals and governments. Within this market, we are meeting and exceeding the expectations of our customers and clients around the world by delivering affordable and personalized solutions. As we look to the future, we have built a growth framework to create ongoing value, leverage our differentiated capabilities for the benefit of our customers. There are 3 components to this framework. First is leveraging our well-positioned existing portfolio businesses to continue to generate attractive value for our customers and clients. We expect to double the size of our company over the next 7 to 8 years. This will result in an average annual revenue growth rate of 8% to 10%, largely driven by our existing portfolio and focused execution. This continues a track record that we have demonstrated over the last 5 years, and our 2015 outlook of 8% to 10% revenue growth is consistent with this goal. 
The second component is targeted and effective capital deployment to create ongoing shareholder value. I would note that over the past 5 years, we have effectively deployed capital through a balance of investments and a business portfolio, strategic M&A and share repurchase. A good reason example of this is our agreement to purchase QualCare Alliance networks. This acquisition is directly aligned with our Go Deep and our physician partnership strategies. Our businesses are generating high margins and our capital efficient allowed us to both find attractive organic growth and generate significant free cash flow. This free cash flow provides us with financial flexibility and the opportunity to deploy capital to create additional value for our shareholders. And given the health of our balance sheet and underlying capitalization of our subsidiaries, we expect to have $1.8 billion of capital available for deployment in 2015. 
The third component of our framework were we seek to drive additional value for our shareholders is through new and emerging opportunities. These opportunities include new distribution marketplaces, such as public and private exchanges; geographic expansion, such as new Medicare Advantage markets and international opportunities; and new buying segments and service expansion, such as medical service organization offerings for the benefit of integrated health care professionals. We are well positioned to pursue each of these potentially attractive future growth opportunities that are aligned with our strategy. As such, we have dedicated resources to fuel future expansion in these areas. 
It illustrate how we are leveraging this framework to create value, I'll highlight how this framework applies to our Seniors business. This market segment includes the population with a variety of complex needs, requiring customer engagement and incentive-based clinical resources programs to drive ongoing success. Our Seniors business pioneered successful positioning gauge and models, including Allianz incentives and collaborative relationships to drive high-quality and a more affordable health care experience for both customers, as well as physicians.
As we continue to leverage our core physician engagement capabilities across all of our health services businesses, we are focused on key investments that improve affordability, enhance personalized services and drive better clinical outcomes. For example, the strategic investments we're making to enhance our physician insight and data tools will enable our clinical data to be accessible in a real-time fashion from wherever physician partners, as well as our service team. Enabled by our physician engagement model, Seniors continue to find our Cigna HealthSpring benefit offerings increasingly compelling, and we expect to have 6% to 8% Medicare Advantage customer growth in 2015. As for positioning, we continue to be among the top 3 players in market share for all our established markets, and we are posing attractive growth in our newer markets. 
In 2014, we expanded our Seniors business in the Georgia and the Carolinas where we successfully leveraged existing CIGNA commercial networks to develop and implement engaged physician relationships for Seniors. Importantly, the quality of care delivered through engaged physician groups is reflected in our stars ratings where we increased our memberships in 4 star or higher plans from approximately 40% to nearly 60% in 2016. 
Looking to 2017, we again expect to deliver an increase in this result. These improvement in star ratings have allowed us to enhance our benefit offerings and position our Seniors business to be an earnings accelerant in 2016 and beyond. 
Relative to our expanding opportunities, we currently operate Illinois markets. Here, we are leveraging our care coordination capabilities to serve the dual eligible population within our Medicaid platform. Focusing our growth efforts on improving care for the underserved, including the dual eligible and age, blind and disabled population complements our proven experience with complex care quarters nation, differentiated clinical outcomes and affordability focus. While Illinois plan is relatively new having just begun in 2014, our Texas plan has been in operation since 2011 and is on track record of delivering affordable care and better health outcomes. In a testament of our commitment to servicing these customers, our Texas plan recently was acknowledged by the Medicare Health Plans of America for our cutting-edge behavioral health care program. We 
are well-positioned and have a capital flexibility to pursue this accelerating geographic and market segment opportunities either organically or through M&A as Seniors remains a strategic growth priority for us. As a global company, our efforts to leverage capabilities have also expanded across key markets beyond the United States. 
In Korea, for example, where the age population is seeking new solutions to meet their emerging needs, we developed an innovative and new health membership program targeting seniors known as Heyday. This organically built affinity program delivers value-added services directly to seniors in Korea. And while only a year into this expansion, we now serve more than 300,000 Korean seniors. So overall, we have a clear strategy and the capabilities to deliver value and improve the health and wellbeing of senior customers today and into the future. 
Whether it's Seniors business we discuss today or other growth businesses we have addressed in previous calls, we will continue to deliver attractive growth producing deploy capital effectively and investment position ourselves to win in emerging market segments. 
Now to summarize my comments before Tom offers more detail on our 2014 results and expectations for 2015. Cigna's strong 2014 financial performance extend a multiyear record on track with that of developing track record revenue and earnings and free cash flow. Continued execution of our growth strategy is creating value for our customers and clients, complimented by our differentiated capabilities and innovative physicians and customer engagement solutions. As a rapidly changing industry and economic environment continues to unfold and new challenges arise, we are positioned to capitalize on new growth opportunities, while we continue to leverage our core businesses for growth. And by embracing change, we continue to position our company for successful investing in the future preparing for a significant new opportunities, such as those we shared this morning for our senior segment, including in existing programs and markets; new market expansion; new offerings for health care professionals through our medical service organization solutions; new segments, such as dual eligibles and new affinity programs, such as HeyDay in Korea. We expect to meet our growth objectives of 8% to 10% on average, doubling the size of our company again over the next 7 to 8 years. And based on our focused strategy, strong market positioning and ability to leverage capital as well as further for growth, we expect to continue to deliver competitively attractive and sustained long-term EPS growth of 10% to 13% on average, all while continuing to invest back in our company. 
And with that, I'll the call over to Tom."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone, and in my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015. We had another strong year in 2014 with revenue growth of 8% and industry-leading earnings-per-share growth of 9% over 2",2053,"Thanks, David. Good morning, everyone, and in my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015. 
We had another strong year in 2014 with revenue growth of 8% and industry-leading earnings-per-share growth of 9% over 2013 results. 2014 represents our fifth consecutive year of consistently strong revenue earnings and EPS growth and attractive results on an absolute and competitive basis. 
In addition, we continue to generate strong free cash flow in 2014, which resulted in approximately $1.6 billion being returned to shareholders through share repurchase. The strength of our 2014 performance provides us with a solid foundation for growth in 2015. 
Now moving to operating results. Our full year consolidated revenues grew 8% to $35 million, driven by growth in each of our business segments and in our targeted markets. Earnings grew 3% to $2 billion and earnings per share grew 9% to $7.43 in 2014. Our ability to grow revenue earnings and EPS in a challenging operating environment reflects the strength of our underlying businesses and focused execution. 
Regarding the segments, I will first comment on our Global Health Care segment. Overall, Global Health Care delivered another good year. 2014 premiums and fees grew 7% to $24.5 million, reflecting growth in all of our Global Health Care businesses, including ongoing growth in our self-funded programs and specialty products. We ended 2014 with $14.5 million Global medical customers, growing by approximately 380,000 customers or 3% for the year. 
Full year earnings were $1.65 billion, reflecting business growth, specialty contributions, operating efficiencies and effective medical cost management. 
Turning to medical costs. We continue to deliver medical cost to reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. 
For our total U.S. commercial book of business, full year medical cost trend was slightly less than the low-end of our previous range of 4.5% to 5.5% for 2014. Our commercial medical trend result continues our multiyear track record of industry-leading performance, and given that over 85% of our U.S. Commercial customers are in transfer ASO funding arrangements, our clients directly benefit from these favorable medical costs. 
Regarding medical care ratios, in our U.S. commercial guaranteed cost business, our full year 2014 medical care ratio, or MCR, was 81.8% on a reported basis or 82.7%, excluding prior-year reserve development. 
Consistent with our expectations, our fourth quarter 2014 Guaranteed Cost MCR of 86.6% reflects an increase seasonal impact from the growing share of high deductible plans in our employer group and individual businesses. We also expected and saw this increased seasonal impact across multiple America Mr. Tier commercial business, including our stoploss and businesses. Overall, our employer risk businesses continued to deliver solid results in the quarter and throughout the year, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results that are individual business, while still below long-term expectation, continue to improve in the fourth quarter. 
In our Government business, our full year 2014 MCR for Medicare advantage was 83.5% on a reported basis or 84%, excluding prior-year reserve development, reflecting the impact of medical cost improvement initiatives implemented during 2014. 
Moving to operating expenses for 2014, our total Global Health Care operating expense ratio was 22%. This includes the impact of health reform-related taxes, which added 110 basis points to the expense ratio for the year. Overall, we've had another strong year in our Global Health Care business. 
Now I'll discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability. Premiums and fees grew 14% year-over-year in global supplemental. 2014 Global Supplemental Benefits business were $230 million, reflecting attractive operating margins, continued strategic investments to drive future growth and nonrecurring favorable tax items of $21 million after-tax recorded in the third quarter. Fourth quarter earnings of $33 million reflect claim seasonality, our funding of long-term strategic investments and the impact from the strengthening of the U.S. dollar. 
Our Group Disability and Life, total year results were result 6% over 2013. 2014 earnings in Group business were $317 million and reflects favorable claim experience in our life business, and our lower operating expense ratio. While our corporate and other operations results after-tax loss of $197 million for full year 2014. 
Overall, our 2014 results reflect revenue earnings growth for each of our business segments and a significant free cash flow as a result of the continued effective execution of our strategy. 
Turning to our investment portfolio. For 2014, we reported net realized investment gains of $106 million after-tax, coupled with a strong net investment income result. The higher quality and diversification of our investment portfolio continue to drive our overall investment results. 
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to meet and exceed expectations of our customers and clients by delivering affordable and personalized solutions effectively deploying capital and targeting new and emerging opportunities where we seek to drive additional value for our shareholders. 
For full year 2015, we expect consolidated revenues to grow in the range of 8% to 10% over 2014, with continued growth across our target market segments. We expect full year 2015 consolidated adjusted income from operations to be in the range of $2.1 billion to $2.2 billion, or $8 to $8.40 per share. As we noted earlier, our full year 2015 consolidated and business segment adjusted income from operations, as well as earnings-per-share estimates now exclude acquisition-related amortization expense. 
In 2015, the impact of excluding acquisition-related amortization expense is approximately $0.40 per share or $100 million after-tax, including $85 million on our Global Health Care business and $15 million in Global Supplemental Benefits. Lastly, consistent with prior practice, our exclude any contribution from capital employment, as well as any prior-year claim development, which in 2014 totaled $53 million after-tax. 
Putting our 2015 outlook and our 2014 actual results on a comparable basis, that is, adjusting for the development reported in our 2014 results and adjusting to a consistent basis for reporting P&L amortization, our outlook for operating earnings in 2015 reflects 3% to 8% growth over 2014, and our outlook for EPS growth is 5% to 10% before considering the impact of additional capital deployment. 
I will now discuss the components of our 2015 outlook starting with Global Health Care. We expect full year Global Health Care earnings in the range of approximately $1.73 billion to $1.79 billion. This outlook reflects continued benefits from organic revenue growth, specialty contributions, effective medical cost management and operating spend efficiencies. This also includes our updated view of the annual results for both Medicare and the public exchange business. 
I'll ow summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015 starting with our customer base. Regarding global medical customers, we expect 2015 customer growth of 1% to 3%. This growth was driven by expected ongoing growth in our commercial employer business led by continued double-digit customer growth in our select business, as well as mid to upper single-digit growth in our Medicare advantage customers, with some expected reduction in our non-ACA compliant individual customers.
Turning to medical cost. Our 2015 outlook assumes some increase in medical utilization versus current levels and this increase had been reflected in our pricing. For our total U.S. book of business, we expect full year medical cost trend to be in the range of 5% to 6%. As well noted earlier, we are changing the basis of push to provide guidance for MCRs to total commercial and total government. We believe this basis will provide better insight into our ability to effectively manage medical cost for our Commercial and Seniors customers.
For our total commercial book of business, we expect the 2015 medical care ratio to be in the range of 78% to 79%. This compares to our full year 2014 total commercial MCR of 78.9% on an operating basis.
For our total government book of business, we expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%. This compares to our full year 2014 total government MCR of 84.7% on an operating basis.
Regarding operating expenses, our 2015 Global Health Care operating expense ratio is expected to be in the range of 20.5% to 21.5%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.73 billion to $1.79 billion. We believe this is a competitively attractive results, reflecting our focus on growing segments of the health care market and continued strong execution of our business strategy. 
Now moving to the other components of our outlook. For our Global Supplemental Benefits business, we continue to expect strong top line growth. We expect earnings in the range of $230 million to $250 million. This represents earnings growth of 3% to 12% after adjusting for $21 million of nonrecurring favorable tax items recognized in this segment in 2014. 
Regarding the Group Disability and Life business, we expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations that is other operations incorporate, we expect a loss of $180 million for 2015. 
So all in, for full year 2015, we expect consolidated adjusted income from operations of $2.1 billion to $2.2 billion or $8.00 to $8.40 per share. Our outlook continues to exclude the impact of prior plan development or earning future capital deployment. While we do not anticipate the impact of future capital deployment in our EPS outlook, we do expect the digital free cash flow that we generate will be deployed for the benefit of shareholders either through value-creating acquisitions or share repurchase. 
Overall, these results represent a competitively attractive outlook and underscore the benefit of our diverse and differentiated portfolio of businesses. I would also note that due to the timing of some strategic investments, as well as the growth of our Medicare Part D business, which traditionally reports low first quarter earnings, we expect our first quarter 2015 earnings will be lower than first quarter of 2014. 
Now moving to our 2015 capital management position and outlook. Overall, we continued to have excellent financial flexibility. Our subsidiaries remain well capitalized free in our generated free cash flow is apparent with a strong return on capital needs of our segments. Our capital employment strategy and priorities have not changed. These priorities are providing the capital necessary to support the growth of our ongoing operations, pursuing M&A activity with a focus on acquiring capabilities and scale to further grow our targeted areas of focus, and after considering these 2 items, we'll return capital to shareholders primarily through share repurchase. 
Regarding free cash flow, during 2014, we repurchased 18.5 million shares of stock for approximately $1.6 billion, and we ended the year with parent company cash of approximately $400 million. For full year 2015, we expect subsidiary dividends of approximately $1.7 billion, driven by strong performance in each of our business segments. 
After considering all sources and uses of parent company cash, including the funding of our recently announced acquisition of QualCare, this outlook implies we would have approximately $1.8 billion available for capital deployment in 2015, including approximately $115 million we deployed to repurchase 1.1 million shares from January 1 through February 4. 
Our free cash flow outlook reflects the industry-leading margins returned on capital businesses and a high level of capital efficiency, particularly from our fee-based businesses. These capital efficiency allows us to find attractive organic growth, while continuing to generate significant free cash flow to be deployed for the benefit of shareholders. 
Now to recap. Our full year 2014 consolidated results reflect the strength of our diversified portfolio of global businesses and a continued track record of effective execution of our focused strategy. The fundamentals of our business remain strong, as evidenced by strong growth in revenue earnings, industry-leading medical cost and quality outcomes and continued strong free cash flow. Based on the strength of these results, we are confident on our ability to achieve our full year 2015 earnings outlook. 
And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] The first question is from Justin Lake with JPMorgan.",11,"[Operator Instructions] The first question is from Justin Lake with JPMorgan."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, David, can you walk us through your view of initial 2015 guidance from the length of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds,  tailwinds investment spending, et cetera, that you see",44,"First question, David, can you walk us through your view of initial 2015 guidance from the length of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds,  tailwinds investment spending, et cetera, that you see in '15."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Justin, first, the headlines. We're pleased with the 8% to 10% revenue outlook continued growth of our well-positioned businesses. As Tom noted, the 3% to 8% earnings growth on a same-store basis and the underlying 5% to 10% EPS growth on the same-store b",322,"Justin, first, the headlines. We're pleased with the 8% to 10% revenue outlook continued growth of our well-positioned businesses. As Tom noted, the 3% to 8% earnings growth on a same-store basis and the underlying 5% to 10% EPS growth on the same-store basis. And as we've done in the past, we will continue to make ongoing investments in our company, while seeking to generate an attractive and competitively differentiated outcomes for our business. Also very importantly, all the numbers I just referenced exclude the impact of the $1.8 billion of deployable capital we have for 2015. As it relates to tailwinds, if you can think about several tailwinds for us, clearly, the revenue in customer base growth number 1. two, expense leverage. We have a track record of continuing to generate efficiency gains and expense leverage, some of which were redeploy for the benefit of innovation. Third, ongoing specialty penetration. We have a good track record of driving for the specialty penetration. And fourth, some improvement in the performance of our individual portfolio of businesses. As relates to headwinds, you can think about a few. As we've discussed before, the impact of specialty pharma on the overall medical cost trend and specifically, for example, its impact on Seniors portfolio of business. Two, as you know, another step up in the industry tax. A portion of it, our assumptions are we'll not pass through fully in the Medicare arena. And thirdly for us, given our global nature, some FX impact into 2015. But taken as a whole, we feel good about the 2015 impact that we were's able to generate here with growth, earnings and EPS growth, capital positioning. And then finally, Justin, the positioning this gives us for 2016 as we would expect further earnings and tailwinds off of the positioning with taken relative to our Seniors business in. So taken as a whole, we're pleased with the outlook for '15."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what your strategy around not including any benef",54,"And David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what your strategy around not including any benefit from that $1.8 billion in the guidance going forward."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. We were quite transparent providing update to each quarter, so I'm stepping back our capital deployment priorities are clear and unchanged. Certainly the existing needs of the corporation and for the underlying growth and investments to targ",153,"Sure, Justin. We were quite transparent providing update to each quarter, so I'm stepping back our capital deployment priorities are clear and unchanged. Certainly the existing needs of the corporation and for the underlying growth and investments to targeted and strategically attractive M&A.  Three, return to shareholders. And to your point, our track record demonstrates preferred approach and interests relative to share repurchase. And our objective is to provide you the transparency of what the free capital available for deployment and allow you to draw your judgment in terms of how you want to look at that. The headline here is really strong and well-performing balance sheet, really strong and well-positioned operating subsidiaries from an underlying capitalization level that provides the 1.8 available for deployment. And I would suggest you look at our track record relative to how effectively and how efficiently we have deployed that in be provide an update each quarter."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Matthew Borsch with Goldman Sachs.",10,"The next question is from Matthew Borsch with Goldman Sachs."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Could you talk to the drivers in your outlook for global supplemental business? It seems like the growth rate and maybe some of that is the impact of foreign currency is lower than we might have expected for a typical year.",41,"Could you talk to the drivers in your outlook for global supplemental business? It seems like the growth rate and maybe some of that is the impact of foreign currency is lower than we might have expected for a typical year."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Our Global Supplemental Benefits business has a track record of delivering strong revenue and earnings growth. Spokesman leveraging the broad innovated distribution and strong analytic and customers capabilities. We saw that result in '14 and we're really",129,"Our Global Supplemental Benefits business has a track record of delivering strong revenue and earnings growth. Spokesman leveraging the broad innovated distribution and strong analytic and customers capabilities. We saw that result in '14 and we're really seeing that results in '15 also. There are a few layers to the result of '15 though. Our outlook for 2015 earnings of $230 million to $250 million reflects continued strong operating margins, the continued funding of growth initiatives and continued currency pressure as you suggested of about $10 mil to $15 million after-tax. So if you adjust for the $21 million onetime tax benefit reported in the '14, the deamortization change and the impact of the currency pressure, the underlying growth for Global South is in the 8% to 18% range."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, that makes more sense. And I'm sorry, did you give the revenue outlook on global South for '15?",19,"Okay, that makes more sense. And I'm sorry, did you give the revenue outlook on global South for '15?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","We don't tend to provide revenue outlooks by a business segment, but we're expecting continued strong revenue growth in Global South.",22,"We don't tend to provide revenue outlooks by a business segment, but we're expecting continued strong revenue growth in Global South."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Joshua Raskin with Barclays.",9,"The next question is from Joshua Raskin with Barclays."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I want to talk a little bit about the public exchanges and the impact on the commercial business. I guess, first, if you're going to help us size what the revenues were in public exchanges this year and maybe what the impact on the overall commercial MLR",62,"I want to talk a little bit about the public exchanges and the impact on the commercial business. I guess, first, if you're going to help us size what the revenues were in public exchanges this year and maybe what the impact on the overall commercial MLR was? And then as a part of that, what assumptions you've made regarding the 3Rs."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Josh, David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs, as well as the -- our positioning growth relative the 3Rs. Consistent with our prior conve",172,"Josh, David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs, as well as the -- our positioning growth relative the 3Rs. Consistent with our prior conversation, we've positioned this book of business for 2014, as well as 2015. Our expectation is it will be a small portion of our overall franchise. Think of it in order of magnitude, this was talked about 3% of the overall franchise revenue in terms of 2014, and we would expect it to be in the similar range in 2015 with some puts and takes in terms of the run off of the gram-positive business and some growth on the exchange business. So I think the headline here that's quite important is a small percentage of the overall portfolio that we have been seeking to manage in the context of the performance of the franchise. Tom, could you put some more color on the MCR?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure. So just the MCR dynamics in individual have been improving over the course of the year, so also reflecting, of course, increased seasonality I the fourth quarter. It's just basically been improving from our initial expectations in year. Still a litt",236,"Sure. So just the MCR dynamics in individual have been improving over the course of the year, so also reflecting, of course, increased seasonality I the fourth quarter. It's just basically been improving from our initial expectations in year. Still a little higher than what we'd like to be. But that improvement has been driven basically by both better assessment of the early part of the year claims as they developed favorably and a bit of improvement in the run rate. And as you kind of suggested, the 3Rs. So just a couple of minutes on the 3Rs. Our year end accrual for 3Rs now totals about $200 million after-tax. The majority of the accrual continues to be related to the reinsurance element of the 3R program, which risk adjusters presenting higher amount of remaining balance and a smaller amount for this quarter of recoveries. And I'll give you some more specific color on our approach. We have accrued reinsurance at the 80% coinsurance level consistent with the design of the program. We have not accrued any risk adjuster impact for our taxes business due to the current lack of industry data. And we accrued amounts under the risk quarter because we're comfortable with the statutes and administrative guidelines that support that program. So as you know, there are some interplay among each of these program elements, but overall, we're very comfortable with our total accrual."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So I guess more specifically, I think, but I know it's a small portion about the MLRs is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that these guys have moved the buckets around a little bit. But I'm assumin",174,"So I guess more specifically, I think, but I know it's a small portion about the MLRs is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that these guys have moved the buckets around a little bit. But I'm assuming there's an assumption of the public exchanges getting a little bit better. You've got the industry tax uptick, which assuming your price worth is actually a little bit of a tailwind as well and the guidance is for 40 basis points of improvement, the midpoint. So are there -- I'm just trying if there's any other moving parts? My guess is you've got a little bit of a benefit on the hep C and specialty Pharmacy for the new Gilead relationships announced yesterday. So I'm just -- is there anything underlying? Are you guys just basically assuming apples-to-apples on your total -- on your sort of commercial book flat type of MLRs with a couple of these moving parts that's helping you with a couple basis points?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Josh, I think you got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14, and it's driven by the items you mentioned that reflects continued good performance i",73,"Josh, I think you got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14, and it's driven by the items you mentioned that reflects continued good performance in our employer group business, some benefit from pricing for the incremental industry in 2015 and some improvements in individual. That essentially summarizes the major moving pieces."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And I'm sorry, did you guys quantified the FX headwind in the fourth quarter?",15,"Okay. And I'm sorry, did you guys quantified the FX headwind in the fourth quarter?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the fourth quarter things have been moving around. I'd say low-single digit million dollars impact. So I didn't before, but that's about the quantity.",25,"Well, the fourth quarter things have been moving around. I'd say low-single digit million dollars impact. So I didn't before, but that's about the quantity."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from A.J. Rice with UBS.",10,"The next question is from A.J. Rice with UBS."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It doesn't seem like we're hearing much about it, but in your ASO book of business, did you see much attrition? And can you",68,"Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It doesn't seem like we're hearing much about it, but in your ASO book of business, did you see much attrition? And can you just sort of comment on the state of place from your perspective and private exchanges at this point?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","It's David. Just a little color on our view in our positioning and our results. First, we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourselves in just about all of the various p",201,"It's David. Just a little color on our view in our positioning and our results. First, we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourselves in just about all of the various private exchanges that are in the marketplace today. In addition to that, we have our own proprietary exchange and a dedicated leadership team managing the overall exchange activities. As it relates to outcomes to your point, there had been a lot of conversation in the market as we expected, but consistent with our prior dialogues, we do not expect to see a significant amount of movement in the overall landscape in the marketplace in '14 or '15. And that's what manifested for both industry, as a whole, as well as for ourselves. So specific to Cigna, some movement in both directions, but it all out with de minimis amount of activity. Lastly, as we look in 2016, as I noted, we're well-positioned in the respective exchanges. We'll be actively engaged in target clients that we believe align very well with our value proposition, present good growth opportunities, but slow activity thus far, in line with our expectations."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to potential capital deployment opportunities acquisitions. Are you thinking about that? Or are you looking what will be an attractive opportunity f",78,"Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to potential capital deployment opportunities acquisitions. Are you thinking about that? Or are you looking what will be an attractive opportunity for you? Is it something that just broadens your geography? Or you're looking for something that you think you can run better than it's currently being run? Maybe have some color on what would be attractive there."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","AJ, we've been very consistent relative to MA is over a long term, a very attractive growth opportunity. And in our view is that a sustainable MA program has 2 major dimensions, effective consumer engagement and personalization capabilities and then stron",177,"AJ, we've been very consistent relative to MA is over a long term, a very attractive growth opportunity. And in our view is that a sustainable MA program has 2 major dimensions, effective consumer engagement and personalization capabilities and then strong clinical partnership and physician engagement capabilities with the value-based reimbursement structure, which is what our model is. As to capital employment, hit the nail on the head. We see both organic geographic expansion opportunities, as well as inorganic geographic expansion opportunities. So that leave one, targeted geographies that are inorganically attractive. Second would be if you expand a little more broadly relative to Seniors and the broader kind of population, additional capabilities or opportunities to serve the Medicare, Medicaid duals or other parts of the population we think are underserved. As I noted in my prepared remarks, we've seen good success in taxes, emerging success in Illinois and we're going to seek to grow those programs. So those will be the 2 areas for capital deployment, geographic, as well as what we would call segment expansion."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Scott Fidel with Deutsche Bank.",10,"The next question is from Scott Fidel with Deutsche Bank."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, just wondering if you can drill into the select growth? It looks like the trajectories don't have their double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market share downstream into ASO and in",72,"First question, just wondering if you can drill into the select growth? It looks like the trajectories don't have their double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market share downstream into ASO and in terms of how much increased ASO market penetration you're seeing and then as compared to some of the market share gains that you're maybe driving in that segment."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees. So that's our Select Segment. To your point, it has been, and continues to be, a very attractive growth segment for us. Continuing to double-dig",191,"Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees. So that's our Select Segment. To your point, it has been, and continues to be, a very attractive growth segment for us. Continuing to double-digit customer base growth for us and something we're quite pleased with. Our approach to this base is somewhat different in the marketplace. So it's to be consultative and work with employers to design the right consumer engagement and benefit designs and network structures and then offer multiple funding alternatives, one of which, is, as you referenced, an ASO proposition that gives them much more transparency and tighter alignment. As you know, the overall employer landscape in the U.S. is not growing. Shrinking up market a little bit of growth down market, so there's little bit of growth. But net network taking share in this space, and we tend to take share in this space from more traditionally designed financing alternatives for health care to more progressively designed health engagement programs, incentive alliance program that have a high degree of transparency and the outlook area is very positive."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just on a follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then just within RX, what type of impact year-over-year you think that the new",55,"Okay. And then just on a follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then just within RX, what type of impact year-over-year you think that the new preferred partnership with Gilead for Harmonic could benefit?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So we're really pleased with our medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and buildi",101,"Scott, it's Tom. So we're really pleased with our medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and building on a very strong trends results we reported for several years. Our outlook for 2015 of 5% to 6% reflects some uptick in utilization and some increase in pharmacy trend, specially drug costs. And, of course, some impacts from the flu. Components are generally in the mid-single digit range with maybe pharmacy in the double-digit range."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, to 2 questions relative to the specialty item, you're correct. We will see some impact of positive impact. But per prior discussions, our team is effectively manages specialty drug component and specifically, the hep C specialty component in 2014.",100,"Scott, to 2 questions relative to the specialty item, you're correct. We will see some impact of positive impact. But per prior discussions, our team is effectively manages specialty drug component and specifically, the hep C specialty component in 2014. We are pleased with the recent announcements we have with Gilead. And importantly, I would note that both organizations have committed to innovating performance-based and outcome-based component to the ongoing activities. So we're pleased with the overall development that transpired, but also the commitment of both organizations to collaborate on an outcome-based program for the benefit of customers as well."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Kevin Fischbeck with Bank of America Merrill Lynch.",13,"The next question is from Kevin Fischbeck with Bank of America Merrill Lynch."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. Grat. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally the VMR was 8.7, that's ex development, right? So you're basically saying, there should be relatively flat to up in 2015 versus 2014? And I guess",103,"Okay. Grat. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally the VMR was 8.7, that's ex development, right? So you're basically saying, there should be relatively flat to up in 2015 versus 2014? And I guess when I think about PDP coming, we also thought that you guys probably would have made some progress there next year. And then MA, obviously, you've got a funding gap, but there was a lot of you are doing in 2014 to try to offset that. So just trying to understand how you think about the margins."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Kevin, it's Tom. You've got the dynamics right. We've got an outlook of 84.5%, 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. The picture is, I think, generally like t",103,"Kevin, it's Tom. You've got the dynamics right. We've got an outlook of 84.5%, 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. The picture is, I think, generally like this. We generally expecting stable Medicare MCRs between Medicare advantage and PDP with some mix impact some actually driving the dynamic here. We're growing some of the higher MCR Medicaid business we have as a portion of the portfolio. Again, all in the margin, but that's generally the result. And I think the outlook calls generally for a staple results."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then I guess when you talk about accelerating the M&A -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective of the kind of 6% to 8% that you're looking forward this year in the membership",61,"Okay. And then I guess when you talk about accelerating the M&A -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective of the kind of 6% to 8% that you're looking forward this year in the membership basis? Or is that margins? Is it both? How do we think about that?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both revenue, a",120,"Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both revenue, as well as margin. As I noted in my prepared remarks, we expect to see further improvement in the stars ratings, for example. And the positioning we took in 2015 was the position products and key markets with an expectation and what we saw was a step up in 2016 stars. So we will see both revenue contribution going into 2016, as well as margin expansion contribution in 2016, therefore, an earnings accelerant."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Next question is from Christine Arnold with Cowan.",8,"Next question is from Christine Arnold with Cowan."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","A couple of . The exempted ex-patient businesses from the health insurance fee. Is there a quantifiable impact there?",18,"A couple of . The exempted ex-patient businesses from the health insurance fee. Is there a quantifiable impact there?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, good morning. It's David. First and foremost, there have been a variety of administrative release that's in place post the passage to the Bill back in 2012 and up to as you reference, the because the administrators recognized that there was una",138,"Christine, good morning. It's David. First and foremost, there have been a variety of administrative release that's in place post the passage to the Bill back in 2012 and up to as you reference, the because the administrators recognized that there was unattended consequence for that business. We're pleased with the outcome from the legislatively, rectifying that for the benefit of global employers. And I would suggest to the biggest impact here is taking away the administrative complexity that applying the ACA to the global employers expatriate benefit business would create. That was putting a burden on that business portfolio that we're managing. That's the biggest benefit on the small economic benefit, but that's a few of the byline. The bigger piece is it cleans it up  for purposes of global employers not to be exposed to that."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then can you talk about why first quarter '15 will be lower than first quarter 2014? And give us some order of magnitude on the factors? And then do you think you need Medicaid in order to serve the duals? Or you're still kind of the view that y",59,"Okay. And then can you talk about why first quarter '15 will be lower than first quarter 2014? And give us some order of magnitude on the factors? And then do you think you need Medicaid in order to serve the duals? Or you're still kind of the view that you've got the portfolio you need for those duals?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. First, I'll address the first quarter and spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than first quarter 2014 and we attributed to 2 things, strategic investments and the growth of our",131,"Christine, it's Tom. First, I'll address the first quarter and spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than first quarter 2014 and we attributed to 2 things, strategic investments and the growth of our Part D business in the first quarter. On the strategic investment side, I think about additional start-up costs in Medicaid expansions, increased grant spend in 2014 and the part D impact reflects both the first quarter pressure typical in Part D, given the benefit structure. We all know that Part D first quarter results tend to be low. And the impacts of the drug transition requirements for new customers. So all in, on a comparable basis, we are expecting first quarter '15 to be lower than first quarter 4."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's David. On your second part in the pretty efficient working in the multi questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunit",118,"Christine, it's David. On your second part in the pretty efficient working in the multi questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity for us because we believe that they're under service it relates to clinical care coordination and our clinical programs actually play quite affectively there as noted in our Texas programs. We're going to seek to grow those activities organically and then opportunistically as we noted in our M&A priorities. Opportunistically for geographic density, we will also look to do capabilities from an MA standpoint. So I would view that as both organic and inorganic opportunities for us."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","And next question is from Andy Schenker from Morgan Stanley.",10,"And next question is from Andy Schenker from Morgan Stanley."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just wondering of the earlier questions here. For PDP specifically, highlight some pressures around specialty drugs and higher brand mix. And maybe just how did that continue to play out or evolve in the fourth quarter and then relates pretty strong an",65,"So just wondering of the earlier questions here. For PDP specifically, highlight some pressures around specialty drugs and higher brand mix. And maybe just how did that continue to play out or evolve in the fourth quarter and then relates pretty strong annual enrollment growth in the annual enrollment period, about 200,000-plus lives. So what are your expectations on those costs continuing into next year?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Andy. It's Tom. I'll start and then David will address the growth issues. So as you pointed out, PDP results do reflect higher drug cost in the Fourth Quarter and the Full Year. That includes some impact from the mixed and drug purchases and some",135,"Thanks, Andy. It's Tom. I'll start and then David will address the growth issues. So as you pointed out, PDP results do reflect higher drug cost in the Fourth Quarter and the Full Year. That includes some impact from the mixed and drug purchases and some impact from specialty drugs, so both. We've taken action to try to prove results here. That will improve results here. We made network and formulary adjustments when we merged the health spring and plans for 2015, so that resulted in leaner formulary and expanded utilization plan -- management for the merged plans, which we expect will improve cost. As you pointed out, we also expect unfavorable impact from recent agreement Gilead on hep C drugs, but we have factored some underlying pressure in Part D into our 2015 outlook."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Relative to growth, as Tom noted. We merged the HealthSpring in the programs and thought to take the best of both organizations. For 2015, we are growth efforts. We're targeting the population. We saw a very good traction in our sales efforts there. We'd",114,"Relative to growth, as Tom noted. We merged the HealthSpring in the programs and thought to take the best of both organizations. For 2015, we are growth efforts. We're targeting the population. We saw a very good traction in our sales efforts there. We'd note that our early results through January from utilization and performance standpoint for the new population are in line with our expectation for that chooser population, meaning the aggregate utilization levels, importantly, the mix of utilization by generic and otherwise. And as Tom noted, we expect, generally speaking, stable MCRs going from 2014 to '15 for this portfolio. And again, present an opportunity for further earnings expansion looking into 2016."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And just maybe follow-up question. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into the how much business did you guys have up for renewal maybe versus an average year?",59,"And just maybe follow-up question. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into the how much business did you guys have up for renewal maybe versus an average year? And any opportunities out there that you guys are really looking to target?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Randy, as you noted, it's early, I mean, in the cycle. But to give you some color, and again, when I give you color, we'll define what we talk about in national account. So commercial employers with 5,000 #1 employees in a multistate. We're actually seein",211,"Randy, as you noted, it's early, I mean, in the cycle. But to give you some color, and again, when I give you color, we'll define what we talk about in national account. So commercial employers with 5,000 #1 employees in a multistate. We're actually seeing a pretty robust pipeline of new opportunities unfolds, so it's unfolding both meaningful scale and early in the cycle. So we're seeing a robust pipeline begin to unfold early in the cycle. And with an elevation, further elevation and intensity looking for what we call engagement incentive-based programs, exploring a lot of the value-based networks configuration and the like, which play very well to our strategy. As it relates to the last part of your question, the percent our book out to bid, we see a smaller percentage of our book out to bid for 2016 than we did prior year, and that's consistent with the dialogue we had last year. We indicated that we had an elevated percentage based on procurement cycle, so we managed through that you pretty well for 2015 and now looking to 2016, while the smaller percentage of  of book business out to bid. And again, we're seeing a pretty nice robust pipeline beginning to unfold early in the cycle."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Roth Jacoby with Crdit Suisse.",10,"The next question is from Roth Jacoby with Crdit Suisse."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? You guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more movement",52,"Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? You guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more movement between and ASO segment amongst peers."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ralph, it's David. As you know, the vast majority of our commercial business, U.S. commercial business, dis ASO. So as we're able to grow our portfolio, the preponderance of that is ASO-oriented. I'd also note that our expectation, as the results unfold i",129,"Ralph, it's David. As you know, the vast majority of our commercial business, U.S. commercial business, dis ASO. So as we're able to grow our portfolio, the preponderance of that is ASO-oriented. I'd also note that our expectation, as the results unfold in line with a guidance that some provide, the 1% to 3% customer growth, were to excludes our QualCare network acquisition. We would expect that our guaranteed cost lives, our risk lives, would decrease because of the run off of the individual non-ACA compliant lives. So very important, as we get into the more detail, is that manifest itself. But net-net, you should think about our growth as being predominantly ASO-oriented, and that transcends through select, the regional segment, et cetera, and we see good traction there."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just in terms of just the competitive environment for ASO broadly?",14,"Okay. And then just in terms of just the competitive environment for ASO broadly?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the competitive environment -- maybe I'll flip around bit the other way and then I'll try answer your competitive environment. The buying environment, so the client portfolio, and we call them care for clients. Clients continue to seek what we call",173,"Well, the competitive environment -- maybe I'll flip around bit the other way and then I'll try answer your competitive environment. The buying environment, so the client portfolio, and we call them care for clients. Clients continue to seek what we call -- you might call alternative funding. We'll call it transparent funding. So the demand for more transparent funding continues to grow as employers are seeking to get alignment of incentives and better visibility through how their funds are being deployed and aligns the incentives for their employees or customers. And so that trend continues. So hence, the competitive environment, competitive are seeing more selectivity as well for Cigna. That's good for us because we're extremely well-positioned in that environment from benefit design, the consultative nature. And very importantly, the employer reporting an insights to go with that monthly, quarterly and annually to provide a guidance in terms of what's transpiring. So yes, elevation, but it's elevation because of the client demand, not competitive activity. And client demand continues to go up."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, that's fair. And then second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect the incremental for 2015? And then your specialty is separate from that deal. Is there any timeline or",61,"Okay, that's fair. And then second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect the incremental for 2015? And then your specialty is separate from that deal. Is there any timeline or decision and what you want to keep it that way or whether exploring options at this point?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our",189,"Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our strong clinical outcomes, continued customer growth and strong earnings performance. We continue to invest I that. So relative to your letter question, specialty, we run our own specialty operations within the organization. It's performing well. Our team continues to look to means to further expand and strengthening that either through collaboration or otherwise, but we're investing and continue to run on our own. As for results and per prior conversations, for 2014, our results track in line with our expectations. In fact, they track  a little bit ahead of our expectation, largely because of actions we took around rate and pace of investments for the timing of that inherent level. So we're actually a little bit ahead of our track record. For 2014 and for 2015, our overall targets for our pharmacy business are in line with our expectations, maybe slightly favorable for the overall franchise."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ana Gupte from the Rink partners.",11,"The next question is from Ana Gupte from the Rink partners."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I just wanted to follow up on the select ASO mixture have been move from a stop perspective. I'm trying to understand firstly whether the company has adjust that just to Stop Loss are competing on a bundled or unbundled basis with all of you. And it looks",60,"I just wanted to follow up on the select ASO mixture have been move from a stop perspective. I'm trying to understand firstly whether the company has adjust that just to Stop Loss are competing on a bundled or unbundled basis with all of you. And it looks like United and Aetna have started to play a bigger role here."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Anna, it's David. First and foremost, as we've talked now for multiple years around the select space and ASO, ASO stop-loss, variety funding mechanisms, we believe and proven out, we believe that there will be increasing demand. We believe there's as a re",267,"Anna, it's David. First and foremost, as we've talked now for multiple years around the select space and ASO, ASO stop-loss, variety funding mechanisms, we believe and proven out, we believe that there will be increasing demand. We believe there's as a result to be increasing competitive activity, and we believe to be successful without to continue to innovate. That's what's transpiring in the marketplace. As it relates to standalone, if you Stop Loss players in this space, I don't see that as a primary competitive disruptor, largely because of the impact of the integration here. So if you stop back, what makes these programs work is not a Stop Loss program. What makes these programs work is getting the benefit alignment laid out with the right incentives, the network appropriate, the clinical programs aligned. For example, we have the ability and we do, do on-site biometrics training, on site coaching for million employer. That's a new model. To be able to do that and bring that on board for a client, identify the 1, 2 or 3 high-risk individuals who are not incurring costs today, but we need to engage clinically weighted. And integrating all of that with the ASO funding mechanisms, Stop Loss when it make sense for that employer, as well as reporting, that's the core of our value proposition and we continue to see strong demand for that today and into the future. And we would expect to gain competitors to step into this space because there's a significant amount of demand. Key to us is the results are delivering in ongoing innovation."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose awhile ago still hold?",33,"And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose awhile ago still hold?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","It is Tom. I would think about the standalone Stop Loss segment is a totally different markets than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical cost. And the standalone Sto",171,"It is Tom. I would think about the standalone Stop Loss segment is a totally different markets than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical cost. And the standalone Stop Loss carries typically don't have that feature. In addition, we do have some built in advantages versus them. I mean, we already have this customer in our site, so we have 1 set of acquisition cost. They have to pay incremental acquisition cost to secure this customer. And we have a lot better insight into the underlying claims data, so our ability to effectively employ the program is very superior. So we don't really find ourselves in what sometimes can be hypercompetitive standalone Stop Loss market. Not really a market we are computing in. We don't so Stop Loss underlying programs in Britain were selling Stop Loss, it's part of an integrated package. So the competitive dynamics for the standalone market are very different than the competitive dynamics we see."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Peter Costa with Wells Fargo securities.",11,"The next question is from Peter Costa with Wells Fargo securities."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My questions also on the Stop Losses. Is that business included in the commercial MLR that you're giving us now in the commercial MLR?",24,"My questions also on the Stop Losses. Is that business included in the commercial MLR that you're giving us now in the commercial MLR?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes. Total commercial MLR will include all of our risk businesses in commercial.",13,"Yes. Total commercial MLR will include all of our risk businesses in commercial."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising and loss ratio on that book of business, so that it's not pulli",58,"So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising and loss ratio on that book of business, so that it's not pulling down as much going forward?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","I have to tell you, I haven't done that calculation, but obviously, we're not seeing that in the results. So I don't -- I think you might be missing a little something there. But just a couple of things. First, the loss ratio on Stop Loss is lower than th",186,"I have to tell you, I haven't done that calculation, but obviously, we're not seeing that in the results. So I don't -- I think you might be missing a little something there. But just a couple of things. First, the loss ratio on Stop Loss is lower than the average overall loss ratio, but the premium density and the other businesses is pretty high. So I'd be surprised if there was a 1 point impact, but we'll do that math. Second, on Stop Loss. We actually would expect some modest increase in the Stop Loss law ratio as we continue to sell disproportionately in the lower end. And those customers tend to have a more premium density, so less of an expense factor on the result and a higher MCR. Again, very attractive MCR, so it's not like it's worse profitability. The bottom line margin is still very attractive for their Stop Loss business, but the dynamics in the MLR are a little higher. So I would expect there's marginal impact probably from this change, but I'll do a little more careful look at that."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Chris Rigg with Susquehanna Financial Group.",11,"The next question is from Chris Rigg with Susquehanna Financial Group."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Just wanted to come back to capital deployment again. And I heard your comments on Medicare advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestic",54,"Just wanted to come back to capital deployment again. And I heard your comments on Medicare advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestically? Or you still think international is kind of a better opportunity?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Chris, its David. As it relates to inorganic capital deployment, we have 4 priorities and 4 priorities have remained the same. These are not in order. These are the 4 priorities. Further global footprint, Medicare advantage and dual capabilities, further",95,"Chris, its David. As it relates to inorganic capital deployment, we have 4 priorities and 4 priorities have remained the same. These are not in order. These are the 4 priorities. Further global footprint, Medicare advantage and dual capabilities, further retail base capabilities and then what we call Go Deep bolt-on capabilities for portfolio. So I wouldn't separate international as more than or less than for 2015 versus the last year. It was in our portfolio when we've been opportunistic and focused in terms of opportunities outside the U.S, as well as inside the U.S."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then my follow-up is just on sort of overall growth to the company and specifically, in the health care segment.  I mean, I'm just trying to figure out, you're going your revenues 8% to 10%. Obviously, the bottom line is in growing in line with",121,"Okay. And then my follow-up is just on sort of overall growth to the company and specifically, in the health care segment.  I mean, I'm just trying to figure out, you're going your revenues 8% to 10%. Obviously, the bottom line is in growing in line with that. Obviously,  PPD's having an impact. But do you -- can you give us a sense for when you think you at least start to get some more leverage down the P&L? Is 2015 sort of the last truly difficult year and we should start to see some leverage next year? I know you're not going to give guidance, but just again, big picture wise, just trying to figure out the trajectory of growth."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the direct answer to your question in a little more color is yes. Little more color is as we talked about in 2015 outlook, we're pleased with the 8% to 10% revenue growth outlook. And then the 3-day percent earnings growth outlook on the same-store",145,"Well, the direct answer to your question in a little more color is yes. Little more color is as we talked about in 2015 outlook, we're pleased with the 8% to 10% revenue growth outlook. And then the 3-day percent earnings growth outlook on the same-store basis and the 5% to 10% EPS growth outlook without capital deployment. As we said, looking to 2016, we see margin expansion opportunities within the health care business. Margin expansion opportunities, specifically in the senior space, both for MA, as well as PDP. We see further margin expansion opportunities within our individual block of business where we've seen some improvement move from '14 to '15.  And then we'll see further scale leverage beyond the ongoing fundamentals of our strong performing employer business. So margin expansion opportunities exists in 2016 and '17 and beyond, and we're quite excited about that."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Brian Wright with Sterne Agee.",10,"The next question is from Brian Wright with Sterne Agee."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I apologize if I missed this, but could you give us some color on the number of PDP lives to be added in '15?",24,"I apologize if I missed this, but could you give us some color on the number of PDP lives to be added in '15?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","We didn't, Brian. It's about -- we ended up 1 on 1 enrollment for about 250,000 more lives than we had at the end of the year.",28,"We didn't, Brian. It's about -- we ended up 1 on 1 enrollment for about 250,000 more lives than we had at the end of the year."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so it's to have that. But the to me looks like how you're reporting now. And you have another peer who's been very vocal about kind of",74,"Okay. And just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so it's to have that. But the to me looks like how you're reporting now. And you have another peer who's been very vocal about kind of large-scale acquisition in the space. And you're kind of reporting segments very nicely that would make consolidating 2 models pretty easily. So just any comments on that."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Brian, I think you may be able to work for the nsa if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus one because there are different attribute",152,"Brian, I think you may be able to work for the nsa if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus one because there are different attributes within the government portfolio business versus the commercial business. And while we're at alternatives, we believe that, that was more customer-friendly and provides transparency to drive the dialogue on a go-forward basis. And as we have in the past and as we are willing to go-forward basis, we'll try to give you as much color as possible in terms of the underlying drivers of the overall business portfolio. But this was an attempt to be, again, responsive to the market. But also, maintaining an appropriate amount of transparency and not go to a single modest ratio, but provide 2 loss ratios for the domestic tough business."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from the Dave Windley with Jefferies.",10,"The next question is from the Dave Windley with Jefferies."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My questions on Medicare advantage. David, wondering if through the AP here and your changes in the Mid-Atlantic markets, specifically if your view is that those changes network and to the extent they will benefit design as well are complete and set you u",54,"My questions on Medicare advantage. David, wondering if through the AP here and your changes in the Mid-Atlantic markets, specifically if your view is that those changes network and to the extent they will benefit design as well are complete and set you up for a more normal contribution from that market in 2016?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","In your comments, Dave, we'll point to our 2016. So put MA back in context, we're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth to 6% to 8% customer growth. You're correct. You draw attention back to the market that we sa",140,"In your comments, Dave, we'll point to our 2016. So put MA back in context, we're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth to 6% to 8% customer growth. You're correct. You draw attention back to the market that we saw to do some repositioning and we're feeling the final impact of that or final meaningful impact to that repositioning in 2015 in terms of both the lack of life growth. So even in the 6% to 8%, the lack of life growth in that market is fully contemplated in the 6% to 8%. And we would expect this as we step into 2016, an opportunity to see improvement and performance there. So that's the contributor as we look into the future, but part of that repositioning is being sold in 2015."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then sticking with that, is that also something that you think can have another positive impact to stars ratings when they come out later this year?",27,"And then sticking with that, is that also something that you think can have another positive impact to stars ratings when they come out later this year?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Our organization has demonstrated significant improvement as far as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement goin",125,"Our organization has demonstrated significant improvement as far as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement going from 16 to 17. I'm not going to comment on individual market activities. But more importantly, our organization is highly focused on the intricacies of the stars program. And importantly, making sure we're given the right service experience and clinical experience, both medical and pharmacy for the benefit of our customers and doing so in a way to move the stars rating up in 2017 to another step function off of the very attractive movement we made going to '16."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Our last question is from Michael Baker with Raymond James.",10,"Our last question is from Michael Baker with Raymond James."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enh",56,"David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enhanced engagement and strengthen guarantees, as well as some bent admin element that increases stickiness?"
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we call down markets. So when we think about Select Segment and a portion of the regional employer portfolio. It's a single",241,"Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we call down markets. So when we think about Select Segment and a portion of the regional employer portfolio. It's a single carrier, as you would expect exchange alternative. The value prop, so it's going to the value prop. The value prop is primarily to enable a further retail experience for individuals to get them more actively engaged in the selection of their personal benefits. And we know that when that transpires, whether through a private exchange or other mechanisms, because we do this everyday without private exchanges, to get a higher level of awareness, a higher level of engagement, a higher level of ownership for the individual and their benefits and their understanding of what's the -- that's the primary mechanism. And then you're able to drive the appropriate personalization or efficiency that works for them. So using your term consumer engagement or personalization, there's a primary attribute there. As I noted previously though, we've expected this marketplace more broadly to unfold slowly and it is. Our team has seen some success. We have a dedicated team of resources that will continue to focus on this, but we have not banked on, or we banking on, a significant step function in revenue customer lives or earnings growth here. Rather, we've positioned ourselves to have smart optionality this market moves forward positively."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","I'll now turn the call over to David or Danny for closing remarks.",14,"I'll now turn the call over to David or Danny for closing remarks."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna saw a strong fourth quarter and solid revenue and earnings contributions from each of our business segments. As an organization, we have over 35,000 talented co",170,"Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna saw a strong fourth quarter and solid revenue and earnings contributions from each of our business segments. As an organization, we have over 35,000 talented colleagues around the globe whose work exemplifies our mission of improving health, well-being and sense of security for the people we serve everyday. The momentum we generated off of strong year in 2014, combined with our attractive growth opportunities, gives us confidence we will achieve our full year 2015 outlook. We plan to continue to leverage our proven business and core capabilities to drive meaningful growth in attractive new markets and segments, resulting in doubling of our revenue over the next 7 to 8 years. And we remain committed to achieving, on average, our annual EPS growth objective of 10% to 13% over the long term. We thank you for joining the call today and your continued interest in Cigna, and we look forward to continuing our conversations."
172899,253311656,755343,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days, fo",69,"Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days, following this call. You may access the recorded conference by dialing 1 800-945-4244 or (203) 369-3501. No passcode is required for the replay. Thank you for participating. We will now disconnect."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter and Full Year 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.We'll begin by turni",51,"Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter and Full Year 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.
We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",592,"Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks today, David and Tom will cover a number of topics, including Cigna's full year 2014 financial results as well as our financial outlook for 2015.
As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled ""adjusted income from operations"" and ""earnings per share"" on this same basis as the principal measures of performance for Cigna and our business segments. A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com.
In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC.
Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. First, please note that, when we discuss the number of covered lives for our global medical customers, we will be doing so on a basis that excludes those individuals that were previously covered under Limited Benefits plans. As a reminder, we exited the Limited Benefits business as of December 31, 2013, as required by the Affordable Care Act regulation.
Second, please note that our definition of adjusted income from operations will change for 2015 reporting in that we will now exclude acquisition-related amortization expense from this operating measure. When we discuss our earnings outlook for 2015 today, it will be on a basis of adjusted income from operations that excludes acquisition-related amortization expense. This is a change compared to the basis on which 2014 results are reported and how we have previously provided our 2014 outlook. In 2015, the impact of excluding acquisition-related amortization expense is approximately $100 million after tax or $0.40 per share.
Third, beginning in 2015, we have simplified our guidance and disclosures for our medical care ratios or MCRs by reporting them on a basis of total Commercial and total Government. The total Commercial ratio encompasses all of our commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products, provided through guaranteed cost or experience-rated funding arrangements in both the United States and internationally. The total Government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses. To ease the transition, we have provided historical medical care ratios on these bases within our quarterly financial supplement that was posted in the Investor Relations section of cigna.com this morning.
Lastly, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or prior year development of medical costs. Our outlook also excludes the impact from our recently announced acquisition of QualCare, which we do not expect will have a material impact to our financial results in 2015.
And with that, I will turn the call over to David."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Will. Good morning, everyone, and thank you for joining our call today.To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers, cli",1741,"Thanks, Will. Good morning, everyone, and thank you for joining our call today.
To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers, clients and shareholders in the future. I will also illustrate more specifically how we are creating value in our Seniors business and leveraging our experience and success of that business to drive long-term growth. Then Tom will address our fourth quarter and full year 2014 financial performance in more detail as well as provide the specifics for our outlook for 2015 before we take your questions. And following the Q&A session, I'll wrap up the call with a few closing remarks.
We'll start with some highlights from the year.
Cigna's strong 2014 performance represents the fifth consecutive year of competitively attractive financial results. This outstanding track record of results is driven by the disciplined execution of our growth strategy, all while we continue to invest in new capabilities, expand our offerings and our geographic footprint. Over the past several years, in the face of a particularly challenging and dynamic environment, we have been focused and disciplined with targeted yet meaningful investments to drive innovation, including new clinical programs, aligned incentives for customers, expanded technologies and programs for health care professionals. We have done all these while delivering competitively differentiated results year in and year out.
The full year 2014 consolidated revenues increased 8% to $35 billion, with each business segment delivering strong growth over 2013. We reported adjusted income from operations for the full year of $2 billion or $7.43 per share, which represents a per share increase of 9% over 2013.
Our revenue and earnings performance reflect growth in all of our businesses over the course of the year, the year in which we also grew to more than 85 million customer relationships worldwide and where we continue to generate strong margins and significant free cash flow for the benefit of shareholders. These results position us to once again deliver competitively attractive revenue and earnings growth in 2015.
For 2015, our outlook of 8% to 10% revenue growth and 5% to 10% EPS growth, excluding reserve development recognized in 2014 as well as future capital deployment, reflects the focus and clarity of our strategy and continued strong performance of our team around the world. Tom will walk you through more specifics regarding outlook later on the call.
Now I'd like to talk about how our guiding framework, global strategy and multiple avenues for growth have enabled our long track record of success and will drive ongoing future value creation.
Across our business, we operate in an ever-changing market landscape with diverse needs across customers, employers, health care professionals and governments. Moving in this market, we are meeting and exceeding the expectations of our customers and clients around the world by delivering affordable and personalized solutions. As we look to the future, we have built a growth framework to create ongoing value, leverage our differentiated capabilities for the benefit of our customers.
There are 3 components to this framework. First is leveraging our well-positioned existing portfolio of businesses to continue to generate attractive value for our customers and clients. We expect to double the size of our company over the next 7 to 8 years. This will result in an average annual revenue growth rate of 8% to 10% largely driven by our existing portfolio and focused execution. This continues a track record that we have demonstrated over the last 5 years, and our 2015 outlook of 8% to 10% revenue growth is consistent with this goal.
The second component is targeted and effective capital deployment to create ongoing shareholder value. I would note that, over the past 5 years, we have effectively deployed capital through a balance of investments in our business portfolio, strategic M&A and share repurchase. A good recent example of this is our agreement to purchase QualCare Alliance Networks. This acquisition is directly aligned with our Go Deep and our physician partnership strategies.
Our businesses are generating high margins and are capital efficient, allowing us to both fund attractive organic growth and generate significant free cash flow. This free cash flow provide us with financial flexibility and the opportunity to deploy capital to create additional value for our shareholders. And given the health of our balance sheet and underlying capitalization level of our subsidiaries, we expect to have $1.8 billion of capital available for deployment in 2015.
The third component of our framework where we seek to drive additional value for our shareholders is through new and emerging opportunities. These opportunities include new distribution marketplaces such as public and private exchanges, geographic expansion such as new Medicare Advantage markets and international opportunities and new buying segments and service expansion such as medical service organization offerings for the benefit of integrated health care professionals. We are well positioned to pursue each of these potentially attractive future growth opportunities that are aligned with our strategy. As such, we have dedicated resources to fuel future expansion in these areas.
To illustrate how we are leveraging this framework to create value, I'll highlight how this framework applies to our Seniors business. This market segment includes a population with a variety of complex needs, requiring customer engagement and incentive-based clinical resources and programs to drive ongoing success. Our Seniors business pioneered successful positioning gauge and models, including alliance incentives and collaborative relationships to drive high-quality and a more affordable health care experience for both customers as well as physicians. As we continue to leverage our core physician engagement capabilities across all of our health services businesses, we are focused on key investments that improve affordability, enhance personalized services and drive better clinical outcomes. For example, the strategic investments we're making to enhance our physician insight and data tools will enable our clinical data to be accessible in a real-time fashion from more of our physician partners as well as our service team. Enabled by our physician engagement model, seniors continue to find our Cigna HealthSpring benefit offerings increasingly compelling. And we expect to have 6% to 8% Medicare Advantage customer growth in 2015.
As for positioning, we continue to be amongst the top 3 players in market share for all of our established markets, and we are posing attractive growth in our newer markets. In 2014, we expanded our Seniors business into Georgia and the Carolinas, where we successfully leveraged existing Cigna commercial networks to develop and implement engaged physician relationships for seniors. Importantly, the quality of care delivered through our engaged physician groups is reflected in our stars ratings, where we increased our membership in 4-star or higher plans from approximately 40% to nearly 60% in 2016. Looking to 2017, we again expect to deliver an increase in this result. These improvements in star ratings have allowed us to enhance our benefit offerings and position our Seniors business to be an earnings accelerant in 2016 and beyond.
Relative to expanding opportunities, we currently operate Medicaid into eligible plans in Texas and in the Illinois markets. Here, we are leveraging our care coordination capabilities to serve the dual-eligible population within our Medicaid platform. Focusing our growth efforts on improving care for the underserved, including the dual-eligible and age, blind and disabled populations, complements our proven experience with complex care coordinations, differentiated clinical outcomes and affordability focus. While our Illinois plan is relatively new, having just begun in 2014, our Texas plan has been in operations since 2011 and has a track record of delivering affordable care and better health outcomes. In a testament of our commitment to servicing these customers, our Texas plan recently was acknowledged by the Medicaid Health Plans of America for our cutting-edge, intensive behavioral health programs.
We are well positioned and have the capital flexibility to pursue these accelerating geographic and market segment expansion opportunities either organically or through M&A, as Seniors remains a strategic growth priority for us. As a global company, our efforts to leverage these capabilities have also expanded across key markets beyond the United States. In Korea, for example, where the age population is seeking new solutions to meet their emerging needs, we've developed an innovative and new health membership program targeting seniors known as Heyday. This organically built affinity program delivers value-added services directly to seniors in Korea. And while only a year into this expansion, we now serve more than 300,000 Korean seniors. So overall, we have a clear strategy and the capabilities to deliver value and improve the health and well-being of senior customers today and into the future.
Whether in our Seniors business as we discussed today or other growth businesses we have addressed in previous calls, we will continue to deliver attractive growth, produce and deploy capital effectively and invest and position ourselves to win in new and emerging markets and segments.
Now to summarize my comments before Tom offers more detail on our 2014 results and expectations for 2015.
Cigna's strong 2014 financial performance extends a multiyear track record of delivering competitively attractive revenue, earnings and free cash flow. Continued execution of our growth strategy is creating value for our customers and clients, complemented by our differentiated capabilities and innovative physician and customer engagement solutions. As a rapidly changing industry and economic environment continues to unfold and new challenges arise, we are positioned to capitalize on new growth opportunities while we continue to leverage our core businesses for growth. And by embracing change, we continue to position our company for successful investing in the future, preparing for significant new opportunities such as those we shared this morning for our Seniors segment, including in existing programs and markets, new market expansion, new offerings for health care professionals through our medical service organization solutions, new segments such as dual eligibles and new affinity programs such as HeyDay in Korea.
We expect to meet our growth objectives of 8% to 10% on average, doubling the size of our company again over the next 7 to 8 years. And based on our focused strategy, strong market positioning and ability to leverage capital, as well as further opportunities we have for growth, we expect to continue to deliver competitively attractive and sustained long-term EPS growth of 10% to 13% on average, all while continuing to invest back in our company.
And with that, I'll turn the call over to Tom."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone.In my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015.We had another strong year in 2014, with revenue growth of 8% and industry-leading earnings per share growth of 9% over 2013",2097,"Thanks, David. Good morning, everyone.
In my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015.
We had another strong year in 2014, with revenue growth of 8% and industry-leading earnings per share growth of 9% over 2013 results. 2014 represents our fifth consecutive year of consistently strong revenue, earnings and EPS growth; and attractive result both on an absolute and competitive basis. In addition, we continued to generate strong free cash flow in 2014, which resulted in approximately $1.6 billion being returned to shareholders through share repurchase. The strength of our 2014 performance provides us with a solid foundation for growth in 2015.
Now moving to operating results.
Our full year consolidated revenues grew 8% to $35 billion, driven by growth in each of our business segments and in our targeted markets. Earnings grew 3% to $2 billion, and earnings per share grew 9% to $7.43 in 2014. Our ability to grow revenue, earnings and EPS in a challenging operating environment reflects the strength of our underlying businesses and focused execution.
Regarding the segments, I will first comment on our Global Health Care segment. Overall, Global Health Care delivered another good year. 2014 premiums and fees grew 7% to $24.5 billion, reflecting growth in all of our Global Health Care businesses, including ongoing growth in our self-funded programs and specialty products. We ended 2014 with 14.5 million global medical customers, growing by approximately 380,000 customers or 3% for the year.
Full year earnings were $1.65 billion, reflecting business growth, specialty contributions, operating expense efficiency and effective medical cost management.
Turning to medical costs. We continue to deliver medical costs that reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. For our total U.S. commercial book of business, full year medical cost trend was slightly less than the low end of our previous range of 4.5% to 5.5% for 2014. Our commercial medical trend result continues our multiyear track record of industry-leading performance. And given that over 85% of our U.S. Commercial customers are in transfer and ASO funding arrangements, our clients directly benefit from these favorable medical costs.
Regarding medical care ratios. In our U.S. Commercial guaranteed cost business, our full year 2014 medical care ratio or MCR was 81.8% on a reported basis or 82.7% excluding prior year reserve development. Consistent with our expectations, our fourth quarter 2014 guaranteed cost MCR of 86.6% reflects an increased seasonal impact from the growing share of high-deductible plans in our employer group and individual businesses. We also expected and saw this increased seasonal impact across most of our Commercial business, including our stop loss and experience-rated businesses.
Overall, our employer risk businesses continued to deliver solid results in the quarter and throughout the year, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results in our individual business, while still below long-term expectations, continued to improve in the fourth quarter.
In our Government business, our full year 2014 MCR for Medicare Advantage was 83.5% on a reported basis or 84% excluding prior year reserve development, reflecting the impact of medical cost improvement initiatives implemented during 2014.
Moving to operating expenses for 2014. Our total Global Health Care operating expense ratio was 22%. This includes the impact of health reform-related taxes, which added 110 basis points to the expense ratio for the year. Overall, we've had another strong year in our Global Health Care business.
Now I'll discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability.
Premiums and fees grew 14% year-over-year in global supplemental. 2014 earnings in our Global Supplemental Benefits business were $230 million, reflecting attractive operating margins, continued strategic investments to drive future growth and nonrecurring favorable tax items of $21 million after tax recorded in the third quarter. Fourth quarter earnings of $33 million reflect claims seasonality, our funding of long-term strategic investments and the impact from the strengthening of the U.S. dollar.
For Group Disability and Life, full year results reflect premium and fee increase of 6% over 2013. 2014 earnings in our group business were $317 million and reflect favorable claim experience in our life business and a lower operating expense ratio.
For our Corporate and Other Operations, results totaled to an after-tax loss of $197 million for full year 2014.
Overall, our 2014 results reflect revenue earnings growth from each of our business segments and a significant free cash flow as the result of the continued effective execution of our strategy.
Turning to our investment portfolio. For 2014, we reported net realized investment gains of $106 million after tax, coupled with a strong net investment income result. The high quality and diversification of our investment portfolio continued to drive our overall investment results.
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to meet and exceed the expectations of our customers and clients by delivering affordable and personalized solutions, effectively deploying capital and targeting new and emerging opportunities where we will seek to drive additional value for our shareholders.
For full year 2015, we expect consolidated revenues to grow in a range of 8% to 10% over 2014, with continued growth across our targeted market segments. We expect full year 2015 consolidated adjusted income from operations to be in the range of $2.1 billion to $2.2 billion or $8 to $8.40 per share. As Will noted earlier, our full year 2015 consolidated and business segment adjusted income from operations, as well as earnings per share, estimates now exclude acquisition-related amortization expense.
In 2015, the impact of excluding acquisition-related amortization expense is approximately $0.40 per share or $100 million after tax, including $85 million in our Global Health Care business and $15 million in Global Supplemental Benefits. Lastly, consistent with prior practice, our outlook excludes any contribution from additional capital deployment as well as any prior-year claim development, which in 2014 totaled $53 million after tax.
Putting our 2015 outlook and our 2014 actual results on a comparable basis, that is adjusting for the reserve development reported in our 2014 results and adjusting to a consistent base with -- basis for reporting P&L amortization, our outlook for operating earnings in 2015 reflects 3% to 8% growth over 2014, and our outlook for EPS growth is 5% to 10% before considering the impact of additional capital deployment.
I will now discuss the components of our 2015 outlook, starting with Global Health Care. We expect full year Global Health Care earnings in the range of approximately $1.73 billion to $1.79 billion. This outlook reflects continued benefits from organic revenue growth, specialty contributions, effective medical cost management and operating expense efficiencies. This also includes our updated view of the annual enrollment period results for both Medicare and the public exchange business.
I'll now summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015, starting with our customer base. Regarding global medical customers, we expect 2015 customer growth of 1% to 3%. This growth is driven by expected ongoing growth in our Commercial employer business led by continued double-digit customer growth in our Select business, as well as mid- to upper single-digit growth in our Medicare Advantage customers, with some expected reduction in our non-ACA-compliant individual customers.
Turning to medical costs. Our 2015 outlook assumes some increase in medical utilization versus current levels, and this increase has been reflected in our pricing. For our total U.S. Commercial book of business, we expect full year medical cost trend to be in the range of 5% to 6%.
As Will noted earlier, we are changing the basis on which we provide guidance for MCRs to total Commercial and total Government. We believe this basis will provide better insight into our ability to effectively manage medical costs for our Commercial and Seniors customers. For our total Commercial book of business, we expect the 2015 medical care ratio to be in the range of 78% to 79%. This compares to our full year 2014 total Commercial MCR of 78.9% on an operating basis. For our total Government book of business, we expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%. This compares to our full year 2014 total Government MCR of 84.7% on an operating basis.
Regarding operating expenses, our 2015 Global Health Care operating expense ratio is expected to be in the range of 20.5% to 21.5%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.73 billion to $1.79 billion. We believe this is a competitively attractive result reflecting our focus on growing segments of the health care market and continued strong execution of our business strategy.
Now moving to the other components of our outlook.
For our Global Supplemental Benefits business, we continue to expect strong top line growth. We expect earnings in the range of $230 million to $250 million. This represents earnings growth of 3% to 12% after adjusting for $21 million of nonrecurring favorable tax items recognized in this segment in 2014. Regarding the Group Disability and Life business, we expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations, that is Other Operations and Corporate, we expect a loss of $180 million for 2015.
So all in, for full year 2015, we expect consolidated adjusted income from operations of $2.1 billion to $2.2 billion or $8.00 to $8.40 per share. Our outlook continues to exclude the impact of prior plan development or any future capital deployment. While we do not anticipate the impact of future capital deployment in our EPS outlook, we do expect the additional free cash flow that we generate will be deployed for the benefit of shareholders either through value-creating acquisitions or share repurchase.
Overall, these results represent a competitively attractive outlook and underscore the benefit of our diverse and differentiated portfolio of businesses. I would also note that due to the timing of some strategic investments as well as the growth of our Medicare Part D business, which traditionally reports low first quarter earnings, we expect our first quarter 2015 earnings will be lower than first quarter of 2014.
Now moving to our 2015 capital management position and outlook. Overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow to the parent, with a strong return on capital in each of our business segments. Our capital deployment strategy and priorities have not changed. These priorities are providing the capital necessary to support the growth of our ongoing operations; pursuing M&A activity with a focus on acquiring capabilities and scale to further grow in our targeted areas of focus; and after considering these first 2 items, we'll return capital to shareholders, primarily through share repurchase.
Regarding free cash flow. During 2014, we repurchased 18.5 million shares of stock for approximately $1.6 billion, and we ended the year with parent company cash of approximately $400 million. For full year 2015, we expect subsidiary dividends of approximately $1.7 billion, driven by strong performance in each of our business segments. After considering all sources and uses of parent company cash, including the funding of our recently announced acquisition of QualCare, this outlook implies we would have approximately $1.8 billion available for capital deployment in 2015, including approximately $115 million we deployed to repurchase 1.1 million shares from January 1 through February 4.
Our free cash flow outlook reflects the industry-leading margins and returns on capital in our businesses; and a high level of capital efficiency, particularly from our fee-based businesses. This capital efficiency allows us to fund attractive organic growth while continuing to generate significant free cash flow to be deployed for the benefit of shareholders.
Now to recap. Our full year 2014 consolidated results reflect the strength of our diversified portfolio of global businesses and a continued track record of effective execution of our focused strategy. The fundamentals of our business remain strong, as evidenced by strong growth in revenue and earnings, industry-leading medical costs and quality outcomes and continued strong free cash flow. Based on the strength of these results, we are confident on our ability to achieve our full year 2015 earnings outlook.
And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] The first question is from Justin Lake with JPMorgan.",11,"[Operator Instructions] The first question is from Justin Lake with JPMorgan."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, David, can you walk us through your view of initial 2015 guidance from the lens of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds, tailwinds, investment spending, et cetera that you see in",44,"First question, David, can you walk us through your view of initial 2015 guidance from the lens of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds, tailwinds, investment spending, et cetera that you see in '15."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. So first, the headlines. We're pleased with the 8% to 10% revenue outlook; continued growth of our well-positioned businesses; and as Tom noted, the 3% to 8% earnings growth on a same-store basis and the underlying 5% to 10% EPS growth on a",327,"Sure, Justin. So first, the headlines. We're pleased with the 8% to 10% revenue outlook; continued growth of our well-positioned businesses; and as Tom noted, the 3% to 8% earnings growth on a same-store basis and the underlying 5% to 10% EPS growth on a same-store basis. And as we've done in the past, we will continue to make ongoing investments in our company while seeking to generate an attractive and a competitively differentiated outcomes for our business. Also very importantly, all the numbers I just referenced exclude the impact of the $1.8 billion of deployable capital we'll have for 2015. As it relates to tailwinds, you can think about several tailwinds for us: clearly, the revenue and customer base growth, number one; two, expense leverage. We have a track record of continuing to generate efficiency gains and expense leverage, some of which we redeploy for the benefit of innovation. Third, ongoing specialty penetration. We have a good track record of driving further specialty penetration. And fourth, some improvement in the performance of our individual portfolio of businesses. As it relates to headwinds, you can think about a few: as we've discussed before, the impact of specialty pharma on the overall medical cost trend and specifically, for example, its impact on Seniors portfolio of business; two, as you know, another step-up in the industry tax. A portion of it, well, our assumptions are, will not pass through fully in the Medicare arena. And thirdly, for us, given our global nature, some FX impact into 2015. But taken as a whole, we feel good about the 2015 impact that we're able to generate here with growth, earnings and EPS growth; capital positioning; and then finally, Justin, the positioning this gives us for 2016, as we would expect to have further earnings accelerants off of the positioning we've taken relative to our Seniors business in that portfolio. So taken as a whole, we're pleased with the outlook for '15."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what -- your strategy around not including a",56,"And then David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what -- your strategy around not including any benefit from that $1.8 billion in the guidance going forward."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. We've really been quite transparent providing you updates each quarter, so stepping back, our capital deployment priorities are clear and unchanged: serve the existing needs of the corporation and support the underlying growth and investment",153,"Sure, Justin. We've really been quite transparent providing you updates each quarter, so stepping back, our capital deployment priorities are clear and unchanged: serve the existing needs of the corporation and support the underlying growth and investments; two, targeted and strategically attractive M&A; three, return to shareholders. And to your point, our track record demonstrates our preferred approach there is relative to share repurchase. And our objective is to provide you the transparency of what the free capital available for deployment and allow you to draw your judgments in terms of how you want to look at that. The headline here is really strong and well-performing balance sheet, really strong and well-positioned operating subsidiaries from an underlying capitalization level that provides the $1.8 billion available for deployment. And I would suggest you look at our track record relative to how effectively and how efficiently we've deployed that and we provide updates each quarter."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Matthew Borsch with Goldman Sachs.",10,"The next question is from Matthew Borsch with Goldman Sachs."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Could you talk to the drivers in your outlook for the global supplemental business? It seems like the growth rate, and maybe some of that is the impact of foreign currency, is lower than we might have expected for a typical year.",42,"Could you talk to the drivers in your outlook for the global supplemental business? It seems like the growth rate, and maybe some of that is the impact of foreign currency, is lower than we might have expected for a typical year."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Matt. It's Tom. Our Global Supplemental Benefits business has a track record of building strong revenue and earnings growth. And it's focused by leveraging the broad and innovative distribution and strong analytic and customer insight capabilities",141,"Thanks, Matt. It's Tom. Our Global Supplemental Benefits business has a track record of building strong revenue and earnings growth. And it's focused by leveraging the broad and innovative distribution and strong analytic and customer insight capabilities, and we saw that result in '14 and we're really seeing that result in '15 also. There are a few layers to the result in '15, though. Our outlook for 2015 earnings of $230 million to $250 million reflects continued strong operating margins; the continued funding of growth initiatives; and continued currency pressure, as you suggested, of about $10 million to $15 million after tax. So if you adjust for the $21 million onetime tax benefit reported in the '14, the deal amortization change and the impact of the currency pressure, the underlying growth for global supp is in the 8% to 18% range."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, okay, that makes more sense. And I'm sorry, did you give a revenue outlook on global supp for '15?",20,"Okay, okay, that makes more sense. And I'm sorry, did you give a revenue outlook on global supp for '15?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","No, we don't intend to provide revenue outlooks by business segment, but we're expecting continued strong revenue growth in global supp.",21,"No, we don't intend to provide revenue outlooks by business segment, but we're expecting continued strong revenue growth in global supp."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Joshua Raskin with Barclays.",9,"The next question is from Joshua Raskin with Barclays."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I want to talk a little about the public exchanges and the impact on the Commercial business. I guess, first, if you can help us size what the revenues were in public exchanges this year; and maybe what the impact on the overall Commercial MLR was; and th",60,"I want to talk a little about the public exchanges and the impact on the Commercial business. I guess, first, if you can help us size what the revenues were in public exchanges this year; and maybe what the impact on the overall Commercial MLR was; and then as a part of that, what assumptions you've made regarding the 3Rs."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Josh, it's David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs as well as the -- our positioning relative to the 3Rs. Consistent with our prior conve",180,"Josh, it's David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs as well as the -- our positioning relative to the 3Rs. Consistent with our prior conversations, we've positioned this book of business for 2014 as well as 2015. Our expectations is it will be a small portion of our overall franchise. Think of it, in order of magnitude, as we've talked about before, about 3% of the overall franchise revenue in terms of 2014. And we would expect it to be in the similar range in 2015, with some puts and takes in terms of the runoff of the grant part of the [ph] business and some growth on the -- on exchange business. So I think the headline here that's quite important is a small percentage of the overall portfolio that we've been seeking to manage in the context of the performance of the franchise. Tom, could you put a little more color on the MCR?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure. So Josh, the MCR dynamics in an individual have been improving over the course of the year. So also reflecting, of course, increased seasonality in the fourth quarter. It's just basically been improving from our initial expectations in the year. It'",244,"Sure. So Josh, the MCR dynamics in an individual have been improving over the course of the year. So also reflecting, of course, increased seasonality in the fourth quarter. It's just basically been improving from our initial expectations in the year. It's still a little higher than where we'd like to be. That improvement has been driven basically by both a better assessment of the early part of the year claims as they developed a little favorably and a little bit of an improvement in the run rate and, as you kind of suggested, the 3Rs. 
So just a couple of minutes on the 3Rs. Our year-end accrual for 3Rs now totals about $200 million after tax. The majority of the accrual continues to be related to the reinsurance element of the 3R program with risk adjusters representing the higher amount of the remaining balance and a smaller amount for risk quarter of recoveries. 
And I'll give you some more specific color on our approach. We have accrued reinsurance at the 80% coinsurance level consistent with the design of the program. We have not accrued any risk adjuster impact for our Texas business due to the current lack of industry data. And we accrued amounts under the risk quarter because we're comfortable with the statutes and administrative guidelines that support that program. 
So as you know, there's some interplay among each of these program elements. But overall, we're very comfortable with our total accrual."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So I guess more specifically, I think -- but I know it's a small portion, but obviously, the MLRs is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that these guys have moved the buckets around a little bit. But",184,"So I guess more specifically, I think -- but I know it's a small portion, but obviously, the MLRs is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that these guys have moved the buckets around a little bit. But I'm assuming there's an assumption of the public exchanges getting a little bit better. You've got the industry tax uptick, which assuming you price quarter [ph] is actually a little bit of a tailwind as well, and the guidance is for, let's call it 40 basis points of improvement at the midpoint. 
So are there -- I'm just trying if there's any other moving parts? My guess is you've got a little bit of a benefit on the hep C and Specialty Pharmacy from the new Gilead relationship announced yesterday. So I'm just -- is there anything underlying? Are you guys just basically assuming apples to apples on your total -- on your sort of commercial book flat type of MLRs with a couple of these moving parts that is helping you with a couple basis points?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, Josh, I think you've got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14. And it is driven by the items you mentioned that reflects continued good per",76,"Well, Josh, I think you've got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14. And it is driven by the items you mentioned that reflects continued good performance in our employer group business, some benefit from pricing for the incremental industry fee in 2015 and some improvements in individual. That essentially summarizes the major moving pieces."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And I'm sorry, did you guys quantify the FX headwind in the fourth quarter?",15,"Okay. And I'm sorry, did you guys quantify the FX headwind in the fourth quarter?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the fourth quarter, things had been moving around I'd say low single-digit million dollars impact. So I didn't before, but that's about the quantity.",25,"Well, the fourth quarter, things had been moving around I'd say low single-digit million dollars impact. So I didn't before, but that's about the quantity."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from A.J. Rice with UBS.",10,"The next question is from A.J. Rice with UBS."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It didn't -- it doesn't seem like we're hearing as much about it. But in your ASO book of business, did you see much attriti",72,"Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It didn't -- it doesn't seem like we're hearing as much about it. But in your ASO book of business, did you see much attrition? And can you just sort of comment on the state of play from your perspective in private exchanges at this point?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","It's David. Just a little color on our view and our positioning and then our results. First, and most -- we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourself in just about all",208,"It's David. Just a little color on our view and our positioning and then our results. First, and most -- we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourself in just about all of the various private exchanges that are in the marketplace today.  In addition to that, we have our own proprietary exchange and a dedicated leadership team managing the overall exchange activities. 
As it relates to outcomes to your point, there had been a lot of conversation in the market as we expected. But consistent with our prior dialogues, we did not expect to see a significant amount of movement in the overall landscape in the marketplace in '14 or '15, and that's what manifested for both the industry as a whole, as well as for ourselves. So specific to Cigna, some movement in both directions, but it all nets out to a de minimis amount of activity. 
Lastly, as we look to 2016, as I noted, we're well-positioned in the respective exchanges. We'll be actively engaged if target clients that, we believe, align very well with our value proposition, present good growth opportunities. But slow activity thus far in line with our expectations."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to -- for potential capital deployment opportunities, acquisitions. Are you thinking about that? Or are you looking -- what will be an attractive op",81,"Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to -- for potential capital deployment opportunities, acquisitions. Are you thinking about that? Or are you looking -- what will be an attractive opportunity for you? Is it something that just broadens your geography? Or you're looking for something that you think you can run better than it's currently being run? Maybe add some color on what would be attractive there."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, AJ. We've been very consistent relative to MA is, over the long term, a very attractive growth opportunity. And our view is that a sustainable MA program has 2 major dimensions, effective consumer engagement and personalization capabilities and then",181,"Sure, AJ. We've been very consistent relative to MA is, over the long term, a very attractive growth opportunity. And our view is that a sustainable MA program has 2 major dimensions, effective consumer engagement and personalization capabilities and then strong clinical partnership and physician engagement capabilities with the value-based reimbursement structure, which is what our model is. 
As it relates to capital employment, you hit the nail on the head. We see both organic geographic expansion opportunities, as well as inorganic geographic expansion opportunities. So that would be one, targeted geographies that are inorganically attractive. 
Second would be if you expand a little more broadly relative to seniors and the broader kind of population, additional capabilities or opportunities to serve the Medicare, Medicaid duals or other parts of the population we think are underserved. As I noted in my prepared remarks, we've seen good success in Texas, emerging success in Illinois, and we're going to seek to grow those programs. 
So those would be the 2 areas for capital deployment, geographic, as well as what we would call segment expansion."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Scott Fidel with Deutsche Bank.",10,"The next question is from Scott Fidel with Deutsche Bank."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, just wondering if you could drill into the Select growth, and it looks like the trajectories don't hack their double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market shift downstream into ASO i",75,"First question, just wondering if you could drill into the Select growth, and it looks like the trajectories don't hack their double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market shift downstream into ASO in terms of how much increased ASO market penetration you're seeing as -- and then as compared to some of the market share gains that you may be driving in that segment?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees, so that's our Select Segment. To your point, it has been and continues to be a very attractive growth segment for us, continuing to notch double",191,"Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees, so that's our Select Segment. To your point, it has been and continues to be a very attractive growth segment for us, continuing to notch double-digit customer base growth for us and something we're quite pleased with. 
Our approach to this base is somewhat different than the marketplace. So it's to be consultative and work with employers to design the right consumer engagement and benefit designs and network structures, and then offer multiple funding alternatives, one of which is, as you referenced, an ASO proposition that gives them much more transparency and tighter alignment. 
As you know, the overall employer landscape in the U.S. is not growing, shrinking up market, a little bit of growth down market. So there's little bit of growth. But net-net, we're taking share in this space and we tend to take share in this space from more traditionally designed financing alternatives for healthcare to more progressively design health engagement programs, incentive aligned programs that have a high degree of transparency, and the outlook area is very positive."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just on the follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then, just within RX, what type of impact year-over-year you think that the",55,"Okay. And then, just on the follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then, just within RX, what type of impact year-over-year you think that the new preferred partnership with Gilead for Harvoni could benefit?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So we're really pleased over the medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and buildi",100,"Scott, it's Tom. So we're really pleased over the medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and building on the very strong trends results we reported for several years. 
Our outlook for 2015 of 5% to 6% reflects some uptick in utilization and some increase in pharmacy trend, especially drug costs and, of course, some impacts from the flu. Components are generally in the mid-single-digit range with maybe pharmacy in the double-digit range."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, [indiscernible] it's your question relative to the specialty item. You're correct. We will see some impact -- a positive impact. But per prior discussions, our team is effectively manages the specialty drug component and specifically, the hep C spe",104,"Scott, [indiscernible] it's your question relative to the specialty item. You're correct. We will see some impact -- a positive impact. But per prior discussions, our team is effectively manages the specialty drug component and specifically, the hep C specialty component in 2014. We're pleased with the recent announcement we have with Gilead. And importantly, I would note that both organizations have committed to innovating a performance-based and an outcome-based component to the ongoing activities. So we're pleased with the overall development that transpired, but also the commitment of both organizations to collaborate on an outcome-based program for the benefit of customers as well."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Kevin Fischbeck with Bank of America Merrill Lynch.",13,"The next question is from Kevin Fischbeck with Bank of America Merrill Lynch."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, great. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally that the MLR was like 84.7%, that's x development, right? So you're basically saying MLR should be relatively flat to up in 2015 versus 2014? And",109,"Okay, great. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally that the MLR was like 84.7%, that's x development, right? So you're basically saying MLR should be relatively flat to up in 2015 versus 2014? And I guess, when I think about PDP coming in worse, I thought that you guys probably would have made some progress there next year. And then MA, obviously, you've got a funding gap, but it seemed like there was a lot that you were doing in 2014 to try to offset that. So just trying to understand how you think about the margins."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes, Kevin. It's Tom. And you've got the dynamics right. Our -- we've got an outlook of 84.5% to 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. And the picture, I th",109,"Yes, Kevin. It's Tom. And you've got the dynamics right. Our -- we've got an outlook of 84.5% to 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. 
And the picture, I think, is generally like this. We're generally expecting stable Medicare MCRs between Medicare Advantage and PDP with some mix impact actually driving the dynamic here as we're growing some of the higher MCR Medicaid business we have as a portion of the portfolio. Again, all in the margin, but that's generally the result. And I think the outlook calls, generally, for a stable result."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, I guess when you talk about accelerating the MA -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective off the kind of 6% to 8% that you're looking for this year in a membership basis",61,"Okay. And then, I guess when you talk about accelerating the MA -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective off the kind of 6% to 8% that you're looking for this year in a membership basis? Or is it margins? Is it both? How do we think about that?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with the outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both reve",120,"Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with the outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. 
As we look to 2016, we would expect to be able to grow both revenue, as well as margin. As I noted in my prepared remarks, we expect to see further improvement in the Stars Ratings, for example. And the positioning we took in 2015 was to position products in key markets within expectation, and what we saw was a step up in 2016 Stars. So we will see both revenue contribution going into 2016, as well as margin expansion contribution in 2016. Therefore, an earnings accelerant."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Christine Arnold with Cowen.",9,"The next question is from Christine Arnold with Cowen."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","A couple of this and thats. The CRomnibus exempted the expatriate businesses from the health insurance fee. Is there a quantifiable impact there?",23,"A couple of this and thats. The CRomnibus exempted the expatriate businesses from the health insurance fee. Is there a quantifiable impact there?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, good morning. It's David. First and foremost, there have been a variety of administrative release that took place post the passage of the bill back in 2012 and up to, as you referenced, the CRomnibus because the administration recognized that t",146,"Christine, good morning. It's David. First and foremost, there have been a variety of administrative release that took place post the passage of the bill back in 2012 and up to, as you referenced, the CRomnibus because the administration recognized that there was an unintended consequence to that business. We're pleased with the outcome from the CRomnibus, legislatively rectifying that for the benefit of global employers. 
And I would suggest to you the biggest impact here is taking away the administrative complexity that applying the ACA to the global employers expatriate benefit business would create, that was putting a burden on that business portfolio that we are managing, that's the biggest benefit. There's a small economic benefit, but that's the -- that's a few of the byline. The bigger piece is it cleans it up for purposes of global employers not to be exposed to that."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, can you talk about why first quarter '15 will be lower than first quarter '14 and give us some kind of order of magnitude on the factors? And then, do you think you need Medicaid in order to serve the duals? Or you're still kind of the v",61,"Okay. And then, can you talk about why first quarter '15 will be lower than first quarter '14 and give us some kind of order of magnitude on the factors? 
And then, do you think you need Medicaid in order to serve the duals? Or you're still kind of the view that you've got the portfolio you need for those duals?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. First, I'll address the first quarter in spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than the first quarter of 2014. And we attributed to 2 things, strategic investments and the growth",133,"Christine, it's Tom. First, I'll address the first quarter in spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than the first quarter of 2014. And we attributed to 2 things, strategic investments and the growth of our Part D business in the first quarter. 
On the strategic investment side, I think about additional start-up costs in Medicaid expansions, increased grant spend compared to 2014, and the Part D impact reflects both the first quarter pressure typical in Part D, given the benefit structure, we all know that Part D first quarter results tend to be low, and the impacts of the drug transition requirements for new customers. So all in, on a comparable basis, we're expecting first quarter '15 to be lower than first quarter '14."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's David. On your second part -- and pretty efficient working in multiple questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity",116,"Christine, it's David. On your second part -- and pretty efficient working in multiple questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity for us because we believe they're underserved as it relates to clinical care coordination. And our clinical programs actually play quite affectively there as noted in our Texas program. We're going to seek to grow those activities organically, and then opportunistically as we noted in our M&A priorities, opportunistically for geographic density. We will also look to dual capabilities from an M&A standpoint. So I would view that as both organic and inorganic opportunities for us."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Andy Schenker with Morgan Stanley.",10,"The next question is from Andy Schenker with Morgan Stanley."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So I just wanted from one of the earlier questions here for PDP specifically, the very last career highlights and pressures around specialty drugs and a higher brand mix, and maybe just how did that continue to play out or evolve in the fourth quarter? An",78,"So I just wanted from one of the earlier questions here for PDP specifically, the very last career highlights and pressures around specialty drugs and a higher brand mix, and maybe just how did that continue to play out or evolve in the fourth quarter? And then, your rates [ph] are pretty strong annual enrollment -- growth in the annual enrollment period, again, about 200,000-plus lives. So what are your expectations on those costs continuing into next year?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Andy. It's Tom. I'll start and then David will address some of the growth issues. So as you pointed out, PDP results do reflect higher drug cost in the fourth quarter and the full year. And that includes some impact from the mix in channel of drug",147,"Thanks, Andy. It's Tom. I'll start and then David will address some of the growth issues. So as you pointed out, PDP results do reflect higher drug cost in the fourth quarter and the full year. And that includes some impact from the mix in channel of drug purchases and some impact from specialty drugs, so both. 
We've taken actions to try and improve results here -- that will improve results here. We made network and formulary adjustments when we merged the HealthSpring and Cigna Part D plans for 2015, so that resulted in a leaner formulary and expanded utilization plan -- management for the merged plans, which we expect will improve cost. 
As you pointed out, we also expect some favorable impact from our recent agreement with Gilead on hep C drugs. But we have factored some ongoing pressure in Part D into our 2015 outlook."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Relative to growth, as Tom noted, we merged the HealthSpring and the legacy Cigna programs and sought to take the best of both organizations. For 2015, we -- our growth efforts, we're targeting the chooser population and we saw a very good traction in o",121,"Relative to growth, as Tom noted, we merged the HealthSpring and the legacy Cigna programs and sought to take the best of both organizations. 
For 2015, we -- our growth efforts, we're targeting the chooser population and we saw a very good traction in our sales efforts there. We'd note that our early results through January from a utilization and performance standpoint for the new population are in line with our expectation for that chooser population, meaning the aggregate utilization levels, importantly, the mix of utilization by generic and otherwise. And as Tom noted, we expect, generally speaking, stable MCRs going from 2014 to '15 for this portfolio. And again, it presents an opportunity for further earnings expansion looking into 2016."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And just maybe a -- changing gears a little bit to follow-up question here. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into it? Have you -- how much business do you guy",70,"And just maybe a -- changing gears a little bit to follow-up question here. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into it? Have you -- how much business do you guys have up for renewal to maybe versus an average year? And any opportunities out there that you guys really looking to target?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Andy. As you noted, it's early in the cycle. But to give you some color -- and again, when I give you color, just -- we'll define what we talk about in national account, so commercial employers with 5,000 or more employees that are multistate. We'",220,"Sure, Andy. As you noted, it's early in the cycle. But to give you some color -- and again, when I give you color, just -- we'll define what we talk about in national account, so commercial employers with 5,000 or more employees that are multistate. 
We're actually seeing a pretty robust pipeline of new opportunities unfold. So it's unfolding both meaningful scale and early in the cycle. So we're seeing a robust pipeline begin to unfold early in the cycle. And with an elevation -- a further elevation in intensity looking for what we call engagement and incentive-based programs, exploring a lot of the value-based network configuration and the like, which play very well to our strategy. 
As it relates to the last part of your question, the percent our book that's out to bid, we see a smaller percentage of our book that's out to bid for 2016 than we did prior year, and that's consistent with the dialogue we had last year. We indicated that we had an elevated percentage based on procurement cycle. So we managed through that queue pretty well for 2015. And now looking to 2016, while the smaller percentage of our book of business out to bid and, again, we're seeing a pretty nice robust pipeline beginning to unfold early in the cycle."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ralph Giacobbe with Crdit Suisse.",10,"The next question is from Ralph Giacobbe with Crdit Suisse."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? And you guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more move",53,"Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? And you guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more movement within the ASO segment amongst peers."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Ralph. It's David. As you know, the vast majority of our commercial business, U.S. commercial business, is ASO. So as we're able to grow our portfolio, the preponderance to that is ASO-oriented. I'd also note that our expectation, as the results u",135,"Sure, Ralph. It's David. As you know, the vast majority of our commercial business, U.S. commercial business, is ASO. So as we're able to grow our portfolio, the preponderance to that is ASO-oriented. 
I'd also note that our expectation, as the results unfold and in line with the guidance that Tom provided, the 1% to 3% customer growth, which excludes our QualCare network acquisition. 
We would expect that our guaranteed cost lives, or our risk lives, would decrease because of the run off of the individual non-ACA compliant lives, so very important. As we get into the year, we'll provide you more detail as that manifests itself. 
But net-net, you should think about our growth as being predominantly ASO-oriented, and that transcends through Select, the regional segment, et cetera. And we see good traction there."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just in terms of just the competitive environment for ASO broadly?",14,"Okay. And then, just in terms of just the competitive environment for ASO broadly?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the competitive environment -- maybe I'll flip it around a little bit the other way, and then try to answer your competitive environment -- the buying environment. So the client portfolio -- and we call them care with [ph] clients. Clients continu",181,"Well, the competitive environment -- maybe I'll flip it around a little bit the other way, and then try to answer your competitive environment -- the buying environment. 
So the client portfolio -- and we call them care with [ph] clients. Clients continue to seek what we call -- you might call alternative funding. We'll call it transparent funding. So the demand for more transparent funding continues to grow as employers are seeking to get alignment of incentives and better visibility through how their funds are being deployed and align the incentives for their employees or customers. And so that trend continues. So hence, the competitive environment, competitors are seeing more ASO activity as well for Cigna. 
That's good for us because we're extremely well-positioned in that environment from benefit design, the consultative nature. And very importantly, the employer reporting and insights that go along with that monthly, quarterly and annually to provide the guidance in terms of what's transpiring. So yes, elevation, but it's elevation because of the client demand, not competitive activity. And client demand continues to go up."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, that's fair. And then, second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect the incremental for 2015? And then, your Specialty is separate from that deal. Is there any timeline",62,"Okay, that's fair. And then, second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect the incremental for 2015? And then, your Specialty is separate from that deal. Is there any timeline or decision on whether you want to keep it that way or if you're exploring options at this point?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our",196,"Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our strong clinical outcomes, continued customer growth and strong earnings performance. And we continue to invest in that. 
So relative to your latter question on Specialty, we run our own Specialty operations within the organization. It's performing well. Our team continues to look to means to further expand and strengthen that, either through collaboration or otherwise. But we're investing in and continue to run that on our own. 
As for results, and per prior conversations, for 2014, our results tracked in line with our expectations. In fact, they tracked a little bit ahead of our expectations largely because of actions that we took around rate and pace of investments, the timing of that in an inherent level. So we actually are a little bit ahead of our track record for 2014. And for 2015, our overall targets for our pharmacy business are in line with our expectations, maybe slightly favorable for the overall franchise."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ana Gupte with Leerink Partners.",10,"The next question is from Ana Gupte with Leerink Partners."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I just wanted to follow-up on the Select and the ASO mix shift that moved from a stop loss perspective. So I'm trying to understand firstly whether the company that just do stop loss are competing on a bundled or an unbundled basis with all of you? And it",63,"I just wanted to follow-up on the Select and the ASO mix shift that moved from a stop loss perspective. So I'm trying to understand firstly whether the company that just do stop loss are competing on a bundled or an unbundled basis with all of you? And it looks like United and Aetna have started to play a bigger role here."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ana, it's David. First and foremost, as we've talked now for multiple years around the Select space and ASO, ASO stop loss, variety funding mechanisms, we believed, and it's proven out, we believe that there will be increasing demand. We believe that's a",271,"Ana, it's David. First and foremost, as we've talked now for multiple years around the Select space and ASO, ASO stop loss, variety funding mechanisms, we believed, and it's proven out, we believe that there will be increasing demand. We believe that's a result of the increasing competitive activity, and we believe to be successful without continuing to innovate. And that's what's transpiring in the marketplace. 
As it relates to standalone, if you'll stop loss players in this space, I don't see that as a primary competitive disruptor largely because of the impact of integration here. So if you step back, what makes these programs work is not a stop loss program. What makes these programs work is getting the benefit alignment laid out with the right incentives, the network configuration appropriate, the clinical programs aligned. For example, we have the ability, and we do, do on-site biometric screening, on-site coaching for a hundred like [ph] employer. That's a new model, to be able to do that and bring that on board for a client and identify the 1, 2 or 3 high-risk individuals who are not incurring costs today, but we need to engage clinically with. And integrating all of that with the ASO funding mechanism, stop loss when it makes sense for that employer, as well as the reporting, that's the core of our value proposition and we continue to see strong demand for that today and into the future. And we would expect, again, competitors to step into this space because there's a significant amount of demand. Key to us is the results we're delivering and ongoing innovation."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose anyway -- a while ago still hold?",36,"And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose anyway -- a while ago still hold?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ana, it's Tom. I would think about the standalone stop loss segment is a totally different market than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical costs. And the standalone",175,"Ana, it's Tom. I would think about the standalone stop loss segment is a totally different market than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical costs. And the standalone stop loss carriers typically don't have that feature. 
In addition, we do have some built-in advantages versus them. I mean, we already have this customer in our sights, so we have one set of acquisition costs that they have to pay incremental acquisition cost to secure this customer. And we have a lot better insight into the underlying claims data, so our ability to effectively approach the program is very superior. So we don't really find ourselves in what sometimes can be a hypercompetitive standalone stop loss market, not really a market we're computing in. We don't sell stop loss unless we write the underlying program. And when we're selling stop loss, it's part of an integrated package. So the competitive dynamics for the standalone market are very different than the competitive dynamics we see."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Peter Costa with Wells Fargo Securities.",11,"The next question is from Peter Costa with Wells Fargo Securities."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My question is also on the stop loss business. Is that business included in the commercial MLR that you're giving us now in the total commercial MLR?",27,"My question is also on the stop loss business. Is that business included in the commercial MLR that you're giving us now in the total commercial MLR?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes. Total commercial MLR will include all of our risk businesses in commercial.",13,"Yes. Total commercial MLR will include all of our risk businesses in commercial."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising in loss ratio on that book of business, so that it is not pulli",60,"So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising in loss ratio on that book of business, so that it is not pulling it down as much going forward?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes, Peter. I have to tell you, I haven't done that calculation. But obviously, we're not seeing it in the results, so I don't -- I think you might be missing a little -- something there. But just a couple of things. First, the loss ratio on stop loss i",192,"Yes, Peter. I have to tell you, I haven't done that calculation. But obviously, we're not seeing it in the results, so I don't -- I think you might be missing a little -- something there. 
But just a couple of things. First, the loss ratio on stop loss is lower than the average overall loss ratio, but the premium density in the other businesses is pretty high. So I'd be surprised if there was a one point impact, but we'll do that math. 
Second, on stop loss, we actually would expect some modest increase in the stop loss loss ratio as we continue to sell disproportionately in the lower end. And those customers tend to have a more premium density, so less of an expense factor in the result and a higher MCR. Again, very attractive MCR, so it's not like it's worse profitability. The bottom line margin is still very attractive for the -- that stop loss business. But the dynamics in the MLR are a little higher. So I would expect that there's marginal impact probably from this change, but I'll do a little more careful look at that."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Chris Rigg with Susquehanna Financial Group.",11,"The next question is from Chris Rigg with Susquehanna Financial Group."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Just wanted to come back to capital deployment again. And I heard your comments on Medicare Advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestic",54,"Just wanted to come back to capital deployment again. And I heard your comments on Medicare Advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestically? Or you still think international is kind of a better opportunity?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Chris, it's David. As it relates to inorganic capital deployment, we have 4 priorities and the 4 priorities have remained the same. These are not in order. These are the 4 priorities: Further global footprint, Medicare Advantage and dual capabilities, fur",97,"Chris, it's David. As it relates to inorganic capital deployment, we have 4 priorities and the 4 priorities have remained the same. These are not in order. These are the 4 priorities: Further global footprint, Medicare Advantage and dual capabilities, further our retail-based capabilities, and then what we call Go Deep bolt-on capabilities for our portfolio. So I wouldn't separate international as more than or less than for 2015 versus the last year. It was in our portfolio when we've been opportunistic and focused in terms of opportunities outside the U.S, as well as inside the U.S."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, my follow-up is just on sort of overall growth to the company, and specifically in the health care segment.  I mean, I'm just trying to figure out, you're growing your revenues 8% to 10%. Obviously, the bottom line isn't growing in line wi",124,"Okay. And then, my follow-up is just on sort of overall growth to the company, and specifically in the health care segment.  I mean, I'm just trying to figure out, you're growing your revenues 8% to 10%. Obviously, the bottom line isn't growing in line with that. Obviously, PPD is having an impact. But do you -- can you give us a sense for when you think you'll at least start to get some more leverage down the P&L? Is it -- is 2015 sort of the last truly difficult year and we should start to see some leverage next year? I know you're not going to give guidance. But just, again, big picture wise, just trying to figure out the trajectory of growth."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the direct answer to your question in a little more color is yes. A little more color is as we talked about the 2015 outlook, we're pleased with it with the 8% to 10% revenue growth outlook. And then, the 3-day percent earnings growth outlook on the",148,"Well, the direct answer to your question in a little more color is yes. A little more color is as we talked about the 2015 outlook, we're pleased with it with the 8% to 10% revenue growth outlook. And then, the 3-day percent earnings growth outlook on the same-store basis and the 5% to 10% EPS growth outlook without capital deployment. 
As we said, looking to 2016, we see margin expansion opportunities within the health care business. Margin expansion opportunities, specifically in the senior space, both for MA, as well as PDP. We see further margin expansion opportunities within our individual block of business where we've seen some improvement move from '14 to '15.  And then, we'll see further scale leverage beyond the ongoing fundamentals of our strong performing employer business. So margin expansion opportunities exists in 2016 and '17 and beyond, and we're quite excited about that."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Brian Wright with Sterne Agee.",10,"The next question is from Brian Wright with Sterne Agee."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And I apologize if I missed this, but could you give us some color on the number of PDP lives to be added in '15?",25,"And I apologize if I missed this, but could you give us some color on the number of PDP lives to be added in '15?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","We didn't, Brian. It's about -- we ended up one one [ph] in enrollment period. It's about 250,000 more lives than we had at the end of the year.",30,"We didn't, Brian. It's about -- we ended up one one [ph] in enrollment period. It's about 250,000 more lives than we had at the end of the year."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so thrilled to have that. But the conspiracy theorist in me looks at how you're reporting now, and you have another peer who's",77,"Okay. And then, just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so thrilled to have that. 
But the conspiracy theorist in me looks at how you're reporting now, and you have another peer who's been very vocal about kind of large-scale acquisition in this space, and you're kind of reporting segments very nicely that would make consolidating 2 models pretty easily. So just any comments on that."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Brian, I think you may be able to work for the NSA if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus one because there are different attribute",152,"Brian, I think you may be able to work for the NSA if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus one because there are different attributes within the government portfolio business versus the commercial business. And while we had alternatives, we believe that, that was more customer-friendly and provided the transparency to drive the dialogue on a go-forward basis. And as we have in the past, and as we are willing going forward basis, we'll try to give you as much color as possible in terms of the underlying drivers of the overall business portfolio. But this was an attempt to be, again, responsive to the market, but also maintaining appropriate amount of transparency and not go to a single loss ratio, but provide 2 loss ratios for the domestic health business."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from the Dave Windley with Jefferies.",10,"The next question is from the Dave Windley with Jefferies."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My question's on Medicare Advantage. David, wondering if through the AAP here and your changes in the mid-Atlantic market, specifically if your view is that those changes network, and to the extent they were benefit design as well are complete and set you",55,"My question's on Medicare Advantage. David, wondering if through the AAP here and your changes in the mid-Atlantic market, specifically if your view is that those changes network, and to the extent they were benefit design as well are complete and set you up for a more normal contribution from that market in 2016?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","In your comments, Dave, were pointed toward 2016, so put MA back in context. We're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth, the 6% to 8% customer growth. You're correct. You draw attention back to a market that we s",140,"In your comments, Dave, were pointed toward 2016, so put MA back in context. We're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth, the 6% to 8% customer growth. You're correct. You draw attention back to a market that we sought to do some repositioning in, and we're feeling the final impact of that, or a final meaningful impact to that repositioning in 2015 in terms of both the lack of life growth. So even in the 6% to 8%, the lack of life growth in that market is fully contemplated in the 6% to 8%. And we would expect, as we step into 2016, an opportunity to see improvement and performance there. So that's a contributor as we look to the future, but part of that repositioning is being felt in 2015."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then, sticking with that, is that also something that you think can have another positive impact to Stars Ratings when they come out later this year?",27,"And then, sticking with that, is that also something that you think can have another positive impact to Stars Ratings when they come out later this year?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Our organization has demonstrated significant improvement as far as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement goin",125,"Our organization has demonstrated significant improvement as far as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement going from '16 to '17. I'm not going to comment on individual market activities. But more importantly, our organization is highly focused on the intricacies of the Stars program. And importantly, making sure we're given the right service experience and clinical experience, both medical and pharmacy, for the benefit of our customers, and doing so in a way to move the Stars Rating up in 2017 to another step function off of the very attractive movement we made going to '16."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Our last question is from Michael Baker with Raymond James.",10,"Our last question is from Michael Baker with Raymond James."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enh",56,"David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enhanced engagement and strengthened guarantees, as well as some ben admin element that increases stickiness?"
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we call down market, so think about Select Segment and a portion of the regional employer portfolio. It's a single carrier,",246,"Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we call down market, so think about Select Segment and a portion of the regional employer portfolio. It's a single carrier, as you would expect, exchange alternative. The value prop -- so it's going to the value prop. The value prop is primarily to enable a further retail experience for individuals to get them more actively engaged in the selection of their personal benefits. And we know that when that transpires, whether through a private exchange or other mechanisms because we do this everyday without private exchanges, you get a higher level of awareness, a higher level of engagement, a higher level of ownership for the individual and their benefits and their understanding of what's the -- that's the primary mechanism. And then, you're able to drive the appropriate personalization or efficiency that works for them. So using your term, consumer engagement or personalization, there's a primary attribute there. 
As I noted previously though, we've expected this marketplace more broadly to unfold slowly and it is. Our team has seen some success. And we have a dedicated team of resources that will continue to focus on this, but we have not banked on, or are we banking on a significant step function in revenue customer lives or earnings growth here. Rather, we've positioned ourselves to have smart optionality to accept this [ph] market moves forward very positively."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","I'll now turn the call over to David Cordani for closing remarks.",13,"I'll now turn the call over to David Cordani for closing remarks."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna's strong fourth quarter and full year results reflect solid revenue and earnings contributions from each of our business segments. As an organization, we have o",173,"Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna's strong fourth quarter and full year results reflect solid revenue and earnings contributions from each of our business segments. As an organization, we have over 35,000 talented colleagues around the globe whose work exemplifies our mission of improving health, well-being and sense of security for the people we serve everyday. The momentum we generated off of another strong year in 2014, combined with our attractive growth opportunities give us confidence we will achieve our full year 2015 outlook. We plan to continue to leverage our proven business and core capabilities to drive meaningful growth in attractive new markets and segments, resulting in doubling of our revenue over the next 7 to 8 years. And we remain committed to achieving, on average, our annual EPS growth objective of 10% to 13% over the long term. 
We thank you for joining the call today and your continued interest in Cigna, and we look forward to continuing our conversations."
172899,253311656,755685,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days fol",68,"Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 1-800-945-4244 or (203) 369-3501. No passcode is required for the replay. 
Thank you for participating. We will now disconnect."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter and Full Year 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.We'll begin by turni",51,"Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter and Full Year 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.
We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",592,"Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks today, David and Tom will cover a number of topics, including Cigna's full year 2014 financial results as well as our financial outlook for 2015.
As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled ""adjusted income from operations"" and ""earnings per share"" on this same basis as the principal measures of performance for Cigna and our business segments. A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com.
In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC.
Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. First, please note that when we discuss the number of covered lives for our global medical customers, we will be doing so on a basis that excludes those individuals that were previously covered under Limited Benefits plans. As a reminder, we exited the Limited Benefits business as of December 31, 2013, as required by the Affordable Care Act regulation.
Second, please note that our definition of adjusted income from operations will change for 2015 reporting in that we will now exclude acquisition-related amortization expense from this operating measure. When we discuss our earnings outlook for 2015 today, it will be on a basis of adjusted income from operations that excludes acquisition-related amortization expense. This is a change compared to the basis on which 2014 results are reported and how we have previously provided our 2014 outlook. In 2015, the impact of excluding acquisition-related amortization expense is approximately $100 million after tax or $0.40 per share.
Third, beginning in 2015, we have simplified our guidance and disclosures for our medical care ratios or MCRs by reporting them on a basis of total Commercial and total Government. The total Commercial ratio encompasses all of our commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products, provided through guaranteed cost or experience-rated funding arrangements in both the United States and internationally. The total Government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses. To ease the transition, we have provided historical medical care ratios on these bases within our quarterly financial supplement that was posted in the Investor Relations section of cigna.com this morning.
Lastly, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or prior year development of medical costs. Our outlook also excludes the impact from our recently announced acquisition of QualCare, which we do not expect will have a material impact to our financial results in 2015.
And with that, I will turn the call over to David."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Will. Good morning, everyone, and thank you for joining our call today.To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers, cli",1743,"Thanks, Will. Good morning, everyone, and thank you for joining our call today.
To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers, clients and shareholders in the future. I will also illustrate more specifically how we are creating value in our Seniors business and leveraging our experience and success of that business to drive long-term growth. Then Tom will address our fourth quarter and full year 2014 financial performance in more detail as well as provide the specifics for our outlook for 2015 before we take your questions. And following the Q&A session, I'll wrap up the call with a few closing remarks.
We'll start with some highlights from the year.
Cigna's strong 2014 performance represents the fifth consecutive year of competitively attractive financial results. This outstanding track record of results is driven by the disciplined execution of our growth strategy, all while we continue to invest in new capabilities, expand our offerings and our geographic footprint. Over the past several years, in the face of a particularly challenging and dynamic environment, we have been focused and disciplined with targeted yet meaningful investments to drive innovation, including new clinical programs, aligned incentives for customers, expanded technologies and programs for health care professionals. We have done all this while delivering competitively differentiated results year in and year out.
The full year 2014 consolidated revenues increased 8% to $35 billion, with each business segment delivering strong growth over 2013. We reported adjusted income from operations for the full year of $2 billion or $7.43 per share, which represents a per share increase of 9% over 2013.
Our revenue and earnings performance reflect growth in all of our businesses over the course of the year, a year in which we also grew to more than 85 million customer relationships worldwide and where we continue to generate strong margins and significant free cash flow for the benefit of shareholders. These results position us to once again deliver competitively attractive revenue and earnings growth in 2015.
For 2015, our outlook of 8% to 10% revenue growth and 5% to 10% EPS growth, excluding reserve development recognized in 2014 as well as future capital deployment, reflects the focus and clarity of our strategy and continued strong performance of our team around the world. Tom will walk you through more specifics regarding our outlook later on the call.
Now I'd like to talk about how our guiding framework, global strategy and multiple avenues for growth have enabled our long track record of success and will drive ongoing future value creation.
Across our business, we operate in an ever-changing market landscape with diverse needs across customers, employers, health care professionals and governments. Moving [ph] in this market, we are meeting and exceeding the expectations of our customers and clients around the world by delivering affordable and personalized solutions. As we look to the future, we have built a growth framework to create ongoing value, leverage our differentiated capabilities for the benefit of our customers.
There are 3 components to this framework. First is leveraging our well-positioned existing portfolio of businesses to continue to generate attractive value for our customers and clients. We expect to double the size of our company over the next 7 to 8 years. This will result in an average annual revenue growth rate of 8% to 10%, largely driven by our existing portfolio and focused execution. This continues a track record that we have demonstrated over the last 5 years, and our 2015 outlook of 8% to 10% revenue growth is consistent with this goal.
The second component is targeted and effective capital deployment to create ongoing shareholder value. I would note that, over the past 5 years, we have effectively deployed capital through a balance of investments in our business portfolio, strategic M&A and share repurchase. A good recent example of this is our agreement to purchase QualCare Alliance Networks. This acquisition is directly aligned with our Go Deep and our physician partnership strategies.
Our businesses are generating high margins and are capital efficient, allowing us to both fund attractive organic growth and generate significant free cash flow. This free cash flow provides us with financial flexibility and the opportunity to deploy capital to create additional value for our shareholders. And given the health of our balance sheet and underlying capitalization level of our subsidiaries, we expect to have $1.8 billion of capital available for deployment in 2015.
The third component of our framework where we seek to drive additional value for our shareholders is through new and emerging opportunities. These opportunities include new distribution marketplaces such as public and private exchanges, geographic expansion such as new Medicare Advantage markets and international opportunities, and new buying [ph] segments and service expansion such as medical service organization offerings for the benefit of integrated health care professionals. We are well positioned to pursue each of these potentially attractive future growth opportunities that are aligned with our strategy. As such, we have dedicated resources to fuel future expansion in these areas.
To illustrate how we are leveraging this framework to create value, I'll highlight how this framework applies to our Seniors business. This market segment includes a population with a variety of complex needs, requiring customer engagement and incentive-based clinical resources and programs to drive ongoing success. Our Seniors business pioneered successful physician engagement models, including aligned incentives and collaborative relationships to drive high-quality and a more affordable health care experience for both customers as well as physicians. As we continue to leverage our core physician engagement capabilities across all of our health services businesses, we are focused on key investments that improve affordability, enhance personalized services and drive better clinical outcomes. For example, the strategic investments we're making to enhance our physician insight and data tools will enable our clinical data to be accessible in a real-time fashion for more of our physician partners as well as our service teams. Enabled by our physician engagement model, seniors continue to find our Cigna HealthSpring benefit offerings increasingly compelling. And we expect to have 6% to 8% Medicare Advantage customer growth in 2015.
As for positioning, we continue to be amongst the top 3 players in market share for all of our established markets, and we are posting attractive growth in our newer markets. In 2014, we expanded our Seniors business into Georgia and the Carolinas, where we successfully leveraged existing Cigna commercial networks to develop and implement engaged physician relationships for seniors. Importantly, the quality of care delivered through our engaged physician groups is reflected in our stars ratings, where we increased our membership in 4-star or higher plans from approximately 40% to nearly 60% in 2016. Looking to 2017, we again expect to deliver an increase in this result. These improvements in star ratings have allowed us to enhance our benefit offerings and position our Seniors business to be an earnings accelerant in 2016 and beyond.
Relative to our expanding opportunities, we currently operate Medicaid into eligible plans in Texas and in the Illinois markets. Here, we are leveraging our care coordination capabilities to serve the dual-eligible population within our Medicaid platform. Focusing our growth efforts on improving care for the underserved, including the dual-eligible and aged, blind and disabled populations, complements our proven experience with complex care coordinations, differentiated clinical outcomes and affordability focus. While our Illinois plan is relatively new, having just begun in 2014, our Texas plan has been in operation since 2011 and has a track record of delivering affordable care and better health outcomes. In a testament of our commitment to servicing these customers, our Texas plan recently was acknowledged by the Medicaid Health Plans of America for our cutting-edge, intensive behavioral health programs.
We are well-positioned and have the capital flexibility to pursue these accelerating geographic and market segment expansion opportunities, either organically or through M&A, as Seniors remains a strategic growth priority for us. As a global company, our efforts to leverage these capabilities have also expanded across key markets beyond the United States. In Korea, for example, where the aged population is seeking new solutions to meet their emerging needs, we've developed an innovative and new health membership program targeting seniors known as Heyday. This organically built affinity program delivers value-added services directly to seniors in Korea. And while only a year into this expansion, we now serve more than 300,000 Korean seniors. So overall, we have a clear strategy and the capabilities to deliver value and improve the health and well-being of senior customers today and into the future.
Whether in our Seniors business as we discussed today or other growth businesses we have addressed in previous calls, we will continue to deliver attractive growth, produce and deploy capital effectively, and invest and position ourselves to win in new and emerging markets and segments.
Now to summarize my comments before Tom offers more detail on our 2014 results and expectations for 2015.
Cigna's strong 2014 financial performance extends a multiyear track record of delivering competitively attractive revenue, earnings and free cash flow. Continued execution of our growth strategy is creating value for our customers and clients, complemented by our differentiated capabilities and innovative physician and customer engagement solutions. As a rapidly changing industry and economic environment continues to unfold and new challenges arise, we are positioned to capitalize on new growth opportunities while we continue to leverage our core businesses for growth. And by embracing change, we continue to position our company for successful investing in the future, preparing for significant new opportunities such as those we shared this morning for our Seniors segment, including: in existing programs and markets, new market expansion, new offerings for health care professionals through our medical service organization solutions, new segments such as dual eligibles and new affinity programs such as HeyDay in Korea.
We expect to meet our growth objectives of 8% to 10% on average, doubling the size of our company again over the next 7 to 8 years. And based on our focused strategy, strong market positioning and ability to leverage capital, as well as further opportunities we have for growth, we expect to continue to deliver competitively attractive and sustained long-term EPS growth of 10% to 13% on average, all while continuing to invest back in our company.
And with that, I'll turn the call over to Tom."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone.In my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015.We had another strong year in 2014, with revenue growth of 8% and industry-leading earnings per share growth of 9% over 2013",2099,"Thanks, David. Good morning, everyone.
In my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015.
We had another strong year in 2014, with revenue growth of 8% and industry-leading earnings per share growth of 9% over 2013 results. 2014 represents our fifth consecutive year of consistently strong revenue, earnings and EPS growth -- an attractive result both on an absolute and competitive basis. In addition, we continued to generate strong free cash flow in 2014, which resulted in approximately $1.6 billion being returned to shareholders through share repurchase. The strength of our 2014 performance provides us with a solid foundation for growth in 2015.
Now moving to operating results.
Our full year consolidated revenues grew 8% to $35 billion, driven by growth in each of our business segments and in our targeted markets. Earnings grew 3% to $2 billion, and earnings per share grew 9% to $7.43 in 2014. Our ability to grow revenue, earnings and EPS in a challenging operating environment reflects the strength of our underlying businesses and focused execution.
Regarding the segments, I will first comment on our Global Health Care segment. Overall, Global Health Care delivered another good year. 2014 premiums and fees grew 7% to $24.5 billion, reflecting growth in all of our Global Health Care businesses, including ongoing growth in our self-funded programs and specialty products. We ended 2014 with 14.5 million global medical customers, growing by approximately 380,000 customers or 3% for the year.
Full year earnings were $1.65 billion, reflecting business growth, specialty contributions, operating expense efficiency and effective medical cost management.
Turning to medical costs. We continue to deliver medical costs that reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. For our total U.S. commercial book of business, full year medical cost trend was slightly less than the low end of our previous range of 4.5% to 5.5% for 2014. Our commercial medical trend result continues our multiyear track record of industry-leading performance. And given that over 85% of our U.S. Commercial customers are in transfer and ASO funding arrangements, our clients directly benefit from these favorable medical costs.
Regarding medical care ratios. In our U.S. Commercial guaranteed cost business, our full year 2014 medical care ratio or MCR was 81.8% on a reported basis or 82.7% excluding prior year reserve development. Consistent with our expectations, our fourth quarter 2014 guaranteed cost MCR of 86.6% reflects an increased seasonal impact from the growing share of high-deductible plans in our employer group and individual businesses. We also expected and saw this increased seasonal impact across most of our Commercial business, including our stop loss and experience-rated businesses.
Overall, our employer risk businesses continued to deliver solid results in the quarter and throughout the year, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results in our individual business, while still below long-term expectations, continued to improve in the fourth quarter.
In our Government business, our full year 2014 MCR for Medicare Advantage was 83.5% on a reported basis or 84% excluding prior year reserve development, reflecting the impact of medical cost improvement initiatives implemented during 2014.
Moving to operating expenses for 2014. Our total Global Health Care operating expense ratio was 22%. This includes the impact of health reform-related taxes, which added 110 basis points to the expense ratio for the year. Overall, we've had another strong year in our Global Health Care business.
Now I'll discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability.
Premiums and fees grew 14% year-over-year in global supplemental. 2014 earnings in our Global Supplemental Benefits business were $230 million, reflecting attractive operating margins, continued strategic investments to drive future growth and nonrecurring favorable tax items of $21 million after tax recorded in the third quarter. Fourth quarter earnings of $33 million reflect claims seasonality, our funding of long-term strategic investments and the impact from the strengthening of the U.S. dollar.
For Group Disability and Life, full year results reflect premium and fee increase of 6% over 2013. 2014 earnings in our group business were $317 million and reflect favorable claim experience in our Life business and a lower operating expense ratio.
For our Corporate and Other Operations, results totaled to an after-tax loss of $197 million for full year 2014.
Overall, our 2014 results reflect revenue earnings growth from each of our business segments and a significant free cash flow as the result of the continued effective execution of our strategy.
Turning to our investment portfolio. For 2014, we reported net realized investment gains of $106 million after tax, coupled with a strong net investment income result. The high quality and diversification of our investment portfolio continued to drive our overall investment results.
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to meet and exceed the expectations of our customers and clients by delivering affordable and personalized solutions, effectively deploying capital and targeting new and emerging opportunities where we will seek to drive additional value for our shareholders.
For full year 2015, we expect consolidated revenues to grow in a range of 8% to 10% over 2014, with continued growth across our targeted market segments. We expect full year 2015 consolidated adjusted income from operations to be in the range of $2.1 billion to $2.2 billion or $8 to $8.40 per share. As Will noted earlier, our full year 2015 consolidated and business segment adjusted income from operations, as well as earnings per share estimates, now exclude acquisition-related amortization expense.
In 2015, the impact of excluding acquisition-related amortization expense is approximately $0.40 per share or $100 million after tax, including $85 million in our Global Health Care business and $15 million in Global Supplemental Benefits. Lastly, consistent with prior practice, our outlook excludes any contribution from additional capital deployment as well as any prior-year claim development, which in 2014 totaled $53 million after tax.
Putting our 2015 outlook and our 2014 actual results on a comparable basis, that is adjusting for the reserve development reported in our 2014 results and adjusting to a consistent base with -- basis for reporting deal amortization, our outlook for operating earnings in 2015 reflects 3% to 8% growth over 2014, and our outlook for EPS growth is 5% to 10% before considering the impact of additional capital deployment.
I will now discuss the components of our 2015 outlook, starting with Global Health Care. We expect full year Global Health Care earnings in the range of approximately $1.73 billion to $1.79 billion. This outlook reflects continued benefits from organic revenue growth, specialty contributions, effective medical cost management and operating expense efficiencies. This also includes our updated view of the annual enrollment period results for both Medicare and the public exchange business.
I'll now summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015, starting with our customer base. Regarding global medical customers, we expect 2015 customer growth of 1% to 3%. This growth is driven by expected ongoing growth in our Commercial employer business led by continued double-digit customer growth in our Select business, as well as mid- to upper single-digit growth in our Medicare Advantage customers, with some expected reduction in our non-ACA-compliant individual customers.
Turning to medical costs. Our 2015 outlook assumes some increase in medical utilization versus current levels, and this increase has been reflected in our pricing. For our total U.S. Commercial book of business, we expect full year medical cost trends to be in the range of 5% to 6%.
As Will noted earlier, we are changing the basis on which we provide guidance for MCRs to total Commercial and total Government. We believe this basis will provide better insight into our ability to effectively manage medical costs for our Commercial and Seniors customers. For our total Commercial book of business, we expect the 2015 medical care ratio to be in the range of 78% to 79%. This compares to our full year 2014 total Commercial MCR of 78.9% on an operating basis. For our total Government book of business, we expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%. This compares to our full year 2014 total Government MCR of 84.7% on an operating basis.
Regarding operating expenses, our 2015 Global Health Care operating expense ratio is expected to be in the range of 20.5% to 21.5%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.73 billion to $1.79 billion. We believe this is a competitively attractive result reflecting our focus on growing segments of the health care market and continued strong execution of our business strategy.
Now moving to the other components of our outlook.
For our Global Supplemental Benefits business, we continue to expect strong top line growth. We expect earnings in the range of $230 million to $250 million. This represents earnings growth of 3% to 12% after adjusting for $21 million of nonrecurring favorable tax items recognized in this segment in 2014. Regarding the Group Disability and Life business, we expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations, that is Other Operations and Corporate, we expect a loss of $180 million for 2015.
So all in, for full year 2015, we expect consolidated adjusted income from operations of $2.1 billion to $2.2 billion or $8.00 to $8.40 per share. Our outlook continues to exclude the impact of prior year claim development or any future capital deployment. While we do not anticipate the impact of future capital deployment in our EPS outlook, we do expect the additional free cash flow that we generate will be deployed for the benefit of shareholders either through value-creating acquisitions or share repurchase.
Overall, these results represent a competitively attractive outlook and underscore the benefit of our diverse and differentiated portfolio of businesses. I would also note that due to the timing of some strategic investments, as well as the growth of our Medicare Part D business, which traditionally reports low first quarter earnings, we expect our first quarter 2015 earnings will be lower than first quarter of 2014.
Now moving to our 2015 capital management position and outlook. Overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow to the parent, with a strong return on capital in each of our business segments. Our capital deployment strategy and priorities have not changed. These priorities are: providing the capital necessary to support the growth of our ongoing operations; pursuing M&A activity with a focus on acquiring capabilities and scale to further grow in our targeted areas of focus; and after considering these first 2 items, we'll return capital to shareholders, primarily through share repurchase.
Regarding free cash flow. During 2014, we repurchased 18.5 million shares of stock for approximately $1.6 billion, and we ended the year with parent company cash of approximately $400 million. For full year 2015, we expect subsidiary dividends of approximately $1.7 billion, driven by strong performance in each of our business segments. After considering all sources and uses of parent company cash, including the funding of our recently announced acquisition of QualCare, this outlook implies we would have approximately $1.8 billion available for capital deployment in 2015, including approximately $115 million we deployed to repurchase 1.1 million shares from January 1 through February 4.
Our free cash flow outlook reflects the industry-leading margins and returns on capital in our businesses, and a high level of capital efficiency, particularly from our fee-based businesses. This capital efficiency allows us to fund attractive organic growth while continuing to generate significant free cash flow to be deployed for the benefit of shareholders.
Now to recap. Our full year 2014 consolidated results reflect the strength of our diversified portfolio of global businesses and a continued track record of effective execution of our focused strategy. The fundamentals of our business remain strong, as evidenced by strong growth in revenue and earnings, industry-leading medical costs and quality outcomes, and continued strong free cash flow. Based on the strength of these results, we are confident on our ability to achieve our full year 2015 earnings outlook.
And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] The first question is from Justin Lake with JPMorgan.",11,"[Operator Instructions] The first question is from Justin Lake with JPMorgan."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, David, can you walk us through your view of initial 2015 guidance from the lens of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds, tailwinds, investment spending, et cetera that you see in",44,"First question, David, can you walk us through your view of initial 2015 guidance from the lens of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds, tailwinds, investment spending, et cetera that you see in '15."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. So first, the headlines. We're pleased with the 8% to 10% revenue outlook and continued growth of our well-positioned businesses; as Tom noted, the 3% to 8% earnings growth on a same-store basis; and the underlying 5% to 10% EPS growth on a",327,"Sure, Justin. So first, the headlines. We're pleased with the 8% to 10% revenue outlook and continued growth of our well-positioned businesses; as Tom noted, the 3% to 8% earnings growth on a same-store basis; and the underlying 5% to 10% EPS growth on a same-store basis. And as we've done in the past, we will continue to make ongoing investments in our company while seeking to generate an attractive and competitively differentiated outcomes for our business. Also very importantly, all the numbers I just referenced exclude the impact of the $1.8 billion of deployable capital we'll have for 2015. As it relates to tailwinds, you can think about several tailwinds for us: clearly, the revenue and customer base growth, number one; two, expense leverage -- we have a track record of continuing to generate efficiency gains and expense leverage, some of which we redeploy for the benefit of innovation. Third, ongoing specialty penetration. We have a good track record of driving further specialty penetration. And fourth, some improvement in the performance of our individual portfolio of businesses. As it relates to headwinds, you can think about a few: as we've discussed before, the impact of specialty pharma on the overall medical cost trend and specifically, for example, its impact on Seniors portfolio of business; two, as you know, another step-up in the industry tax -- a portion of it, our assumptions are, will not pass through fully in the Medicare arena. And thirdly, for us, given our global nature, some FX impact into 2015. But taken as a whole, we feel good about the 2015 impact that we're able to generate here with growth, earnings and EPS growth; capital positioning; and then finally, Justin, the positioning this gives us for 2016, as we would expect to have further earnings accelerants off of the positioning we've taken relative to our Seniors business in that portfolio. So taken as a whole, we're pleased with the outlook for '15."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what -- your strategy around not including a",56,"And then David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what -- your strategy around not including any benefit from that $1.8 billion in the guidance going forward."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. We've always been quite transparent providing the updates each quarter, so stepping back, our capital deployment priorities are clear and unchanged: serve the existing needs of the corporation and support the underlying growth and investment",153,"Sure, Justin. We've always been quite transparent providing the updates each quarter, so stepping back, our capital deployment priorities are clear and unchanged: serve the existing needs of the corporation and support the underlying growth and investments; two, targeted and strategically attractive M&A; three, return to shareholders. And to your point, our track record demonstrates our preferred approach there is relative to share repurchase. And our objective is to provide you the transparency of what the free capital available for deployment and allow you to draw your judgments in terms of how you want to look at that. The headline here is really strong and well-performing balance sheet, really strong and well-positioned operating subsidiaries from an underlying capitalization level that provides the $1.8 billion available for deployment. And I would suggest you look at our track record relative to how effectively and how efficiently we've deployed that and we provide updates each quarter."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Matthew Borsch with Goldman Sachs.",10,"The next question is from Matthew Borsch with Goldman Sachs."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Could you talk to the drivers in your outlook for the global supplemental business? It seems like the growth rate, and maybe some of that is the impact of foreign currency, is lower than we might have expected for a typical year.",42,"Could you talk to the drivers in your outlook for the global supplemental business? It seems like the growth rate, and maybe some of that is the impact of foreign currency, is lower than we might have expected for a typical year."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Matt. It's Tom. Our Global Supplemental Benefits business has a track record of building strong revenue and earnings growth. And it's focused by leveraging the broad and innovative distribution and strong analytic and customer insight capabilities",139,"Thanks, Matt. It's Tom. Our Global Supplemental Benefits business has a track record of building strong revenue and earnings growth. And it's focused by leveraging the broad and innovative distribution and strong analytic and customer insight capabilities. We saw that result in '14 and we're really seeing that result in '15 also. There are a few layers to the result in '15, though. Our outlook for 2015 earnings of $230 million to $250 million reflects continued strong operating margins; the continued funding of growth initiatives; and continued currency pressure, as you suggested, of about $10 million to $15 million after tax. So if you adjust for the $21 million onetime tax benefit reported in '14, the deal amortization change and the impact of the currency pressure, the underlying growth for global supp is in the 8% to 18% range."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, okay, that makes more sense. And I'm sorry, did you give a revenue outlook on global supp for '15?",20,"Okay, okay, that makes more sense. And I'm sorry, did you give a revenue outlook on global supp for '15?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","No, we don't intend to provide revenue outlooks by business segment, but we're expecting continued strong revenue growth in global supp.",21,"No, we don't intend to provide revenue outlooks by business segment, but we're expecting continued strong revenue growth in global supp."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Joshua Raskin with Barclays.",9,"The next question is from Joshua Raskin with Barclays."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I want to talk a little about the public exchanges and the impact on the Commercial business. I guess, first, if you could help us size what the revenues were in public exchanges this year; and maybe what the impact on the overall Commercial MLR was; and",60,"I want to talk a little about the public exchanges and the impact on the Commercial business. I guess, first, if you could help us size what the revenues were in public exchanges this year; and maybe what the impact on the overall Commercial MLR was; and then as a part of that, what assumptions you've made regarding the 3Rs."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Josh, it's David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs as well as the -- our positioning relative to the 3Rs. Consistent with our prior conve",175,"Josh, it's David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs as well as the -- our positioning relative to the 3Rs. Consistent with our prior conversations, we've positioned this book of business for 2014 as well as 2015. Our expectations is it will be a small portion of our overall franchise. Think of it, in order of magnitude, as we've talked about before, about 3% of the overall franchise revenue in terms of 2014. And we would expect it to be in the similar range in 2015, with some puts and takes in terms of the runoff of the grandfathered business and some growth on the on exchange business. So I think the headline here that's quite important is a small percentage of the overall portfolio that we've been seeking to manage in the context of the performance of the franchise. Tom, could you put a little more color on the MCR?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure. So Josh, the MCR dynamics in individual have been improving over the course of the year. So also reflecting, of course, increased seasonality in the fourth quarter. It's just basically been improving from our initial expectations in the year. It's s",242,"Sure. So Josh, the MCR dynamics in individual have been improving over the course of the year. So also reflecting, of course, increased seasonality in the fourth quarter. It's just basically been improving from our initial expectations in the year. It's still a little higher than where we'd like to be. That improvement has been driven basically by both a better assessment of the early part of the year claims as they developed a little favorably and a little bit of an improvement in the run rate and, as you kind of suggested, the 3Rs. So just a couple of minutes on the 3Rs. Our year-end accrual for 3Rs now totals about $200 million after tax. The majority of the accrual continues to be related to the reinsurance element of the 3R program, with risk adjusters representing the higher amount of the remaining balance and a smaller amount for risk corridor recoveries. And I'll give you some more specific color on our approach. We have accrued reinsurance at the 80% coinsurance level consistent with the design of the program. We have not accrued any risk adjuster impact for our Texas business due to the current lack of industry data. And we accrued amounts under the risk corridor because we're comfortable with the statutes and administrative guidelines that support that program. So as you know, there's some interplay among each of these program elements, but overall, we're very comfortable with our total accrual."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So I guess more specifically, think about -- I know it's a small portion, but obviously, the MLR is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that you guys have moved the buckets around a little bit. But I'",182,"So I guess more specifically, think about -- I know it's a small portion, but obviously, the MLR is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that you guys have moved the buckets around a little bit. But I'm assuming there's an assumption of the public exchanges getting a little bit better. You've got the industry tax uptick, which assuming you priced for it, is actually a little bit of a tailwind as well, and the guidance is for, let's call it 40 basis points of improvement at the midpoint. So are there -- I'm just trying to think if there's any other moving parts? My guess is you've got a little bit of a benefit on the hep C and Specialty Pharmacy from the new Gilead relationship announced yesterday. So I'm just -- is there anything underlying? Are you guys just basically assuming apples to apples on your total -- on your sort of commercial book flat type of MLRs with a couple of these moving parts helping you a couple basis points?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, Josh, I think you've got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14. And it is driven by the items you mentioned. It reflects continued good perf",77,"Well, Josh, I think you've got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14. And it is driven by the items you mentioned. It reflects continued good performance in our employer group business, some benefit from pricing for the incremental industry fee in 2015 and some improvements in individual. And that essentially summarizes the major moving pieces."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And I'm sorry, did you guys quantify the FX headwind in the fourth quarter?",15,"Okay. And I'm sorry, did you guys quantify the FX headwind in the fourth quarter?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, in the fourth quarter, things have been moving around. I'd say low single-digit million dollars impact. So I didn't before, but that's about the quantity.",26,"Well, in the fourth quarter, things have been moving around. I'd say low single-digit million dollars impact. So I didn't before, but that's about the quantity."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from A.J. Rice with UBS.",10,"The next question is from A.J. Rice with UBS."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It didn't -- it doesn't seem like we're hearing as much about it. But in your ASO book of business, did you see much attriti",72,"Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It didn't -- it doesn't seem like we're hearing as much about it. But in your ASO book of business, did you see much attrition? And can you just sort of comment on the state of play from your perspective in private exchanges at this point?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","It's David. Just a little color on our view and our positioning and then our results. First, and most -- we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourself in just about all",209,"It's David. Just a little color on our view and our positioning and then our results. First, and most -- we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourself in just about all of the various private exchanges that are in the marketplace today. In addition to that, we have our own proprietary exchange and a dedicated leadership team managing the overall exchange activities. As it relates to outcomes to your point, there had been a lot of conversation in the market as we expected. But consistent with our prior dialogues, we did not expect to see a significant amount of movement in the overall landscape in the marketplace in '14 or '15, and that's what manifested for both the industry as a whole, as well as for ourselves. So specific to Cigna, some movement in both directions, but it all nets out to a de minimis amount of activity. Lastly, as we look to 2016, as I noted, we're well-positioned in the respective exchanges. We'll be actively engaged if -- target clients that, we believe, align very well with our value proposition, present good growth opportunities. But slow activity thus far in line with our expectations."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to -- for potential capital deployment opportunities, acquisitions. And thinking about that, are you looking -- what would be an attractive opportun",77,"Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to -- for potential capital deployment opportunities, acquisitions. And thinking about that, are you looking -- what would be an attractive opportunity for you? Something that just broadens your geography? Or you're looking for something that you think you can run better than it's currently being run? Maybe add some color on what would be attractive there."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, AJ. We've been very consistent relative to MA is, over the long term, a very attractive growth opportunity. And our view is that a sustainable MA program has 2 major dimensions; effective consumer engagement and personalization capabilities and then",180,"Sure, AJ. We've been very consistent relative to MA is, over the long term, a very attractive growth opportunity. And our view is that a sustainable MA program has 2 major dimensions; effective consumer engagement and personalization capabilities and then strong clinical partnership and physician engagement capabilities with A value-based reimbursement structure, which is what our model is. As it relates to capital employment, you hit the nail on the head. We see both organic geographic expansion opportunities, as well as inorganic geographic expansion opportunities. So that would be one, targeted geographies that are inorganically attractive. Second would be if you expand a little more broadly relative to Seniors and the broader chronic population, additional capabilities or opportunities to serve the Medicare, Medicaid duals or other parts of the population we think are underserved. As I noted in my prepared remarks, we've seen good success in Texas, emerging success in Illinois, and we're going to seek to grow those programs. So those would be the 2 areas for capital deployment: geographic; as well as what we would call segment expansion."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Scott Fidel with Deutsche Bank.",10,"The next question is from Scott Fidel with Deutsche Bank."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, just wondering if you could drill into the Select growth, and it looks like the trajectory's still intact there -- double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market shift downstream into",76,"First question, just wondering if you could drill into the Select growth, and it looks like the trajectory's still intact there -- double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market shift downstream into ASO in terms of how much increased ASO market penetration you're seeing as -- and then as compared to some of the market share gains that you may be driving in that segment?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees, so that's our Select Segment. To your point, it has been and continues to be a very attractive growth segment for us, continuing to notch double",190,"Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees, so that's our Select Segment. To your point, it has been and continues to be a very attractive growth segment for us, continuing to notch double-digit customer base growth for us and something we're quite pleased with. Our approach to this base is somewhat different than the marketplace. So it's to be consultative and work with employers to design the right consumer engagement and benefit designs and network structures, and then offer multiple funding alternatives, one of which is, as you referenced, an ASO proposition that gives them much more transparency and tighter alignment. As you know, the overall employer landscape in the U.S. is not growing, shrinking up market, a little bit of growth down market. So there's little bit of growth. But net-net, we're taking share in this space and we tend to take share in this space from more traditionally designed financing alternatives for healthcare, to more progressively designed health engagement programs, incentive-aligned programs that have a high degree of transparency, and the outlook there is very positive."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just on the follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then, just within RX, what type of impact year-over-year you think that the",55,"Okay. And then, just on the follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then, just within RX, what type of impact year-over-year you think that the new preferred partnership with Gilead for Harvoni could benefit?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So we're really pleased with our medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and buildi",100,"Scott, it's Tom. So we're really pleased with our medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and building on the very strong trends results we reported for several years. Our outlook for 2015 of 5% to 6% reflects some uptick in utilization and some increase in pharmacy trend, especially drug costs and, of course, some impacts from the flu. Components are generally in the mid-single-digit range with maybe pharmacy in the double-digit range."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, [indiscernible] to your question relative to the specialty item. You're correct. We will see some impact -- a positive impact. But per prior discussions, our team has effectively managed the specialty drug component and specifically, the hep C spec",104,"Scott, [indiscernible] to your question relative to the specialty item. You're correct. We will see some impact -- a positive impact. But per prior discussions, our team has effectively managed the specialty drug component and specifically, the hep C specialty component in 2014. We're pleased with the recent announcement we have with Gilead. And importantly, I would note that both organizations have committed to innovating a performance-based and an outcome-based component to the ongoing activities. So we're pleased with the overall development that transpired, but also the commitment of both organizations to collaborate on an outcome-based program for the benefit of customers as well."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Kevin Fischbeck with Bank of America Merrill Lynch.",13,"The next question is from Kevin Fischbeck with Bank of America Merrill Lynch."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, great. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally that the MLR was like 84.7%, that's x development, right? So you're basically saying MLR should be relatively flat to up in 2015 versus 2014? And",109,"Okay, great. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally that the MLR was like 84.7%, that's x development, right? So you're basically saying MLR should be relatively flat to up in 2015 versus 2014? And I guess, when I think about PDP coming in worse, I thought that you guys probably would have made some progress there next year. And then MA, obviously, you've got a funding gap, but it seemed like there was a lot that you were doing in 2014 to try to offset that. So just trying to understand how you think about the margins."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes, Kevin. It's Tom. And you've got the dynamics right. Our -- we've got an outlook of 84.5% to 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. And the picture, I thin",109,"Yes, Kevin. It's Tom. And you've got the dynamics right. Our -- we've got an outlook of 84.5% to 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. And the picture, I think, is generally like this. We're generally expecting stable Medicare MCRs between Medicare Advantage and PDP with some mix impact actually driving the dynamic here as we're growing some of the higher MCR Medicaid business we have as a portion of the portfolio. Again, all in the margin, but that's generally the result. And I think the outlook calls generally for a stable result."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, I guess when you talk about accelerating the MA -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective off the kind of 6% to 8% that you're looking for this year in a membership basis",61,"Okay. And then, I guess when you talk about accelerating the MA -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective off the kind of 6% to 8% that you're looking for this year in a membership basis? Or is it margins? Is it both? How do we think about that?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with the outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both revenu",119,"Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with the outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both revenue, as well as margin. As I noted in my prepared remarks, we expect to see further improvement in the Stars Ratings, for example. And the positioning we took in 2015 was to position products in key markets within expectation, and what we saw was a step-up in 2016 Stars. So we will see both revenue contribution going into 2016, as well as margin expansion contribution in 2016, therefore, an earnings accelerant."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Christine Arnold with Cowen.",9,"The next question is from Christine Arnold with Cowen."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","A couple of this and thats. The CRomnibus exempted the expatriate businesses from the health insurance fee. Is there a quantifiable impact there?",23,"A couple of this and thats. The CRomnibus exempted the expatriate businesses from the health insurance fee. Is there a quantifiable impact there?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's David. First and foremost, there have been a variety of administrative release that took place post the passage of the bill back in 2012 and up to, as you referenced, the CRomnibus because the administration recognized that there was an un",146,"Christine, it's David. First and foremost, there have been a variety of administrative release that took place post the passage of the bill back in 2012 and up to, as you referenced, the CRomnibus because the administration recognized that there was an unintended consequence to that business. We're pleased with the outcome from the CRomnibus, legislatively rectifying that for the benefit of global employers. And I would suggest to you the biggest impact here is taking away the administrative complexity that applying the ACA to the global employers expatriate benefit business would create, that was putting a burden on that business portfolio that we were managing through; that's the biggest benefit. There's a small economic benefit, but that's the -- that's a few of the [ph]  byline. The bigger piece is it cleans it up for purposes of global employers not to be exposed to that."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, can you talk about why first quarter '15 will be lower than first quarter '14 and give us some kind of order of magnitude on the factors? And then, do you think you need Medicaid in order to serve the duals? Or you're still kind of the vie",61,"Okay. And then, can you talk about why first quarter '15 will be lower than first quarter '14 and give us some kind of order of magnitude on the factors? And then, do you think you need Medicaid in order to serve the duals? Or you're still kind of the view that you've got the portfolio you need for those duals?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. First, I'll address the first quarter earning spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than the first quarter of 2014. And we attribute it to 2 things: strategic investments; and the",136,"Christine, it's Tom. First, I'll address the first quarter earning spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than the first quarter of 2014. And we attribute it to 2 things: strategic investments; and the growth of our Part D business in the first quarter. On the strategic investment side, I think about additional start-up costs in Medicaid expansions, increased grant spend compared to 2014, and the Part D impact reflects both the first quarter pressure typical in Part D, given the benefit structure -- we all know that Part D first quarter results tend to be low -- and the impacts of the drug transition requirements for new customers. So all in, on a comparable basis, we're expecting first quarter '15 to be lower than first quarter '14."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's David. On your second part -- and pretty efficient working in multiple questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity",116,"Christine, it's David. On your second part -- and pretty efficient working in multiple questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity for us because we believe they're underserved as it relates to clinical care coordination. And our clinical programs actually play quite affectively there as noted in our Texas program. We're going to seek to grow those activities organically, and then opportunistically as we noted in our M&A priorities, opportunistically for geographic density. We will also look to dual capabilities from an M&A standpoint. So I would view that as both organic and inorganic opportunities for us."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Andy Schenker with Morgan Stanley.",10,"The next question is from Andy Schenker with Morgan Stanley."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just following up on one of the earlier questions here for PDP specifically, the very last quarter you highlighted some pressures around specialty drugs and a higher brand mix, and maybe just how did that continue to play out or evolve in the fourth qu",80,"So just following up on one of the earlier questions here for PDP specifically, the very last quarter you highlighted some pressures around specialty drugs and a higher brand mix, and maybe just how did that continue to play out or evolve in the fourth quarter? And then, related to that, you saw pretty strong annual enrollment -- growth in the annual enrollment period, again, about 200,000-plus lives. So what are your expectations on those costs continuing into next year?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Andy. It's Tom. I'll start and then David will address some of the growth issues. So as you pointed out, PDP results do reflect higher drug costs in the fourth quarter and the full year. And that includes some impact from the mix in channel of dru",147,"Thanks, Andy. It's Tom. I'll start and then David will address some of the growth issues. So as you pointed out, PDP results do reflect higher drug costs in the fourth quarter and the full year. And that includes some impact from the mix in channel of drug purchases and some impact from specialty drugs, so both. We've taken actions to try and improve results here -- that will improve results here. We made network and formulary adjustments when we merged the HealthSpring and Cigna Part D plans for 2015, so that resulted in a leaner formulary and expanded utilization plan -- management for the merged plans, which we expect will improve cost. As you pointed out, we also expect some favorable impact from our recent agreement with Gilead on hep C drugs. But we have factored some ongoing pressure in Part D into our 2015 outlook."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Relative to growth, as Tom noted, we merged the HealthSpring and the legacy Cigna programs and sought to take the best of both organizations. For 2015, we -- our growth efforts, we're targeting the chooser population and we saw a very good traction in our",121,"Relative to growth, as Tom noted, we merged the HealthSpring and the legacy Cigna programs and sought to take the best of both organizations. For 2015, we -- our growth efforts, we're targeting the chooser population and we saw a very good traction in our sales efforts there. We'd note that our early results through January from a utilization and performance standpoint for the new population are in line with our expectation for that chooser population, meaning the aggregate utilization levels, importantly, the mix of utilization by generic and otherwise. And as Tom noted, we expect, generally speaking, stable MCRs going from 2014 to '15 for this portfolio. And again, it presents an opportunity for further earnings expansion looking into 2016."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And just maybe a -- changing gears a little bit to follow-up question here. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into it? Have you -- how much business do you guy",71,"And just maybe a -- changing gears a little bit to follow-up question here. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into it? Have you -- how much business do you guys have up for renewal to maybe versus an average year? And any opportunities out there that you guys are really looking to target?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Andy. As you noted, it's early in the cycle. But to give you some color -- and again, when I give you color, just -- we'll define what we talk about in national account, so commercial employers with 5,000 or more employees that are multistate. We're",221,"Sure, Andy. As you noted, it's early in the cycle. But to give you some color -- and again, when I give you color, just -- we'll define what we talk about in national account, so commercial employers with 5,000 or more employees that are multistate. We're actually seeing a pretty robust pipeline of new opportunities unfold. So it's unfolding both meaningful scale and early in the cycle. So we're seeing a robust pipeline begin to unfold early in the cycle. And with an elevation -- a further elevation in intensity looking for what we call engagement and incentive-based programs, exploring a lot of the value-based network configurations and the like, which play very well to our strategy. As it relates to the last part of your question, the percent of our book that's out to bid, we see a smaller percentage of our book that's out to bid for 2016 than we did prior year, and that's consistent with the dialogue we had last year. We indicated that we had an elevated percentage based on procurement cycle. So we managed through that queue pretty well for 2015. And now looking to 2016, while the smaller percentage of our book of business out to bid and, again, we're seeing a pretty nice robust pipeline beginning to unfold early in the cycle."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ralph Giacobbe with Crdit Suisse.",10,"The next question is from Ralph Giacobbe with Crdit Suisse."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? And you guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more move",53,"Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? And you guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more movement within the ASO segment amongst peers."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Ralph. It's David. As you know, the vast majority of our commercial business, U.S. commercial business, is ASO. So as we're able to grow our portfolio, the preponderance of that is ASO-oriented. I'd also note that our expectation, as the results unf",135,"Sure, Ralph. It's David. As you know, the vast majority of our commercial business, U.S. commercial business, is ASO. So as we're able to grow our portfolio, the preponderance of that is ASO-oriented. I'd also note that our expectation, as the results unfold and in line with the guidance that Tom provided, the 1% to 3% customer growth, which excludes our QualCare network acquisition, we would expect that our guaranteed cost lives, or our risk lives, would decrease because of the run off of the individual non-ACA compliant lives, so very important. As we get into the year, we'll provide you more detail as that manifests itself. But net-net, you should think about our growth as being predominantly ASO-oriented, and that transcends through Select, the regional segment, et cetera. And we see good traction there."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just in terms of just the competitive environment for ASO broadly?",14,"Okay. And then, just in terms of just the competitive environment for ASO broadly?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the competitive environment -- maybe I'll flip it around a little bit the other way, and then try to answer your competitive environment. The buying environment, so the client portfolio -- and we call them clear as [ph] clients, clients continue to",180,"Well, the competitive environment -- maybe I'll flip it around a little bit the other way, and then try to answer your competitive environment. The buying environment, so the client portfolio -- and we call them clear as [ph] clients, clients continue to seek what we call -- you might call alternative funding, we'll call transparent funding -- so the demand for more transparent funding continues to grow as employers are seeking to get alignment of incentives and better visibility through how their funds are being deployed and align the incentives for their employees or customers. And so that trend continues. So hence, the competitive environment, competitors are seeing more ASO activity as well. For Cigna, that's good for us because we're extremely well-positioned in that environment from benefit design, the consultative nature, and very importantly, the employer reporting and insights that go along with that monthly, quarterly and annually to provide the guidance in terms of what's transpiring. So yes, elevation, but it's elevation because of the client demand, not competitive activity. And client demand continues to go up."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, that's fair. And then, second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect incremental for 2015? And then, your Specialty is separate from that deal. Is there any timeline or d",61,"Okay, that's fair. And then, second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect incremental for 2015? And then, your Specialty is separate from that deal. Is there any timeline or decision on whether you want to keep it that way or if you're exploring options at this point?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our",194,"Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our strong clinical outcomes, continued customer growth and strong earnings performance. And we continue to invest in that. So relative to your latter question on Specialty, we run our own Specialty operations within the organization. It's performing well. Our team continues to look to means to further expand and strengthen that, either through collaboration or otherwise. But we're investing in and continue to run that on our own. As for results, and per prior conversations, for 2014, our results tracked in line with our expectations. In fact, they tracked a little bit ahead of our expectations largely because of actions we took around rate and pace of investments, the timing of that and inherent level. So we actually were a little bit ahead of our track record for 2014. And for 2015, our overall targets for our pharmacy business are in line with our expectations, maybe slightly favorable for the overall franchise."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ana Gupte with Leerink Partners.",10,"The next question is from Ana Gupte with Leerink Partners."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I just wanted to follow-up on the Select and the ASO mix shift that moved from a stop loss perspective. So I'm trying to understand firstly whether the company that just do stop loss are competing on a bundled or an unbundled basis with all of you? And it",63,"I just wanted to follow-up on the Select and the ASO mix shift that moved from a stop loss perspective. So I'm trying to understand firstly whether the company that just do stop loss are competing on a bundled or an unbundled basis with all of you? And it looks like United and Aetna have started to play a bigger role here."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ana, it's David. First and foremost, as we've talked now for multiple years around the Select space and ASO, ASO stop loss, variety of funding mechanisms, we believed, and it's proven out, we believe that there will be increasing demand. We believe that's",274,"Ana, it's David. First and foremost, as we've talked now for multiple years around the Select space and ASO, ASO stop loss, variety of funding mechanisms, we believed, and it's proven out, we believe that there will be increasing demand. We believe that's a result of the increasing competitive activity, and we believe to be successful we'd have to continue to innovate. And that's what's transpiring in the marketplace. As it relates to standalone, if you'll -- stop loss players in the space, I don't see that as a primary competitive disruptor largely because of the impact of integration here. So if you step back, what makes these programs work is not a stop loss program. What makes these programs work is getting the benefit alignment laid out with the right incentives, the network configuration appropriate, the clinical programs aligned. For example, we have the ability, and we do, do on-site biometric screening, on-site coaching for a 100 lives employer. That's a new model, to be  able to do that and bring that on board for a client and identify the 1, 2 or 3 high-risk individuals who are not incurring costs today, but we need to engage clinically with. And integrating all of that with the ASO funding mechanism, stop loss when it makes sense for that employer, as well as the reporting, that's the core of our value proposition and we continue to see strong demand for that today and into the future. And we would expect, again, competitors to step into this space because there's a significant amount of demand. Key to us is the results we're delivering and ongoing innovation."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose anyway a while ago, still hold?",35,"And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose anyway a while ago, still hold?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ana, it's Tom. I would think about the standalone stop loss segment as a totally different market than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical cost. And the standalone",177,"Ana, it's Tom. I would think about the standalone stop loss segment as a totally different market than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical cost. And the standalone stop loss carriers, you typically don't have that feature. In addition, we do have some built-in advantages versus them. I mean, we already have this customer in our sights, so we have one set of acquisition costs that they have to pay -- incremental acquisition cost to secure this customer, and we have a lot better insight into the underlying claims data, so our ability to effectively approach the program is very superior. So we don't really find ourselves in what sometimes can be a hypercompetitive standalone stop loss market, not really a market we're computing in. We don't sell stop loss unless we write the underlying program. And when we're selling stop loss, it's part of an integrated package. So the competitive dynamics for the standalone market are very different than the competitive dynamics we see."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Peter Costa with Wells Fargo Securities.",11,"The next question is from Peter Costa with Wells Fargo Securities."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My question is also on the stop loss business. Is that business included in the commercial MLR that you're giving us now, in the total commercial MLR?",27,"My question is also on the stop loss business. Is that business included in the commercial MLR that you're giving us now, in the total commercial MLR?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes. Total commercial MLR will include all of our risk businesses in commercial.",13,"Yes. Total commercial MLR will include all of our risk businesses in commercial."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising in loss ratio on that book of business, so that it's not pullin",59,"So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising in loss ratio on that book of business, so that it's not pulling it down as much going forward?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes, Peter. I have to tell you, I haven't done that calculation. But obviously, we're not seeing it in the results, so I don't -- I think you might be missing a little -- something there. But just a couple of things. First, the loss ratio on stop loss is",192,"Yes, Peter. I have to tell you, I haven't done that calculation. But obviously, we're not seeing it in the results, so I don't -- I think you might be missing a little -- something there. But just a couple of things. First, the loss ratio on stop loss is lower than the average overall loss ratio, but the premium density in the other businesses is pretty high. So I'd be surprised if there was a 1 point impact, but we'll do that math. Second, on stop loss, we actually would expect some modest increase in the stop loss loss ratio as we continue to sell disproportionately in the lower end. And those customers tend to have a more premium density, so less of an expense factor in the result and a higher MCR. Again, very attractive MCR, so it's not like it's worse profitability. The bottom line margin is still very attractive for the -- that stop loss business. But the dynamics in the MLR are a little higher. So I would expect that there's marginal impact probably from this change, but I'll do a little more careful look at that."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Chris Rigg with Susquehanna Financial Group.",11,"The next question is from Chris Rigg with Susquehanna Financial Group."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Just wanted to come back to capital deployment again. And I heard your comments on Medicare Advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestic",54,"Just wanted to come back to capital deployment again. And I heard your comments on Medicare Advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestically? Or you still think international is kind of a better opportunity?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Chris, it's David. As it relates to inorganic capital deployment, we have 4 priorities and the 4 priorities have remained the same. These are not in order. These are the 4 priorities: further our global footprint, Medicare Advantage and dual capabilities,",97,"Chris, it's David. As it relates to inorganic capital deployment, we have 4 priorities and the 4 priorities have remained the same. These are not in order. These are the 4 priorities: further our global footprint, Medicare Advantage and dual capabilities, further our retail-based capabilities, and then what we call Go Deep bolt-on capabilities for our portfolio. So I wouldn't separate international as more than or less than for 2015 versus the last year. It's within our portfolio when we've been opportunistic and focused in terms of opportunities outside the U.S, as well as inside the U.S."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, my follow-up is just on sort of overall growth to the company, and specifically in the health care segment. I mean, I'm just trying to figure out, you're growing your revenues 8% to 10%. Obviously, the bottom line isn't growing in line wit",123,"Okay. And then, my follow-up is just on sort of overall growth to the company, and specifically in the health care segment. I mean, I'm just trying to figure out, you're growing your revenues 8% to 10%. Obviously, the bottom line isn't growing in line with that. Obviously, PPD is having an impact. But do you -- can you give us a sense for when you think you'll at least start to get some more leverage down the P&L? Is it -- is 2015 sort of the last truly difficult year and we should start to see some leverage next year? I know you're not going to give guidance. But just, again, big picture-wise, just trying to figure out the trajectory of growth."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the direct answer to your question and then a little more color is yes. A little more color is as we talked about the 2015 outlook, we're pleased with it, with the 8% to 10% revenue growth outlook. And then, the 3-day percent earnings growth outlook",149,"Well, the direct answer to your question and then a little more color is yes. A little more color is as we talked about the 2015 outlook, we're pleased with it, with the 8% to 10% revenue growth outlook. And then, the 3-day percent earnings growth outlook on the same-store basis and the 5% to 10% EPS growth outlook without capital deployment. As we said, looking to 2016, we see margin expansion opportunities within the health care business. Margin expansion opportunities, specifically in the senior space, both for MA, as well as PDP. We see further margin expansion opportunities within our individual block of business where we've seen some improvement move from '14 to '15.  And then, we'll see further scale leverage beyond the ongoing fundamentals of our strong performing employer business. So margin expansion opportunities exist in 2016 and '17 and beyond, and we're quite excited about that."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Brian Wright with Sterne Agee.",10,"The next question is from Brian Wright with Sterne Agee."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And I apologize if I missed this, but did you give us some color on the number of PDP lives to be added in '15?",25,"And I apologize if I missed this, but did you give us some color on the number of PDP lives to be added in '15?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","We didn't, Brian. It's about -- we ended up 1:1 enrollment period. It's about 250,000 more lives than we had at the end of the year.",27,"We didn't, Brian. It's about -- we ended up 1:1 enrollment period. It's about 250,000 more lives than we had at the end of the year."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so thrilled to have that.  But the conspiracy theorist in me looks at how you're reporting now, and you have another peer's been",76,"Okay. And then, just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so thrilled to have that.  But the conspiracy theorist in me looks at how you're reporting now, and you have another peer's been very vocal about kind of large-scale acquisition in this space, and you're kind of reporting segments very nicely that would make consolidating 2 models pretty easily. So just any comments on that."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Brian, I think you may be able to work for the NSA if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus 1 because there are different attributes",153,"Brian, I think you may be able to work for the NSA if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus 1 because there are different attributes within the government portfolio business versus the commercial business. And while we had alternatives, we believe that, that was more customer-friendly and provided the transparency to drive the dialogue on a go-forward basis. And as we have in the past, and as we will on a go forward basis, we'll try to give you as much color as possible in terms of the underlying drivers of the overall business portfolio. But this was an attempt to be, again, responsive to the market, but also maintaining appropriate amount of transparency and not go to a single loss ratio, but provide 2 loss ratios for the domestic health business."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from the Dave Windley with Jefferies.",10,"The next question is from the Dave Windley with Jefferies."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My question's on Medicare Advantage. David, wondering if through the AAP here and your changes in the mid-Atlantic market, specifically if your view is that those changes -- network, and to the extent they were benefit design as well, are complete and set",56,"My question's on Medicare Advantage. David, wondering if through the AAP here and your changes in the mid-Atlantic market, specifically if your view is that those changes -- network, and to the extent they were benefit design as well, are complete and set you up for a more normal contribution from that market in 2016?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","In your comments, Dave, were pointed toward 2016, so put MA back in context. We're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth, the 6% to 8% customer growth. You're correct. You draw attention back to a market that we s",140,"In your comments, Dave, were pointed toward 2016, so put MA back in context. We're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth, the 6% to 8% customer growth. You're correct. You draw attention back to a market that we sought to do some repositioning in, and we're feeling the final impact of that, or a final meaningful impact to that repositioning in 2015 in terms of both the lack of life growth. So even in the 6% to 8%, the lack of life growth in that market is fully contemplated in the 6% to 8%. And we would expect, as we step into 2016, an opportunity to see improvement in performance there. So that's a contributor as we look to the future, but part of that repositioning is being felt in 2015."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then, sticking with that, is that also something that you think can have another positive impact to Stars Ratings when they come out later this year?",27,"And then, sticking with that, is that also something that you think can have another positive impact to Stars Ratings when they come out later this year?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Our organization has demonstrated significant improvement in Stars as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement go",125,"Our organization has demonstrated significant improvement in Stars as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement going from '16 to '17. I'm not going to comment on individual market activities. But more importantly, our organization is highly focused on the intricacies of the Stars program. And importantly, making sure we're given the right service experience and clinical experience, both medical and pharmacy, for the benefit of our customers, and doing so in a way to move the Stars Rating up in 2017 to another step function off of the very attractive movement we made going to '16."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Our last question is from Michael Baker with Raymond James.",10,"Our last question is from Michael Baker with Raymond James."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enh",56,"David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enhanced engagement and strengthened guarantees, as well as some ben admin element that increases stickiness?"
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we'll call down market, so think about Select Segment and a portion of the regional employer portfolio. It's a single carrie",246,"Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we'll call down market, so think about Select Segment and a portion of the regional employer portfolio. It's a single carrier, as you would expect, exchange alternative. The value prop -- so let's go into the value prop. The value prop is primarily to enable a further retail experience for individuals to get them more actively engaged in the selection of their personal benefits. And we know that when that transpires, whether through a private exchange or other mechanisms because we do this every day without private exchanges, you get a higher level of awareness, a higher level of engagement, a higher level of ownership of the individual and their benefits and their understanding of what's there, That's the primary mechanism. And then you're able to drive the appropriate personalization or efficiency that works for them. So using your term, consumer engagement or personalization, there's a primary attribute there. As I noted previously though, we've expected this marketplace more broadly to unfold slowly and it is. Our team has seen some success. And we have a dedicated team of resources that will continue to focus on this, but we have not banked on, nor are we banking on a significant step function in revenue, customer lives or earnings growth here. Rather, we've positioned ourselves to have smart optionality to the extent this market moves forward very positively."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","I'll now turn the call over to David Cordani for closing remarks.",13,"I'll now turn the call over to David Cordani for closing remarks."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna's strong fourth quarter and full year results reflect solid revenue and earnings contributions from each of our business segments. As an organization, we have o",174,"Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna's strong fourth quarter and full year results reflect solid revenue and earnings contributions from each of our business segments. As an organization, we have over 35,000 talented colleagues around the globe whose work exemplifies our mission of improving health, well-being and sense of security for the people we serve every day. The momentum we generated off of another strong year in 2014, combined with our attractive growth opportunities, give us confidence we will achieve our full year 2015 outlook. We plan to continue to leverage our proven business and core capabilities to drive meaningful growth in attractive new markets and segments, resulting in doubling of our revenue over the next 7 to 8 years. And we remain committed to achieving, on average, our annual EPS growth objective of 10% to 13% over the long term. We thank you for joining the call today and your continued interest in Cigna, and we look forward to continuing our conversations."
172899,253311656,755880,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days fol",68,"Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 1-800-945-4244 or (203) 369-3501. No passcode is required for the replay.  Thank you for participating. We will now disconnect."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter and Full Year 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.We'll begin by turni",51,"Ladies and gentlemen, thank you for standing by for Cigna's Fourth Quarter and Full Year 2014 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.
We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",592,"Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks today, David and Tom will cover a number of topics, including Cigna's full year 2014 financial results as well as our financial outlook for 2015.
As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled ""adjusted income from operations"" and ""earnings per share"" on this same basis as the principal measures of performance for Cigna and our business segments. A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com.
In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC.
Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. First, please note that when we discuss the number of covered lives for our global medical customers, we will be doing so on a basis that excludes those individuals that were previously covered under Limited Benefits plans. As a reminder, we exited the Limited Benefits business as of December 31, 2013, as required by the Affordable Care Act regulation.
Second, please note that our definition of adjusted income from operations will change for 2015 reporting in that we will now exclude acquisition-related amortization expense from this operating measure. When we discuss our earnings outlook for 2015 today, it will be on a basis of adjusted income from operations that excludes acquisition-related amortization expense. This is a change compared to the basis on which 2014 results are reported and how we have previously provided our 2014 outlook. In 2015, the impact of excluding acquisition-related amortization expense is approximately $100 million after tax or $0.40 per share.
Third, beginning in 2015, we have simplified our guidance and disclosures for our medical care ratios or MCRs by reporting them on a basis of total Commercial and total Government. The total Commercial ratio encompasses all of our commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products, provided through guaranteed cost or experience-rated funding arrangements in both the United States and internationally. The total Government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses. To ease the transition, we have provided historical medical care ratios on these bases within our quarterly financial supplement that was posted in the Investor Relations section of cigna.com this morning.
Lastly, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or prior year development of medical costs. Our outlook also excludes the impact from our recently announced acquisition of QualCare, which we do not expect will have a material impact to our financial results in 2015.
And with that, I will turn the call over to David."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Will. Good morning, everyone, and thank you for joining our call today.To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers, cli",1743,"Thanks, Will. Good morning, everyone, and thank you for joining our call today.
To begin, I'll review highlights of our full year 2014 financial results and our 2015 outlook. I will then discuss how we will continue to create value for our customers, clients and shareholders in the future. I will also illustrate more specifically how we are creating value in our Seniors business and leveraging our experience and success of that business to drive long-term growth. Then Tom will address our fourth quarter and full year 2014 financial performance in more detail as well as provide the specifics for our outlook for 2015 before we take your questions. And following the Q&A session, I'll wrap up the call with a few closing remarks.
We'll start with some highlights from the year.
Cigna's strong 2014 performance represents the fifth consecutive year of competitively attractive financial results. This outstanding track record of results is driven by the disciplined execution of our growth strategy, all while we continue to invest in new capabilities, expand our offerings and our geographic footprint. Over the past several years, in the face of a particularly challenging and dynamic environment, we have been focused and disciplined with targeted yet meaningful investments to drive innovation, including new clinical programs, aligned incentives for customers, expanded technologies and programs for health care professionals. We have done all this while delivering competitively differentiated results year in and year out.
The full year 2014 consolidated revenues increased 8% to $35 billion, with each business segment delivering strong growth over 2013. We reported adjusted income from operations for the full year of $2 billion or $7.43 per share, which represents a per share increase of 9% over 2013.
Our revenue and earnings performance reflect growth in all of our businesses over the course of the year, a year in which we also grew to more than 85 million customer relationships worldwide and where we continue to generate strong margins and significant free cash flow for the benefit of shareholders. These results position us to once again deliver competitively attractive revenue and earnings growth in 2015.
For 2015, our outlook of 8% to 10% revenue growth and 5% to 10% EPS growth, excluding reserve development recognized in 2014 as well as future capital deployment, reflects the focus and clarity of our strategy and continued strong performance of our team around the world. Tom will walk you through more specifics regarding our outlook later on the call.
Now I'd like to talk about how our guiding framework, global strategy and multiple avenues for growth have enabled our long track record of success and will drive ongoing future value creation.
Across our business, we operate in an ever-changing market landscape with diverse needs across customers, employers, health care professionals and governments. Moving [ph] in this market, we are meeting and exceeding the expectations of our customers and clients around the world by delivering affordable and personalized solutions. As we look to the future, we have built a growth framework to create ongoing value, leverage our differentiated capabilities for the benefit of our customers.
There are 3 components to this framework. First is leveraging our well-positioned existing portfolio of businesses to continue to generate attractive value for our customers and clients. We expect to double the size of our company over the next 7 to 8 years. This will result in an average annual revenue growth rate of 8% to 10%, largely driven by our existing portfolio and focused execution. This continues a track record that we have demonstrated over the last 5 years, and our 2015 outlook of 8% to 10% revenue growth is consistent with this goal.
The second component is targeted and effective capital deployment to create ongoing shareholder value. I would note that, over the past 5 years, we have effectively deployed capital through a balance of investments in our business portfolio, strategic M&A and share repurchase. A good recent example of this is our agreement to purchase QualCare Alliance Networks. This acquisition is directly aligned with our Go Deep and our physician partnership strategies.
Our businesses are generating high margins and are capital efficient, allowing us to both fund attractive organic growth and generate significant free cash flow. This free cash flow provides us with financial flexibility and the opportunity to deploy capital to create additional value for our shareholders. And given the health of our balance sheet and underlying capitalization level of our subsidiaries, we expect to have $1.8 billion of capital available for deployment in 2015.
The third component of our framework where we seek to drive additional value for our shareholders is through new and emerging opportunities. These opportunities include new distribution marketplaces such as public and private exchanges, geographic expansion such as new Medicare Advantage markets and international opportunities, and new buying [ph] segments and service expansion such as medical service organization offerings for the benefit of integrated health care professionals. We are well positioned to pursue each of these potentially attractive future growth opportunities that are aligned with our strategy. As such, we have dedicated resources to fuel future expansion in these areas.
To illustrate how we are leveraging this framework to create value, I'll highlight how this framework applies to our Seniors business. This market segment includes a population with a variety of complex needs, requiring customer engagement and incentive-based clinical resources and programs to drive ongoing success. Our Seniors business pioneered successful physician engagement models, including aligned incentives and collaborative relationships to drive high-quality and a more affordable health care experience for both customers as well as physicians. As we continue to leverage our core physician engagement capabilities across all of our health services businesses, we are focused on key investments that improve affordability, enhance personalized services and drive better clinical outcomes. For example, the strategic investments we're making to enhance our physician insight and data tools will enable our clinical data to be accessible in a real-time fashion for more of our physician partners as well as our service teams. Enabled by our physician engagement model, seniors continue to find our Cigna HealthSpring benefit offerings increasingly compelling. And we expect to have 6% to 8% Medicare Advantage customer growth in 2015.
As for positioning, we continue to be amongst the top 3 players in market share for all of our established markets, and we are posting attractive growth in our newer markets. In 2014, we expanded our Seniors business into Georgia and the Carolinas, where we successfully leveraged existing Cigna commercial networks to develop and implement engaged physician relationships for seniors. Importantly, the quality of care delivered through our engaged physician groups is reflected in our stars ratings, where we increased our membership in 4-star or higher plans from approximately 40% to nearly 60% in 2016. Looking to 2017, we again expect to deliver an increase in this result. These improvements in star ratings have allowed us to enhance our benefit offerings and position our Seniors business to be an earnings accelerant in 2016 and beyond.
Relative to our expanding opportunities, we currently operate Medicaid into eligible plans in Texas and in the Illinois markets. Here, we are leveraging our care coordination capabilities to serve the dual-eligible population within our Medicaid platform. Focusing our growth efforts on improving care for the underserved, including the dual-eligible and aged, blind and disabled populations, complements our proven experience with complex care coordinations, differentiated clinical outcomes and affordability focus. While our Illinois plan is relatively new, having just begun in 2014, our Texas plan has been in operation since 2011 and has a track record of delivering affordable care and better health outcomes. In a testament of our commitment to servicing these customers, our Texas plan recently was acknowledged by the Medicaid Health Plans of America for our cutting-edge, intensive behavioral health programs.
We are well-positioned and have the capital flexibility to pursue these accelerating geographic and market segment expansion opportunities, either organically or through M&A, as Seniors remains a strategic growth priority for us. As a global company, our efforts to leverage these capabilities have also expanded across key markets beyond the United States. In Korea, for example, where the aged population is seeking new solutions to meet their emerging needs, we've developed an innovative and new health membership program targeting seniors known as Heyday. This organically built affinity program delivers value-added services directly to seniors in Korea. And while only a year into this expansion, we now serve more than 300,000 Korean seniors. So overall, we have a clear strategy and the capabilities to deliver value and improve the health and well-being of senior customers today and into the future.
Whether in our Seniors business as we discussed today or other growth businesses we have addressed in previous calls, we will continue to deliver attractive growth, produce and deploy capital effectively, and invest and position ourselves to win in new and emerging markets and segments.
Now to summarize my comments before Tom offers more detail on our 2014 results and expectations for 2015.
Cigna's strong 2014 financial performance extends a multiyear track record of delivering competitively attractive revenue, earnings and free cash flow. Continued execution of our growth strategy is creating value for our customers and clients, complemented by our differentiated capabilities and innovative physician and customer engagement solutions. As a rapidly changing industry and economic environment continues to unfold and new challenges arise, we are positioned to capitalize on new growth opportunities while we continue to leverage our core businesses for growth. And by embracing change, we continue to position our company for successful investing in the future, preparing for significant new opportunities such as those we shared this morning for our Seniors segment, including: in existing programs and markets, new market expansion, new offerings for health care professionals through our medical service organization solutions, new segments such as dual eligibles and new affinity programs such as HeyDay in Korea.
We expect to meet our growth objectives of 8% to 10% on average, doubling the size of our company again over the next 7 to 8 years. And based on our focused strategy, strong market positioning and ability to leverage capital, as well as further opportunities we have for growth, we expect to continue to deliver competitively attractive and sustained long-term EPS growth of 10% to 13% on average, all while continuing to invest back in our company.
And with that, I'll turn the call over to Tom."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone.In my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015.We had another strong year in 2014, with revenue growth of 8% and industry-leading earnings per share growth of 9% over 2013",2099,"Thanks, David. Good morning, everyone.
In my remarks today, I will review Cigna's 2014 results and provide our outlook for 2015.
We had another strong year in 2014, with revenue growth of 8% and industry-leading earnings per share growth of 9% over 2013 results. 2014 represents our fifth consecutive year of consistently strong revenue, earnings and EPS growth -- an attractive result both on an absolute and competitive basis. In addition, we continued to generate strong free cash flow in 2014, which resulted in approximately $1.6 billion being returned to shareholders through share repurchase. The strength of our 2014 performance provides us with a solid foundation for growth in 2015.
Now moving to operating results.
Our full year consolidated revenues grew 8% to $35 billion, driven by growth in each of our business segments and in our targeted markets. Earnings grew 3% to $2 billion, and earnings per share grew 9% to $7.43 in 2014. Our ability to grow revenue, earnings and EPS in a challenging operating environment reflects the strength of our underlying businesses and focused execution.
Regarding the segments, I will first comment on our Global Health Care segment. Overall, Global Health Care delivered another good year. 2014 premiums and fees grew 7% to $24.5 billion, reflecting growth in all of our Global Health Care businesses, including ongoing growth in our self-funded programs and specialty products. We ended 2014 with 14.5 million global medical customers, growing by approximately 380,000 customers or 3% for the year.
Full year earnings were $1.65 billion, reflecting business growth, specialty contributions, operating expense efficiency and effective medical cost management.
Turning to medical costs. We continue to deliver medical costs that reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. For our total U.S. commercial book of business, full year medical cost trend was slightly less than the low end of our previous range of 4.5% to 5.5% for 2014. Our commercial medical trend result continues our multiyear track record of industry-leading performance. And given that over 85% of our U.S. Commercial customers are in transfer and ASO funding arrangements, our clients directly benefit from these favorable medical costs.
Regarding medical care ratios. In our U.S. Commercial guaranteed cost business, our full year 2014 medical care ratio or MCR was 81.8% on a reported basis or 82.7% excluding prior year reserve development. Consistent with our expectations, our fourth quarter 2014 guaranteed cost MCR of 86.6% reflects an increased seasonal impact from the growing share of high-deductible plans in our employer group and individual businesses. We also expected and saw this increased seasonal impact across most of our Commercial business, including our stop loss and experience-rated businesses.
Overall, our employer risk businesses continued to deliver solid results in the quarter and throughout the year, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results in our individual business, while still below long-term expectations, continued to improve in the fourth quarter.
In our Government business, our full year 2014 MCR for Medicare Advantage was 83.5% on a reported basis or 84% excluding prior year reserve development, reflecting the impact of medical cost improvement initiatives implemented during 2014.
Moving to operating expenses for 2014. Our total Global Health Care operating expense ratio was 22%. This includes the impact of health reform-related taxes, which added 110 basis points to the expense ratio for the year. Overall, we've had another strong year in our Global Health Care business.
Now I'll discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability.
Premiums and fees grew 14% year-over-year in global supplemental. 2014 earnings in our Global Supplemental Benefits business were $230 million, reflecting attractive operating margins, continued strategic investments to drive future growth and nonrecurring favorable tax items of $21 million after tax recorded in the third quarter. Fourth quarter earnings of $33 million reflect claims seasonality, our funding of long-term strategic investments and the impact from the strengthening of the U.S. dollar.
For Group Disability and Life, full year results reflect premium and fee increase of 6% over 2013. 2014 earnings in our group business were $317 million and reflect favorable claim experience in our Life business and a lower operating expense ratio.
For our Corporate and Other Operations, results totaled to an after-tax loss of $197 million for full year 2014.
Overall, our 2014 results reflect revenue earnings growth from each of our business segments and a significant free cash flow as the result of the continued effective execution of our strategy.
Turning to our investment portfolio. For 2014, we reported net realized investment gains of $106 million after tax, coupled with a strong net investment income result. The high quality and diversification of our investment portfolio continued to drive our overall investment results.
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to meet and exceed the expectations of our customers and clients by delivering affordable and personalized solutions, effectively deploying capital and targeting new and emerging opportunities where we will seek to drive additional value for our shareholders.
For full year 2015, we expect consolidated revenues to grow in a range of 8% to 10% over 2014, with continued growth across our targeted market segments. We expect full year 2015 consolidated adjusted income from operations to be in the range of $2.1 billion to $2.2 billion or $8 to $8.40 per share. As Will noted earlier, our full year 2015 consolidated and business segment adjusted income from operations, as well as earnings per share estimates, now exclude acquisition-related amortization expense.
In 2015, the impact of excluding acquisition-related amortization expense is approximately $0.40 per share or $100 million after tax, including $85 million in our Global Health Care business and $15 million in Global Supplemental Benefits. Lastly, consistent with prior practice, our outlook excludes any contribution from additional capital deployment as well as any prior-year claim development, which in 2014 totaled $53 million after tax.
Putting our 2015 outlook and our 2014 actual results on a comparable basis, that is adjusting for the reserve development reported in our 2014 results and adjusting to a consistent base with -- basis for reporting deal amortization, our outlook for operating earnings in 2015 reflects 3% to 8% growth over 2014, and our outlook for EPS growth is 5% to 10% before considering the impact of additional capital deployment.
I will now discuss the components of our 2015 outlook, starting with Global Health Care. We expect full year Global Health Care earnings in the range of approximately $1.73 billion to $1.79 billion. This outlook reflects continued benefits from organic revenue growth, specialty contributions, effective medical cost management and operating expense efficiencies. This also includes our updated view of the annual enrollment period results for both Medicare and the public exchange business.
I'll now summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015, starting with our customer base. Regarding global medical customers, we expect 2015 customer growth of 1% to 3%. This growth is driven by expected ongoing growth in our Commercial employer business led by continued double-digit customer growth in our Select business, as well as mid- to upper single-digit growth in our Medicare Advantage customers, with some expected reduction in our non-ACA-compliant individual customers.
Turning to medical costs. Our 2015 outlook assumes some increase in medical utilization versus current levels, and this increase has been reflected in our pricing. For our total U.S. Commercial book of business, we expect full year medical cost trends to be in the range of 5% to 6%.
As Will noted earlier, we are changing the basis on which we provide guidance for MCRs to total Commercial and total Government. We believe this basis will provide better insight into our ability to effectively manage medical costs for our Commercial and Seniors customers. For our total Commercial book of business, we expect the 2015 medical care ratio to be in the range of 78% to 79%. This compares to our full year 2014 total Commercial MCR of 78.9% on an operating basis. For our total Government book of business, we expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%. This compares to our full year 2014 total Government MCR of 84.7% on an operating basis.
Regarding operating expenses, our 2015 Global Health Care operating expense ratio is expected to be in the range of 20.5% to 21.5%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.73 billion to $1.79 billion. We believe this is a competitively attractive result reflecting our focus on growing segments of the health care market and continued strong execution of our business strategy.
Now moving to the other components of our outlook.
For our Global Supplemental Benefits business, we continue to expect strong top line growth. We expect earnings in the range of $230 million to $250 million. This represents earnings growth of 3% to 12% after adjusting for $21 million of nonrecurring favorable tax items recognized in this segment in 2014. Regarding the Group Disability and Life business, we expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations, that is Other Operations and Corporate, we expect a loss of $180 million for 2015.
So all in, for full year 2015, we expect consolidated adjusted income from operations of $2.1 billion to $2.2 billion or $8.00 to $8.40 per share. Our outlook continues to exclude the impact of prior year claim development or any future capital deployment. While we do not anticipate the impact of future capital deployment in our EPS outlook, we do expect the additional free cash flow that we generate will be deployed for the benefit of shareholders either through value-creating acquisitions or share repurchase.
Overall, these results represent a competitively attractive outlook and underscore the benefit of our diverse and differentiated portfolio of businesses. I would also note that due to the timing of some strategic investments, as well as the growth of our Medicare Part D business, which traditionally reports low first quarter earnings, we expect our first quarter 2015 earnings will be lower than first quarter of 2014.
Now moving to our 2015 capital management position and outlook. Overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow to the parent, with a strong return on capital in each of our business segments. Our capital deployment strategy and priorities have not changed. These priorities are: providing the capital necessary to support the growth of our ongoing operations; pursuing M&A activity with a focus on acquiring capabilities and scale to further grow in our targeted areas of focus; and after considering these first 2 items, we'll return capital to shareholders, primarily through share repurchase.
Regarding free cash flow. During 2014, we repurchased 18.5 million shares of stock for approximately $1.6 billion, and we ended the year with parent company cash of approximately $400 million. For full year 2015, we expect subsidiary dividends of approximately $1.7 billion, driven by strong performance in each of our business segments. After considering all sources and uses of parent company cash, including the funding of our recently announced acquisition of QualCare, this outlook implies we would have approximately $1.8 billion available for capital deployment in 2015, including approximately $115 million we deployed to repurchase 1.1 million shares from January 1 through February 4.
Our free cash flow outlook reflects the industry-leading margins and returns on capital in our businesses, and a high level of capital efficiency, particularly from our fee-based businesses. This capital efficiency allows us to fund attractive organic growth while continuing to generate significant free cash flow to be deployed for the benefit of shareholders.
Now to recap. Our full year 2014 consolidated results reflect the strength of our diversified portfolio of global businesses and a continued track record of effective execution of our focused strategy. The fundamentals of our business remain strong, as evidenced by strong growth in revenue and earnings, industry-leading medical costs and quality outcomes, and continued strong free cash flow. Based on the strength of these results, we are confident on our ability to achieve our full year 2015 earnings outlook.
And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] The first question is from Justin Lake with JPMorgan.",11,"[Operator Instructions] The first question is from Justin Lake with JPMorgan."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, David, can you walk us through your view of initial 2015 guidance from the lens of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds, tailwinds, investment spending, et cetera that you see in",44,"First question, David, can you walk us through your view of initial 2015 guidance from the lens of a growth perspective versus your typical targets? And maybe talk about some of the key headwinds, tailwinds, investment spending, et cetera that you see in '15."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. So first, the headlines. We're pleased with the 8% to 10% revenue outlook and continued growth of our well-positioned businesses; as Tom noted, the 3% to 8% earnings growth on a same-store basis; and the underlying 5% to 10% EPS growth on a",327,"Sure, Justin. So first, the headlines. We're pleased with the 8% to 10% revenue outlook and continued growth of our well-positioned businesses; as Tom noted, the 3% to 8% earnings growth on a same-store basis; and the underlying 5% to 10% EPS growth on a same-store basis. And as we've done in the past, we will continue to make ongoing investments in our company while seeking to generate an attractive and competitively differentiated outcomes for our business. Also very importantly, all the numbers I just referenced exclude the impact of the $1.8 billion of deployable capital we'll have for 2015. As it relates to tailwinds, you can think about several tailwinds for us: clearly, the revenue and customer base growth, number one; two, expense leverage -- we have a track record of continuing to generate efficiency gains and expense leverage, some of which we redeploy for the benefit of innovation. Third, ongoing specialty penetration. We have a good track record of driving further specialty penetration. And fourth, some improvement in the performance of our individual portfolio of businesses. As it relates to headwinds, you can think about a few: as we've discussed before, the impact of specialty pharma on the overall medical cost trend and specifically, for example, its impact on Seniors portfolio of business; two, as you know, another step-up in the industry tax -- a portion of it, our assumptions are, will not pass through fully in the Medicare arena. And thirdly, for us, given our global nature, some FX impact into 2015. But taken as a whole, we feel good about the 2015 impact that we're able to generate here with growth, earnings and EPS growth; capital positioning; and then finally, Justin, the positioning this gives us for 2016, as we would expect to have further earnings accelerants off of the positioning we've taken relative to our Seniors business in that portfolio. So taken as a whole, we're pleased with the outlook for '15."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what -- your strategy around not including a",56,"And then David, you mentioned the capital deployment not being in the numbers. Every one of your peers now include share repurchase in their guidance. I'm just curious if you could tell us, give us an update on what -- your strategy around not including any benefit from that $1.8 billion in the guidance going forward."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Justin. We've always been quite transparent providing the updates each quarter, so stepping back, our capital deployment priorities are clear and unchanged: serve the existing needs of the corporation and support the underlying growth and investment",153,"Sure, Justin. We've always been quite transparent providing the updates each quarter, so stepping back, our capital deployment priorities are clear and unchanged: serve the existing needs of the corporation and support the underlying growth and investments; two, targeted and strategically attractive M&A; three, return to shareholders. And to your point, our track record demonstrates our preferred approach there is relative to share repurchase. And our objective is to provide you the transparency of what the free capital available for deployment and allow you to draw your judgments in terms of how you want to look at that. The headline here is really strong and well-performing balance sheet, really strong and well-positioned operating subsidiaries from an underlying capitalization level that provides the $1.8 billion available for deployment. And I would suggest you look at our track record relative to how effectively and how efficiently we've deployed that and we provide updates each quarter."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Matthew Borsch with Goldman Sachs.",10,"The next question is from Matthew Borsch with Goldman Sachs."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Could you talk to the drivers in your outlook for the global supplemental business? It seems like the growth rate, and maybe some of that is the impact of foreign currency, is lower than we might have expected for a typical year.",42,"Could you talk to the drivers in your outlook for the global supplemental business? It seems like the growth rate, and maybe some of that is the impact of foreign currency, is lower than we might have expected for a typical year."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Matt. It's Tom. Our Global Supplemental Benefits business has a track record of building strong revenue and earnings growth. And it's focused by leveraging the broad and innovative distribution and strong analytic and customer insight capabilities",139,"Thanks, Matt. It's Tom. Our Global Supplemental Benefits business has a track record of building strong revenue and earnings growth. And it's focused by leveraging the broad and innovative distribution and strong analytic and customer insight capabilities. We saw that result in '14 and we're really seeing that result in '15 also. There are a few layers to the result in '15, though. Our outlook for 2015 earnings of $230 million to $250 million reflects continued strong operating margins; the continued funding of growth initiatives; and continued currency pressure, as you suggested, of about $10 million to $15 million after tax. So if you adjust for the $21 million onetime tax benefit reported in '14, the deal amortization change and the impact of the currency pressure, the underlying growth for global supp is in the 8% to 18% range."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, okay, that makes more sense. And I'm sorry, did you give a revenue outlook on global supp for '15?",20,"Okay, okay, that makes more sense. And I'm sorry, did you give a revenue outlook on global supp for '15?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","No, we don't intend to provide revenue outlooks by business segment, but we're expecting continued strong revenue growth in global supp.",21,"No, we don't intend to provide revenue outlooks by business segment, but we're expecting continued strong revenue growth in global supp."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Joshua Raskin with Barclays.",9,"The next question is from Joshua Raskin with Barclays."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I want to talk a little about the public exchanges and the impact on the Commercial business. I guess, first, if you could help us size what the revenues were in public exchanges this year; and maybe what the impact on the overall Commercial MLR was; and",60,"I want to talk a little about the public exchanges and the impact on the Commercial business. I guess, first, if you could help us size what the revenues were in public exchanges this year; and maybe what the impact on the overall Commercial MLR was; and then as a part of that, what assumptions you've made regarding the 3Rs."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Josh, it's David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs as well as the -- our positioning relative to the 3Rs. Consistent with our prior conve",175,"Josh, it's David. I'll give you some context relative to size and scope of that business in terms of revenue. I'll ask Tom to give you a little bit relative to the MCRs as well as the -- our positioning relative to the 3Rs. Consistent with our prior conversations, we've positioned this book of business for 2014 as well as 2015. Our expectations is it will be a small portion of our overall franchise. Think of it, in order of magnitude, as we've talked about before, about 3% of the overall franchise revenue in terms of 2014. And we would expect it to be in the similar range in 2015, with some puts and takes in terms of the runoff of the grandfathered business and some growth on the on exchange business. So I think the headline here that's quite important is a small percentage of the overall portfolio that we've been seeking to manage in the context of the performance of the franchise. Tom, could you put a little more color on the MCR?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure. So Josh, the MCR dynamics in individual have been improving over the course of the year. So also reflecting, of course, increased seasonality in the fourth quarter. It's just basically been improving from our initial expectations in the year. It's s",242,"Sure. So Josh, the MCR dynamics in individual have been improving over the course of the year. So also reflecting, of course, increased seasonality in the fourth quarter. It's just basically been improving from our initial expectations in the year. It's still a little higher than where we'd like to be. That improvement has been driven basically by both a better assessment of the early part of the year claims as they developed a little favorably and a little bit of an improvement in the run rate and, as you kind of suggested, the 3Rs. So just a couple of minutes on the 3Rs. Our year-end accrual for 3Rs now totals about $200 million after tax. The majority of the accrual continues to be related to the reinsurance element of the 3R program, with risk adjusters representing the higher amount of the remaining balance and a smaller amount for risk corridor recoveries. And I'll give you some more specific color on our approach. We have accrued reinsurance at the 80% coinsurance level consistent with the design of the program. We have not accrued any risk adjuster impact for our Texas business due to the current lack of industry data. And we accrued amounts under the risk corridor because we're comfortable with the statutes and administrative guidelines that support that program. So as you know, there's some interplay among each of these program elements, but overall, we're very comfortable with our total accrual."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So I guess more specifically, think about -- I know it's a small portion, but obviously, the MLR is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that you guys have moved the buckets around a little bit. But I'",182,"So I guess more specifically, think about -- I know it's a small portion, but obviously, the MLR is elevated. I'm just trying to figure out the commercial MLR for 2015 with the understanding that you guys have moved the buckets around a little bit. But I'm assuming there's an assumption of the public exchanges getting a little bit better. You've got the industry tax uptick, which assuming you priced for it, is actually a little bit of a tailwind as well, and the guidance is for, let's call it 40 basis points of improvement at the midpoint. So are there -- I'm just trying to think if there's any other moving parts? My guess is you've got a little bit of a benefit on the hep C and Specialty Pharmacy from the new Gilead relationship announced yesterday. So I'm just -- is there anything underlying? Are you guys just basically assuming apples to apples on your total -- on your sort of commercial book flat type of MLRs with a couple of these moving parts helping you a couple basis points?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, Josh, I think you've got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14. And it is driven by the items you mentioned. It reflects continued good perf",77,"Well, Josh, I think you've got the moving parts pretty well nailed. So again, our MCR outlook for commercial in 2015 is 78% to 79% compared to 78.9% on an operating basis in '14. And it is driven by the items you mentioned. It reflects continued good performance in our employer group business, some benefit from pricing for the incremental industry fee in 2015 and some improvements in individual. And that essentially summarizes the major moving pieces."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And I'm sorry, did you guys quantify the FX headwind in the fourth quarter?",15,"Okay. And I'm sorry, did you guys quantify the FX headwind in the fourth quarter?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, in the fourth quarter, things have been moving around. I'd say low single-digit million dollars impact. So I didn't before, but that's about the quantity.",26,"Well, in the fourth quarter, things have been moving around. I'd say low single-digit million dollars impact. So I didn't before, but that's about the quantity."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from A.J. Rice with UBS.",10,"The next question is from A.J. Rice with UBS."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It didn't -- it doesn't seem like we're hearing as much about it. But in your ASO book of business, did you see much attriti",72,"Maybe first, I'll just ask you if you don't mind about the private exchange dynamic. I know that was a hot topic about a year ago. It didn't -- it doesn't seem like we're hearing as much about it. But in your ASO book of business, did you see much attrition? And can you just sort of comment on the state of play from your perspective in private exchanges at this point?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","It's David. Just a little color on our view and our positioning and then our results. First, and most -- we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourself in just about all",209,"It's David. Just a little color on our view and our positioning and then our results. First, and most -- we continue to view that the private exchanges may create a sustainable attractive long-term market. As such, we positioned ourself in just about all of the various private exchanges that are in the marketplace today. In addition to that, we have our own proprietary exchange and a dedicated leadership team managing the overall exchange activities. As it relates to outcomes to your point, there had been a lot of conversation in the market as we expected. But consistent with our prior dialogues, we did not expect to see a significant amount of movement in the overall landscape in the marketplace in '14 or '15, and that's what manifested for both the industry as a whole, as well as for ourselves. So specific to Cigna, some movement in both directions, but it all nets out to a de minimis amount of activity. Lastly, as we look to 2016, as I noted, we're well-positioned in the respective exchanges. We'll be actively engaged if -- target clients that, we believe, align very well with our value proposition, present good growth opportunities. But slow activity thus far in line with our expectations."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to -- for potential capital deployment opportunities, acquisitions. And thinking about that, are you looking -- what would be an attractive opportun",77,"Okay. And maybe just for the follow-up. You mentioned in the prepared remarks MA is an area you would look to -- for potential capital deployment opportunities, acquisitions. And thinking about that, are you looking -- what would be an attractive opportunity for you? Something that just broadens your geography? Or you're looking for something that you think you can run better than it's currently being run? Maybe add some color on what would be attractive there."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, AJ. We've been very consistent relative to MA is, over the long term, a very attractive growth opportunity. And our view is that a sustainable MA program has 2 major dimensions; effective consumer engagement and personalization capabilities and then",180,"Sure, AJ. We've been very consistent relative to MA is, over the long term, a very attractive growth opportunity. And our view is that a sustainable MA program has 2 major dimensions; effective consumer engagement and personalization capabilities and then strong clinical partnership and physician engagement capabilities with a value-based reimbursement structure, which is what our model is. As it relates to capital employment, you hit the nail on the head. We see both organic geographic expansion opportunities, as well as inorganic geographic expansion opportunities. So that would be one, targeted geographies that are inorganically attractive. Second would be if you expand a little more broadly relative to Seniors and the broader chronic population, additional capabilities or opportunities to serve the Medicare, Medicaid duals or other parts of the population we think are underserved. As I noted in my prepared remarks, we've seen good success in Texas, emerging success in Illinois, and we're going to seek to grow those programs. So those would be the 2 areas for capital deployment: geographic; as well as what we would call segment expansion."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Scott Fidel with Deutsche Bank.",10,"The next question is from Scott Fidel with Deutsche Bank."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","First question, just wondering if you could drill into the Select growth, and it looks like the trajectory's still intact there -- double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market shift downstream into",76,"First question, just wondering if you could drill into the Select growth, and it looks like the trajectory's still intact there -- double-digit growth. Can you maybe just talk a bit about how much is being driven by continued market shift downstream into ASO in terms of how much increased ASO market penetration you're seeing as -- and then as compared to some of the market share gains that you may be driving in that segment?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees, so that's our Select Segment. To your point, it has been and continues to be a very attractive growth segment for us, continuing to notch double",190,"Sure, Scott. It's David. First, relative to Select. So we define Select as employers with 51 to 250 employees, so that's our Select Segment. To your point, it has been and continues to be a very attractive growth segment for us, continuing to notch double-digit customer base growth for us and something we're quite pleased with. Our approach to this base is somewhat different than the marketplace. So it's to be consultative and work with employers to design the right consumer engagement and benefit designs and network structures, and then offer multiple funding alternatives, one of which is, as you referenced, an ASO proposition that gives them much more transparency and tighter alignment. As you know, the overall employer landscape in the U.S. is not growing, shrinking up market, a little bit of growth down market. So there's little bit of growth. But net-net, we're taking share in this space and we tend to take share in this space from more traditionally designed financing alternatives for healthcare, to more progressively designed health engagement programs, incentive-aligned programs that have a high degree of transparency, and the outlook there is very positive."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just on the follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then, just within RX, what type of impact year-over-year you think that the",55,"Okay. And then, just on the follow-up question. Helpful if you could just walk us through your thoughts on the cost components for cost trend relative to the overall 5% to 6%. And then, just within RX, what type of impact year-over-year you think that the new preferred partnership with Gilead for Harvoni could benefit?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So we're really pleased with our medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and buildi",100,"Scott, it's Tom. So we're really pleased with our medical trend results. And just to repeat, we improved our outlook for medical cost trends throughout the year. We ended up delivering our cost trend below the 4.5% low end of our improved range and building on the very strong trends results we reported for several years. Our outlook for 2015 of 5% to 6% reflects some uptick in utilization and some increase in pharmacy trend, especially drug costs and, of course, some impacts from the flu. Components are generally in the mid-single-digit range with maybe pharmacy in the double-digit range."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Scott, [indiscernible] to your question relative to the specialty item. You're correct. We will see some impact -- a positive impact. But per prior discussions, our team has effectively managed the specialty drug component and specifically, the hep C spec",104,"Scott, [indiscernible] to your question relative to the specialty item. You're correct. We will see some impact -- a positive impact. But per prior discussions, our team has effectively managed the specialty drug component and specifically, the hep C specialty component in 2014. We're pleased with the recent announcement we have with Gilead. And importantly, I would note that both organizations have committed to innovating a performance-based and an outcome-based component to the ongoing activities. So we're pleased with the overall development that transpired, but also the commitment of both organizations to collaborate on an outcome-based program for the benefit of customers as well."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Kevin Fischbeck with Bank of America Merrill Lynch.",13,"The next question is from Kevin Fischbeck with Bank of America Merrill Lynch."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, great. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally that the MLR was like 84.7%, that's x development, right? So you're basically saying MLR should be relatively flat to up in 2015 versus 2014? And",109,"Okay, great. I just wanted to drill into the government MLR a little bit. I guess, when you say operationally that the MLR was like 84.7%, that's x development, right? So you're basically saying MLR should be relatively flat to up in 2015 versus 2014? And I guess, when I think about PDP coming in worse, I thought that you guys probably would have made some progress there next year. And then MA, obviously, you've got a funding gap, but it seemed like there was a lot that you were doing in 2014 to try to offset that. So just trying to understand how you think about the margins."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes, Kevin. It's Tom. And you've got the dynamics right. Our -- we've got an outlook of 84.5% to 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. And the picture, I thin",109,"Yes, Kevin. It's Tom. And you've got the dynamics right. Our -- we've got an outlook of 84.5% to 85.5% compared to the 84.7% operating basis result delivered in '14. And as you say, that excludes prior development reported in 2014. And the picture, I think, is generally like this. We're generally expecting stable Medicare MCRs between Medicare Advantage and PDP with some mix impact actually driving the dynamic here as we're growing some of the higher MCR Medicaid business we have as a portion of the portfolio. Again, all in the margin, but that's generally the result. And I think the outlook calls generally for a stable result."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, I guess when you talk about accelerating the MA -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective off the kind of 6% to 8% that you're looking for this year in a membership basis",61,"Okay. And then, I guess when you talk about accelerating the MA -- I'm sorry, the government kind of business in 2016 and beyond, is it accelerated from a revenue perspective off the kind of 6% to 8% that you're looking for this year in a membership basis? Or is it margins? Is it both? How do we think about that?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with the outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both revenu",119,"Kevin, it's David. Again, I think you had the right  lever. So one, we're pleased with the outlook we have for 2015 from a growth standpoint. As Tom noted, generally speaking, stable MCRs. As we look to 2016, we would expect to be able to grow both revenue, as well as margin. As I noted in my prepared remarks, we expect to see further improvement in the Stars Ratings, for example. And the positioning we took in 2015 was to position products in key markets within expectation, and what we saw was a step-up in 2016 Stars. So we will see both revenue contribution going into 2016, as well as margin expansion contribution in 2016, therefore, an earnings accelerant."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Christine Arnold with Cowen.",9,"The next question is from Christine Arnold with Cowen."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","A couple of this and thats. The CRomnibus exempted the expatriate businesses from the health insurance fee. Is there a quantifiable impact there?",23,"A couple of this and thats. The CRomnibus exempted the expatriate businesses from the health insurance fee. Is there a quantifiable impact there?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's David. First and foremost, there have been a variety of administrative release that took place post the passage of the bill back in 2012 and up to, as you referenced, the CRomnibus because the administration recognized that there was an un",146,"Christine, it's David. First and foremost, there have been a variety of administrative release that took place post the passage of the bill back in 2012 and up to, as you referenced, the CRomnibus because the administration recognized that there was an unintended consequence to that business. We're pleased with the outcome from the CRomnibus, legislatively rectifying that for the benefit of global employers. And I would suggest to you the biggest impact here is taking away the administrative complexity that applying the ACA to the global employers expatriate benefit business would create, that was putting a burden on that business portfolio that we were managing through; that's the biggest benefit. There's a small economic benefit, but that's the -- that's a few of the [ph]  byline. The bigger piece is it cleans it up for purposes of global employers not to be exposed to that."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, can you talk about why first quarter '15 will be lower than first quarter '14 and give us some kind of order of magnitude on the factors? And then, do you think you need Medicaid in order to serve the duals? Or you're still kind of the vie",61,"Okay. And then, can you talk about why first quarter '15 will be lower than first quarter '14 and give us some kind of order of magnitude on the factors? And then, do you think you need Medicaid in order to serve the duals? Or you're still kind of the view that you've got the portfolio you need for those duals?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. First, I'll address the first quarter earning spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than the first quarter of 2014. And we attribute it to 2 things: strategic investments; and the",136,"Christine, it's Tom. First, I'll address the first quarter earning spend. Of course, just to reiterate, we're expecting first quarter 2015 earnings to be lower than the first quarter of 2014. And we attribute it to 2 things: strategic investments; and the growth of our Part D business in the first quarter. On the strategic investment side, I think about additional start-up costs in Medicaid expansions, increased grant spend compared to 2014, and the Part D impact reflects both the first quarter pressure typical in Part D, given the benefit structure -- we all know that Part D first quarter results tend to be low -- and the impacts of the drug transition requirements for new customers. So all in, on a comparable basis, we're expecting first quarter '15 to be lower than first quarter '14."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Christine, it's David. On your second part -- and pretty efficient working in multiple questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity",116,"Christine, it's David. On your second part -- and pretty efficient working in multiple questions here. At a headline level, as we've discussed before and I noted, duals, ABD, et cetera, in targeted geographies continue to present an attractive opportunity for us because we believe they're underserved as it relates to clinical care coordination. And our clinical programs actually play quite affectively there as noted in our Texas program. We're going to seek to grow those activities organically, and then opportunistically as we noted in our M&A priorities, opportunistically for geographic density. We will also look to dual capabilities from an M&A standpoint. So I would view that as both organic and inorganic opportunities for us."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Andy Schenker with Morgan Stanley.",10,"The next question is from Andy Schenker with Morgan Stanley."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just following up on one of the earlier questions here for PDP specifically, the very last quarter you highlighted some pressures around specialty drugs and a higher brand mix, and maybe just how did that continue to play out or evolve in the fourth qu",80,"So just following up on one of the earlier questions here for PDP specifically, the very last quarter you highlighted some pressures around specialty drugs and a higher brand mix, and maybe just how did that continue to play out or evolve in the fourth quarter? And then, related to that, you saw pretty strong annual enrollment -- growth in the annual enrollment period, again, about 200,000-plus lives. So what are your expectations on those costs continuing into next year?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thanks, Andy. It's Tom. I'll start and then David will address some of the growth issues. So as you pointed out, PDP results do reflect higher drug costs in the fourth quarter and the full year. And that includes some impact from the mix in channel of dru",147,"Thanks, Andy. It's Tom. I'll start and then David will address some of the growth issues. So as you pointed out, PDP results do reflect higher drug costs in the fourth quarter and the full year. And that includes some impact from the mix in channel of drug purchases and some impact from specialty drugs, so both. We've taken actions to try and improve results here -- that will improve results here. We made network and formulary adjustments when we merged the HealthSpring and Cigna Part D plans for 2015, so that resulted in a leaner formulary and expanded utilization plan -- management for the merged plans, which we expect will improve cost. As you pointed out, we also expect some favorable impact from our recent agreement with Gilead on hep C drugs. But we have factored some ongoing pressure in Part D into our 2015 outlook."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Relative to growth, as Tom noted, we merged the HealthSpring and the legacy Cigna programs and sought to take the best of both organizations. For 2015, we -- our growth efforts, we're targeting the chooser population and we saw a very good traction in our",121,"Relative to growth, as Tom noted, we merged the HealthSpring and the legacy Cigna programs and sought to take the best of both organizations. For 2015, we -- our growth efforts, we're targeting the chooser population and we saw a very good traction in our sales efforts there. We'd note that our early results through January from a utilization and performance standpoint for the new population are in line with our expectation for that chooser population, meaning the aggregate utilization levels, importantly, the mix of utilization by generic and otherwise. And as Tom noted, we expect, generally speaking, stable MCRs going from 2014 to '15 for this portfolio. And again, it presents an opportunity for further earnings expansion looking into 2016."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And just maybe a -- changing gears a little bit to follow-up question here. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into it? Have you -- how much business do you guy",71,"And just maybe a -- changing gears a little bit to follow-up question here. A little bit early, but for the national account selling season, I mean, anything to highlight for us as you start really heading into it? Have you -- how much business do you guys have up for renewal to maybe versus an average year? And any opportunities out there that you guys are really looking to target?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Andy. As you noted, it's early in the cycle. But to give you some color -- and again, when I give you color, just -- we'll define what we talk about in national account, so commercial employers with 5,000 or more employees that are multistate. We're",221,"Sure, Andy. As you noted, it's early in the cycle. But to give you some color -- and again, when I give you color, just -- we'll define what we talk about in national account, so commercial employers with 5,000 or more employees that are multistate. We're actually seeing a pretty robust pipeline of new opportunities unfold. So it's unfolding both meaningful scale and early in the cycle. So we're seeing a robust pipeline begin to unfold early in the cycle. And with an elevation -- a further elevation in intensity looking for what we call engagement and incentive-based programs, exploring a lot of the value-based network configurations and the like, which play very well to our strategy. As it relates to the last part of your question, the percent of our book that's out to bid, we see a smaller percentage of our book that's out to bid for 2016 than we did prior year, and that's consistent with the dialogue we had last year. We indicated that we had an elevated percentage based on procurement cycle. So we managed through that queue pretty well for 2015. And now looking to 2016, while the smaller percentage of our book of business out to bid and, again, we're seeing a pretty nice robust pipeline beginning to unfold early in the cycle."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ralph Giacobbe with Crdit Suisse.",10,"The next question is from Ralph Giacobbe with Crdit Suisse."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? And you guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more move",53,"Can you give us a little more sense of expectations for ASO membership growth versus maybe risk for 2015? And you guys have talked a lot about the Select Segment, but just interested in thoughts maybe more broadly as well since there seems to be more movement within the ASO segment amongst peers."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Sure, Ralph. It's David. As you know, the vast majority of our commercial business, U.S. commercial business, is ASO. So as we're able to grow our portfolio, the preponderance of that is ASO-oriented. I'd also note that our expectation, as the results unf",135,"Sure, Ralph. It's David. As you know, the vast majority of our commercial business, U.S. commercial business, is ASO. So as we're able to grow our portfolio, the preponderance of that is ASO-oriented. I'd also note that our expectation, as the results unfold and in line with the guidance that Tom provided, the 1% to 3% customer growth, which excludes our QualCare network acquisition, we would expect that our guaranteed cost lives, or our risk lives, would decrease because of the run off of the individual non-ACA compliant lives, so very important. As we get into the year, we'll provide you more detail as that manifests itself. But net-net, you should think about our growth as being predominantly ASO-oriented, and that transcends through Select, the regional segment, et cetera. And we see good traction there."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just in terms of just the competitive environment for ASO broadly?",14,"Okay. And then, just in terms of just the competitive environment for ASO broadly?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the competitive environment -- maybe I'll flip it around a little bit the other way, and then try to answer your competitive environment. The buying environment, so the client portfolio -- and we call them clear as [ph] clients, clients continue to",180,"Well, the competitive environment -- maybe I'll flip it around a little bit the other way, and then try to answer your competitive environment. The buying environment, so the client portfolio -- and we call them clear as [ph] clients, clients continue to seek what we call -- you might call alternative funding, we'll call transparent funding -- so the demand for more transparent funding continues to grow as employers are seeking to get alignment of incentives and better visibility through how their funds are being deployed and align the incentives for their employees or customers. And so that trend continues. So hence, the competitive environment, competitors are seeing more ASO activity as well. For Cigna, that's good for us because we're extremely well-positioned in that environment from benefit design, the consultative nature, and very importantly, the employer reporting and insights that go along with that monthly, quarterly and annually to provide the guidance in terms of what's transpiring. So yes, elevation, but it's elevation because of the client demand, not competitive activity. And client demand continues to go up."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay, that's fair. And then, second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect incremental for 2015? And then, your Specialty is separate from that deal. Is there any timeline or d",61,"Okay, that's fair. And then, second question, can you talk about the accretion you've captured from the Catamaran deal in 2014? And maybe what you expect incremental for 2015? And then, your Specialty is separate from that deal. Is there any timeline or decision on whether you want to keep it that way or if you're exploring options at this point?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our",194,"Ralph, I'll try to be responsive. Again, real efficient in getting a bunch of questions in here. For pharmacy, more broadly, as you know, we have a wholly-owned pharmacy organization that we continue to invest in. It's performing well as evidenced by our strong clinical outcomes, continued customer growth and strong earnings performance. And we continue to invest in that. So relative to your latter question on Specialty, we run our own Specialty operations within the organization. It's performing well. Our team continues to look to means to further expand and strengthen that, either through collaboration or otherwise. But we're investing in and continue to run that on our own. As for results, and per prior conversations, for 2014, our results tracked in line with our expectations. In fact, they tracked a little bit ahead of our expectations largely because of actions we took around rate and pace of investments, the timing of that and inherent level. So we actually were a little bit ahead of our track record for 2014. And for 2015, our overall targets for our pharmacy business are in line with our expectations, maybe slightly favorable for the overall franchise."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Ana Gupte with Leerink Partners.",10,"The next question is from Ana Gupte with Leerink Partners."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","I just wanted to follow-up on the Select and the ASO mix shift that moved from a stop loss perspective. So I'm trying to understand firstly whether the company that just do stop loss are competing on a bundled or an unbundled basis with all of you? And it",63,"I just wanted to follow-up on the Select and the ASO mix shift that moved from a stop loss perspective. So I'm trying to understand firstly whether the company that just do stop loss are competing on a bundled or an unbundled basis with all of you? And it looks like United and Aetna have started to play a bigger role here."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ana, it's David. First and foremost, as we've talked now for multiple years around the Select space and ASO, ASO stop loss, variety of funding mechanisms, we believed, and it's proven out, we believe that there will be increasing demand. We believe that's",274,"Ana, it's David. First and foremost, as we've talked now for multiple years around the Select space and ASO, ASO stop loss, variety of funding mechanisms, we believed, and it's proven out, we believe that there will be increasing demand. We believe that's a result of the increasing competitive activity, and we believe to be successful we'd have to continue to innovate. And that's what's transpiring in the marketplace. As it relates to standalone, if you'll -- stop loss players in the space, I don't see that as a primary competitive disruptor largely because of the impact of integration here. So if you step back, what makes these programs work is not a stop loss program. What makes these programs work is getting the benefit alignment laid out with the right incentives, the network configuration appropriate, the clinical programs aligned. For example, we have the ability, and we do, do on-site biometric screening, on-site coaching for a 100 lives employer. That's a new model, to be  able to do that and bring that on board for a client and identify the 1, 2 or 3 high-risk individuals who are not incurring costs today, but we need to engage clinically with. And integrating all of that with the ASO funding mechanism, stop loss when it makes sense for that employer, as well as the reporting, that's the core of our value proposition and we continue to see strong demand for that today and into the future. And we would expect, again, competitors to step into this space because there's a significant amount of demand. Key to us is the results we're delivering and ongoing innovation."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose anyway a while ago, still hold?",35,"And does that mean then, David, that because of your integration, you can keep your pricing more steady? And the 65-ish percent loss ratios that you used to disclose anyway a while ago, still hold?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Ana, it's Tom. I would think about the standalone stop loss segment as a totally different market than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical cost. And the standalone",177,"Ana, it's Tom. I would think about the standalone stop loss segment as a totally different market than the market we're serving. Again, our approach focuses on the integrated benefits of actually more effectively managing medical cost. And the standalone stop loss carriers, you typically don't have that feature. In addition, we do have some built-in advantages versus them. I mean, we already have this customer in our sights, so we have one set of acquisition costs that they have to pay -- incremental acquisition cost to secure this customer, and we have a lot better insight into the underlying claims data, so our ability to effectively approach the program is very superior. So we don't really find ourselves in what sometimes can be a hypercompetitive standalone stop loss market, not really a market we're computing in. We don't sell stop loss unless we write the underlying program. And when we're selling stop loss, it's part of an integrated package. So the competitive dynamics for the standalone market are very different than the competitive dynamics we see."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Peter Costa with Wells Fargo Securities.",11,"The next question is from Peter Costa with Wells Fargo Securities."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My question is also on the stop loss business. Is that business included in the commercial MLR that you're giving us now, in the total commercial MLR?",27,"My question is also on the stop loss business. Is that business included in the commercial MLR that you're giving us now, in the total commercial MLR?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes. Total commercial MLR will include all of our risk businesses in commercial.",13,"Yes. Total commercial MLR will include all of our risk businesses in commercial."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising in loss ratio on that book of business, so that it's not pullin",59,"So just by the growing mix of that in your commercial MLR, it should be pulling the loss ratio down by maybe 100 basis points? Is that a fair number? So does that mean that -- or is it rising in loss ratio on that book of business, so that it's not pulling it down as much going forward?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Yes, Peter. I have to tell you, I haven't done that calculation. But obviously, we're not seeing it in the results, so I don't -- I think you might be missing a little -- something there. But just a couple of things. First, the loss ratio on stop loss is",192,"Yes, Peter. I have to tell you, I haven't done that calculation. But obviously, we're not seeing it in the results, so I don't -- I think you might be missing a little -- something there. But just a couple of things. First, the loss ratio on stop loss is lower than the average overall loss ratio, but the premium density in the other businesses is pretty high. So I'd be surprised if there was a 1 point impact, but we'll do that math. Second, on stop loss, we actually would expect some modest increase in the stop loss loss ratio as we continue to sell disproportionately in the lower end. And those customers tend to have a more premium density, so less of an expense factor in the result and a higher MCR. Again, very attractive MCR, so it's not like it's worse profitability. The bottom line margin is still very attractive for the -- that stop loss business. But the dynamics in the MLR are a little higher. So I would expect that there's marginal impact probably from this change, but I'll do a little more careful look at that."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Chris Rigg with Susquehanna Financial Group.",11,"The next question is from Chris Rigg with Susquehanna Financial Group."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Just wanted to come back to capital deployment again. And I heard your comments on Medicare Advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestic",54,"Just wanted to come back to capital deployment again. And I heard your comments on Medicare Advantage and things generally. But when we think about opportunities sort of broadly here, are you -- do you think opportunities are better at this point domestically? Or you still think international is kind of a better opportunity?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Chris, it's David. As it relates to inorganic capital deployment, we have 4 priorities and the 4 priorities have remained the same. These are not in order. These are the 4 priorities: further our global footprint, Medicare Advantage and dual capabilities,",97,"Chris, it's David. As it relates to inorganic capital deployment, we have 4 priorities and the 4 priorities have remained the same. These are not in order. These are the 4 priorities: further our global footprint, Medicare Advantage and dual capabilities, further our retail-based capabilities, and then what we call Go Deep bolt-on capabilities for our portfolio. So I wouldn't separate international as more than or less than for 2015 versus the last year. It's within our portfolio when we've been opportunistic and focused in terms of opportunities outside the U.S, as well as inside the U.S."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, my follow-up is just on sort of overall growth to the company, and specifically in the health care segment. I mean, I'm just trying to figure out, you're growing your revenues 8% to 10%. Obviously, the bottom line isn't growing in line wit",123,"Okay. And then, my follow-up is just on sort of overall growth to the company, and specifically in the health care segment. I mean, I'm just trying to figure out, you're growing your revenues 8% to 10%. Obviously, the bottom line isn't growing in line with that. Obviously, PPD is having an impact. But do you -- can you give us a sense for when you think you'll at least start to get some more leverage down the P&L? Is it -- is 2015 sort of the last truly difficult year and we should start to see some leverage next year? I know you're not going to give guidance. But just, again, big picture-wise, just trying to figure out the trajectory of growth."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Well, the direct answer to your question and then a little more color is yes. A little more color is as we talked about the 2015 outlook, we're pleased with it, with the 8% to 10% revenue growth outlook. And then, the 3-day percent earnings growth outlook",149,"Well, the direct answer to your question and then a little more color is yes. A little more color is as we talked about the 2015 outlook, we're pleased with it, with the 8% to 10% revenue growth outlook. And then, the 3-day percent earnings growth outlook on the same-store basis and the 5% to 10% EPS growth outlook without capital deployment. As we said, looking to 2016, we see margin expansion opportunities within the health care business. Margin expansion opportunities, specifically in the senior space, both for MA, as well as PDP. We see further margin expansion opportunities within our individual block of business where we've seen some improvement move from '14 to '15.  And then, we'll see further scale leverage beyond the ongoing fundamentals of our strong performing employer business. So margin expansion opportunities exist in 2016 and '17 and beyond, and we're quite excited about that."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from Brian Wright with Sterne Agee.",10,"The next question is from Brian Wright with Sterne Agee."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And I apologize if I missed this, but did you give us some color on the number of PDP lives to be added in '15?",25,"And I apologize if I missed this, but did you give us some color on the number of PDP lives to be added in '15?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","We didn't, Brian. It's about -- we ended up 1:1 enrollment period. It's about 250,000 more lives than we had at the end of the year.",27,"We didn't, Brian. It's about -- we ended up 1:1 enrollment period. It's about 250,000 more lives than we had at the end of the year."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","Okay. And then, just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so thrilled to have that.  But the conspiracy theorist in me looks at how you're reporting now, and you have another peer's been",76,"Okay. And then, just one follow-up. First of all, thanks for the consolidated commercial MLR. We've been waiting for a decade, so thrilled to have that.  But the conspiracy theorist in me looks at how you're reporting now, and you have another peer's been very vocal about kind of large-scale acquisition in this space, and you're kind of reporting segments very nicely that would make consolidating 2 models pretty easily. So just any comments on that."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Brian, I think you may be able to work for the NSA if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus 1 because there are different attributes",153,"Brian, I think you may be able to work for the NSA if you're going try to connect those dots. But the -- really, what you have is continued refinement and responsiveness. We actually chose to provide 2 MCRs versus 1 because there are different attributes within the government portfolio business versus the commercial business. And while we had alternatives, we believe that, that was more customer-friendly and provided the transparency to drive the dialogue on a go-forward basis. And as we have in the past, and as we will on a go forward basis, we'll try to give you as much color as possible in terms of the underlying drivers of the overall business portfolio. But this was an attempt to be, again, responsive to the market, but also maintaining appropriate amount of transparency and not go to a single loss ratio, but provide 2 loss ratios for the domestic health business."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","The next question is from the Dave Windley with Jefferies.",10,"The next question is from the Dave Windley with Jefferies."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","My question's on Medicare Advantage. David, wondering if through the AAP here and your changes in the mid-Atlantic market, specifically if your view is that those changes -- network, and to the extent they were benefit design as well, are complete and set",56,"My question's on Medicare Advantage. David, wondering if through the AAP here and your changes in the mid-Atlantic market, specifically if your view is that those changes -- network, and to the extent they were benefit design as well, are complete and set you up for a more normal contribution from that market in 2016?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","In your comments, Dave, were pointed toward 2016, so put MA back in context. We're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth, the 6% to 8% customer growth. You're correct. You draw attention back to a market that we s",140,"In your comments, Dave, were pointed toward 2016, so put MA back in context. We're pleased in aggregate with the M&A -- MA outlook for 2015 from a customer growth, the 6% to 8% customer growth. You're correct. You draw attention back to a market that we sought to do some repositioning in, and we're feeling the final impact of that, or a final meaningful impact to that repositioning in 2015 in terms of both the lack of life growth. So even in the 6% to 8%, the lack of life growth in that market is fully contemplated in the 6% to 8%. And we would expect, as we step into 2016, an opportunity to see improvement in performance there. So that's a contributor as we look to the future, but part of that repositioning is being felt in 2015."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","And then, sticking with that, is that also something that you think can have another positive impact to Stars Ratings when they come out later this year?",27,"And then, sticking with that, is that also something that you think can have another positive impact to Stars Ratings when they come out later this year?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Our organization has demonstrated significant improvement in Stars as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement go",125,"Our organization has demonstrated significant improvement in Stars as I noted going from 40 to 60 for 2016. We were pleased with that outcome. It was in line with our expectations. And as I noted previously, we would expect to see a further improvement going from '16 to '17. I'm not going to comment on individual market activities. But more importantly, our organization is highly focused on the intricacies of the Stars program. And importantly, making sure we're given the right service experience and clinical experience, both medical and pharmacy, for the benefit of our customers, and doing so in a way to move the Stars Rating up in 2017 to another step function off of the very attractive movement we made going to '16."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Our last question is from Michael Baker with Raymond James.",10,"Our last question is from Michael Baker with Raymond James."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Analysts","David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enh",56,"David, I was wondering if you could give us some color on how you're positioning your proprietary exchange offering. I know at this point, private exchanges has been pretty de minimis to the business. But just curious, is really differentiation around enhanced engagement and strengthened guarantees, as well as some ben admin element that increases stickiness?"
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we'll call down market, so think about Select Segment and a portion of the regional employer portfolio. It's a single carrie",246,"Michael, so relative to our proprietary exchange capabilities, as you would expect, those capabilities are largely focused on what we'll call down market, so think about Select Segment and a portion of the regional employer portfolio. It's a single carrier, as you would expect, exchange alternative. The value prop -- so let's go into the value prop. The value prop is primarily to enable a further retail experience for individuals to get them more actively engaged in the selection of their personal benefits. And we know that when that transpires, whether through a private exchange or other mechanisms because we do this every day without private exchanges, you get a higher level of awareness, a higher level of engagement, a higher level of ownership of the individual and their benefits and their understanding of what's there, That's the primary mechanism. And then you're able to drive the appropriate personalization or efficiency that works for them. So using your term, consumer engagement or personalization, there's a primary attribute there. As I noted previously though, we've expected this marketplace more broadly to unfold slowly and it is. Our team has seen some success. And we have a dedicated team of resources that will continue to focus on this, but we have not banked on, nor are we banking on a significant step function in revenue, customer lives or earnings growth here. Rather, we've positioned ourselves to have smart optionality to the extent this market moves forward very positively."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","I'll now turn the call over to David Cordani for closing remarks.",13,"I'll now turn the call over to David Cordani for closing remarks."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Executives","Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna's strong fourth quarter and full year results reflect solid revenue and earnings contributions from each of our business segments. As an organization, we have o",174,"Thank you. So to conclude, I just want to offer some points from our morning discussion. Cigna's strong fourth quarter and full year results reflect solid revenue and earnings contributions from each of our business segments. As an organization, we have over 35,000 talented colleagues around the globe whose work exemplifies our mission of improving health, well-being and sense of security for the people we serve every day. The momentum we generated off of another strong year in 2014, combined with our attractive growth opportunities, give us confidence we will achieve our full year 2015 outlook. We plan to continue to leverage our proven business and core capabilities to drive meaningful growth in attractive new markets and segments, resulting in doubling of our revenue over the next 7 to 8 years. And we remain committed to achieving, on average, our annual EPS growth objective of 10% to 13% over the long term. We thank you for joining the call today and your continued interest in Cigna, and we look forward to continuing our conversations."
172899,253311656,756306,"Cigna Corp., Q4 2014 Earnings Call, Feb 05, 2015",2015-02-05,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days fol",68,"Ladies and gentlemen, this concludes Cigna's Fourth Quarter and Full Year 2014 Results Review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 1-800-945-4244 or (203) 369-3501. No passcode is required for the replay.  Thank you for participating. We will now disconnect."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2015 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded. We'll begin by turni",48,"Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2015 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded. We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",380,"Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks, today David and Tom will cover a number of topics including Cigna's first quarter 2015 financial results as well as an update on our financial outlook for 2015. As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States otherwise known as GAAP. Specifically, we use the term labeled adjusted income from operations and earnings per share on the same basis as our principal measures of financial performance. A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com. 
In our remarks today, we will be making some of forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. 
Before turning the call over to David, I will cover a few items pertaining to our financial result and disclosures. As a reminder, beginning in 2015, we have simplified our guidance and disclosures for our medical care ratios or MCRs by reporting them on a basis of total commercial and total government. The total commercial ratio encompasses all of our commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products provided through guaranteed cost or experienced rated funding arrangements in both the United States and internationally. The total government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses. 
Finally, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or additional prior year development of medical costs. And with that, I will turn the call over to David."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thanks, Will. Good morning, everyone, and thank you for joining our call today. To begin, I'd like to read the highlights of our financial results for the first quarter. Next, I'll discuss how we are leveraging Cigna's integrated capabilities to engage in",1735,"Thanks, Will. Good morning, everyone, and thank you for joining our call today. To begin, I'd like to read the highlights of our financial results for the first quarter. Next, I'll discuss how we are leveraging Cigna's integrated capabilities to engage individuals to help them optimize their health and well-being and how this is translating into value for customers and clients. Then Tom will provide more detail around our first quarter financial performance and update our full year 2015 outlook. And following your questions, I'll leave you with a few closing remarks. 
Let's dive in with some highlights for the quarter. Cigna's first quarter 2015 performance represents a strong start to the year. We are pleased with our results which extends our track record of attractive financial performance. Once again, our success was driven by the effective and disciplined execution of our strategy, which continuously guide our actions in a dynamic marketplace. Our first quarter 2015 consolidated revenue increased 11% to $9.5 billion, with strong contributions across our business segments. We reported adjusted income from operations for the first quarter of $513 million or $1.96 per share. Our Global Health Care revenues increased 12% driven by strong performance in our Commercial and Government businesses. Our Global Supplemental Benefits business once again drove strong revenue growth in high single-digit after-tax margins while we continue to make targeted investments in support of future growth, and we achieved 6% revenue growth in our Group Disability and Life business. Overall, our diversified portfolio of businesses continues to produce significant free cash flow that further enables our financial flexibility with more than $500 million deployed for share repurchase on a year-to-date basis. Our continued focus and effective strategic execution are generating strong results enabling ongoing investments in our business portfolio and helping us meet the unique local market needs to the right balance of affordability and personalization of our products and services. 
As we've discussed previously, we have a clear framework to drive ongoing future value creation for Cigna. First, our diversified businesses are well positioned to create attractive value for our customers and clients and, as a result, differentiated revenue growth. Second, we are focused on targeted and effective capital deployment to create ongoing shareholder value through investments in our business, strategic M&A and share repurchase. Our businesses generate high levels of free cash flow, which give us financial flexibility and the opportunity to deploy capital to further create value for the benefit of shareholders. And finally, we continue to seek new and emerging opportunities to expand in new distribution marketplaces, new geographies and new buying segments. Guided by this framework and coupled with effective execution, we continue to expect to deliver average annual revenue growth rate of 8% to 10% over the long term. This framework also positions us to support our focus on enabling health care over financing sick care, which is well aligned with Cigna's efforts to improve the current health care system. 
The United States spends $3 trillion a year in health care. Studies consistently show approximately 25% of the total expenditures are wasted through inefficiency or breakage. At the same time, 50% of all adults have at least one chronic disease, conditions which translate to 7 out of the top 10 causes of death in the U.S. In this dynamic environment, Cigna continues to convene key stakeholders to work toward a sustainable health care system. Health care stakeholders from individuals to corporate employers and government organizations are seeking a common set of core goals. These include maintaining or improving health and productivity, affordable and predictable cost outcomes and greater personalization of solutions and services. To meet these goals, we must continue to accelerate the transition from yesterday's health insurance as a mechanism for financing the cost of illness to an orientation center around maintaining and improving the health and wellness of individuals. At Cigna, we are and we'll continue to make significant strides toward achieving a more sustainable health care system by engaging with individuals and physicians through coordinated offerings and alliance incentives. We have moved beyond the typical multi-product sales and services approach to engaging individuals and coordinate care at a very personal level as we work to improve health and wellness, all by harnessing information, incenting and support individuals and partnering with physicians, the result of which is a service experience for customers that achieves the right balance of personalization and affordability. 
I'd like to share with you a few examples of how we are leveraging the power of integration and coordination with our broad solution suite by encouraging maintenance and prevention among the healthy, providing coaching to the healthy at risk, enabling coordinated care for those with chronic conditions and facilitating access to centers of excellence for those with acute conditions. Our health care professionals engage with customers and clinicians to improve health every day, leveraging the breadth of our clinical capabilities, which spans over 4,000 professionals from doctors and nurses to behavioral professionals, health coaches and pharmacists. 
Relative to our behavioral professionals, our capabilities include engaging with a cardiology team when a health event transpires as we have seen a strong correlation between these types of illness and depression; engaging with our experts and disability programs to improve health and maximize personal productivity; and helping individuals recover from an injury by taking a more holistic view of mind and body. As a result, our customers are empowered by active coordinated care through coaching support services incentive programs. And the impact, Cigna clients with integrated offerings have 29% pure mental health and substance abuse related outpatient visits and 8% fewer inpatient events compared with those without integrated offerings. 
Another powerful example of our success with our coordinated approach is for customers who are expectant moms. In today's health care system, the cost of a premature birth is nearly 11x higher than that of a full-term birth, not to mention the impact on the family stress and, in some cases, lifelong health challenges. Cigna's healthy pregnancy healthy babies program engage with customers to optimize health during pregnancy by working with nurses who can assess risks, develop personalized care plans and continue to support outreach and coordination with OB/GYN teams and, finally, providing coaching on newborn care. Active participation by expected mothers in our integrated program is key. In fact, for those who enroll, there is nearly 50% reduction in premature births versus the U.S. average. This is a huge impact for the family, the child and society overall. 
The benefit of integrated and coordinated care is also impactful within Cigna Specialty Pharmacy programs, where our pharmacists and clinicians engage with customers and health care professionals to improve the effectiveness of drug regimes to drive better overall health outcomes. Our engaged customers have higher medication adherence and lower specialty drug costs, resulting in a 15% [ph] lower overall medical cost versus individuals who do not have these coordinated offerings. 
Our coordination also works with dental care customers, where there's a high correlation between periodontal health and improved health outcomes. In our dental programs, individuals with diabetes, heart disease or stroke who have both medical and dental coverage with Cigna has seen higher quality and lower medical costs. For example, patients with diabetes participating in our coordinated and dental programs saw lower average annual medical costs of approximately 28% when receiving coordinated care. And for patients with heart disease, costs were lowered by approximately 25%. 
As a final example across the U.S., our 4,000 plus clinical professionals continue to engage and help our customers and an increasing numbers through a rapidly growing collaborative care relationships. Today, we have more than 120 of these relationships spanning 29 states. As for impact, more than 90% of Cigna's collaborative care relationships with at least 2 years of experience are seeing success in managing improved medical costs and nearly 80% with at least 1 year of experience are seeing success in total medical cost results or clinical quality measures. Examples of medical results include an improvement in blood pressure, an improvement in BMI and an improvement in total cholesterol levels. These examples reinforce our successful efforts to improve health and quality-of-life while working to remove cost from the system. By leveraging our integrated capabilities and coordinating clinical care resources for each individual through their health journey, we are improving affordability while creating a more sustainable health care system. Over the long term, we believe our approach to health care rather than sick care will promote better health, sustainability and economic vibrancy and lower the cost burden on customers as well as employers. 
And this success translates to shareholder value as we leverage our capabilities and meet customer needs with products and services that are enhanced through our highly aligned coordinated offerings. This value is evidenced by our industry-leading medical cost trend over the last several years, high customer retention levels and strong growth in our specialty and integrated services that achieve the personalization of services outcomes that I previously referenced. 
As demonstrated by our discussion this morning, our integration and coordination of care has moved beyond the simple multiproduct solution. Today, we are engaging individuals in a very personalized way, leveraging actionable information, partnering with health care professionals and utilizing care resources that both reduce cost and produce superior health outcomes. 
Now to summarize my remarks before turning it over to Tom. Cigna's strong start to 2015 continues our long-term track record of financial performance in delivering competitively attractive revenue and earnings and gives us confidence in our increased full year 2015 outlook. The strong free cash flow from a high return on capital and high-margin portfolio of businesses provide ongoing financial flexibility in capital management and deployment. We are effectively executing our strategy and creating value for our customers and clients by leveraging integrated capabilities that promote health care rather than sick care and driving improved personalization and affordability for the benefit of the individuals we serve. We remain committed to our long-term objective, which is to double the size of our business over the next 7 to 8 years, yielding an 8% to 10% annual revenue growth rate on average. And over this time horizon, we expect to continue to deliver competitively attractive long-term EPS growth of 10% to 13% annually on average, all while we continue to invest in our company's business portfolio. And with that, I'd like to turn the call over to Tom."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone. In my remarks today, I will review Cigna's first quarter 2015 results and discuss our outlook for the full year. We've had a good start of the year with strong revenue and earnings contributions across our diversifie",1643,"Thanks, David. Good morning, everyone. In my remarks today, I will review Cigna's first quarter 2015 results and discuss our outlook for the full year. We've had a good start of the year with strong revenue and earnings contributions across our diversified portfolio of businesses, driven by continued effective execution of our strategy. 
Key highlights in the quarter include consolidated revenue growth of 11% to $9.5 billion; consolidated earnings of $513 million; quarterly earnings per share of $1.96; and continued strong free cash flow with approximately $515 [ph] million return to shareholders through share repurchase on a year-to-date basis. Overall, the strength of our first quarter performance provides us with solid momentum for the year. 
Regarding the segments, I will first comment on our Global Health Care segment. Global Health Care results were solid in the quarter. First quarter premiums and fees grew 12% to $6.7 billion, driven by customer growth in our Commercial and Government businesses as well as specialty contributions and rates actions. We ended first quarter of 2015 with 14.7 million global medical customers, including approximately 200,000 new customers from our QualCare Alliance Networks acquisition. First quarter earnings were $444 million, reflecting medical and specialty business growth, continued effective medical cost management, improving results in our individual business with some offset from increased spending for strategic investments as well as higher seasonal costs in our growing Medicare Part D business. 
Turning to medical costs. We continued to deliver medical cost that reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. Our commercial medical trend results continues to be among the lowest in the industry. And given that over 85% of our U.S. Commercial customers are in transparent ASO funding arrangements, our clients directly benefit from these favorable medical costs. 
Regarding medical care ratios, our first quarter 2015 total commercial medical care ratio or MCR was 75.2% on a reported basis or 75.9% excluding prior year reserve development. Overall, we are pleased with the results of our commercial risk businesses in the quarter, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results in our individual business continue to improve from the first quarter and are in-line with our expectations. 
In our government business, our first quarter 2015 total government MCR was 89.4% on a reported basis or 89.9% excluding prior year's reserve development, reflecting continued good performance in our Medicare Advantage business, partially offset by seasonal costs from our growing Medicare Part D business. Across our Commercial and Government risk book of business, our first quarter earnings included favorable prior year reserve development of $25 million after-tax compared to the $30 million after-tax in the first quarter 2014. 
Moving to operating expenses, for first quarter 2015, our total Global Health Care operating expense ratio was 21.7%, which reflects an expected increase in spending for strategic investments. Overall, we've had a strong start to 2015 in our Global Health Care business. 
Now I will discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability. Premiums and fees grew 8% quarter-over-quarter in global supplemental or 12% on a currency-adjusted basis. First quarter earnings grew 21% or 25% on a currency-adjusted basis to $69 million, reflecting business growth and strong operating expense management as well as some favorable operating expense timing. 
For Group Disability and Life, first quarter premium and fees increased 7% over first quarter 2014, reflecting growth across the Disability Life and Accident product lines. First quarter earnings in our group business were $51 million, which include unfavorable claims experienced in our life insurance business as well as an expected increase in operating expenses. 
For our Corporate and Other operations, results totaled to an after-tax loss of $51 million in the first quarter of 2015. Overall, as a result of the continued effective execution of our strategy, our first quarter results reflect strong revenue and earnings contributions from our ongoing businesses and significant free cash flow. 
Turning to our investment portfolio. In the first quarter, we recognized net realized investment gains of $48 million after-tax, coupled with the strong investment income result. The high quality and diversification of our investment portfolio continue to drive our overall segment results. 
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to deliver affordable and personalized solutions, effectively deploying capital and targeting new and emerging opportunities where we will seek to drive additional value for shareholders. We continue to expect consolidated revenues to grow in the range of 8% to 10% over 2014. 
Our outlook for full year 2015 consolidated adjusted income from operations is now in the range of approximately $2.12 billion to $2.21 billion or $8.15 to $8.50 per share. This represents an increase of $0.10 to $0.15 per share over our previous expectations. 
I will now discuss the components of our 2015 outlook starting with Global Health Care. We now expect full year Global Health Care earnings in the range of approximately $1.75 billion  to $1.8 billion, an increase over our prior expectations. 
I'll now summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015 starting with our customer base. Regarding global medical customers, we now expect 2015 customer growth of 2% to 4%. This increase over previous expectations primarily reflects customers added through the acquisition of QualCare Alliance Networks, which was completed in the first quarter of 2015. 
Turning to medical costs. In our 2015 -- our 2015 outlook continues to assume some increase in medical utilization versus current levels which has been reflected in our pricing. For our total U.S. Commercial book of business, we continue to expect full year medical cost trend to be in the range of 5% to 6%. 
Now turning to our medical care ratio outlook. For our total commercial book of business, we continue to expect the 2015 medical care ratio to be in the range of 78% to 79%. For our total government book of business, we continue to expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%. 
Regarding operating expenses, we continue to expect our 2015 Global Health Care operating expense ratio to be in the range of 21% to 22%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.75 billion to $1.8 billion. 
The other components of our outlook are unchanged. For our Global Supplemental Benefits business, we continue to expect strong top line growth in earnings in the range of $230 million to $250 million. Regarding our Group Disability and Life business, we continue to expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations, that is other operations and corporate, we expect a loss of $180 million for 2015. So all-in, for full year 2015, we now expect consolidated adjusted income from operations of $2.12 billion to $2.21 billion or $8.15 to $8.50 per share. This represents an increase of $0.10 to $0.15 per share. I would remind you that our outlook continues to exclude the impact of additional prior year reserve development or earning future capital deployment. While we do not anticipate impact of future capital deployment in our EPS outlook, we continue to expect the additional free cash flow that we generate to be deployed for the benefit of of our shareholders either through value-creating acquisitions or share repurchase. 
Now moving to our 2015 capital management position and outlook. Overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow with the parent with a strong return on capital in each of our business segments. Our capital deployment strategy and priorities have not changed. These priorities are providing the capital necessary to support the growth of our ongoing operations; pursuing M&A activity with a focus on acquiring capabilities and scale to further grow in our target area of focus; and after considering these first 2 items, we'd return capital to shareholders primarily through share repurchase. 
Regarding free cash flow, we ended the quarter with parent company cash of approximately $1.3 billion, which includes approximately $900 million of proceeds from our recent issuance of long-term debt. These proceeds were subsequently used to redeem existing debt in the second quarter of 2015. During the period February 5 through April 29, we repurchased 3.2 million shares of stock for approximately $400 million, bringing our year-to-date share repurchase to 4.3 million shares for approximately $515 million. After considering all sources and uses of parent company cash, we now expect to have approximately $1.3 billion available for capital deployment during the balance of the year. Our free cash flow outlook continues to reflect the industry-leading margins and returns on capital in our businesses and the high level of capital efficiency, particularly from our fee-based businesses. This capital efficiency allows us to fund attractive organic growth while continuing to generate significant free cash flow to be deployed for the benefit of shareholders. 
Now to recap. Our first quarter 2015 consolidated results reflect the strength of our diversified portfolio of global businesses and continued effective execution of our focused strategy. The fundamentals of our business remain strong as evidenced by our first quarter results, which reflected strong revenue and earnings contributions across our diversified portfolio of businesses, industry-leading medical cost trends and high clinical quality and continued strong free cash flow. Based on the strength of these results, we are confident in our ability to achieve our increased full year 2015 earnings outlook. And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] Our first question comes from Scott Fidel with Deutsche Bank.",12,"[Operator Instructions] Our first question comes from Scott Fidel with Deutsche Bank."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","I was hoping we could just drill into the government MLR for a little bit and maybe just talk about first just on Medicare Advantage, how utilization trends looked in the quarter and if you've seen any type of recent indications of any type of inpatient a",112,"I was hoping we could just drill into the government MLR for a little bit and maybe just talk about first just on Medicare Advantage, how utilization trends looked in the quarter and if you've seen any type of recent indications of any type of inpatient admission acceleration in recent weeks. And then second, just relative to the PDP MLR, just how that tracked relative to your expectations in the quarter. And clearly, given when there's outsized growth in PDP membership there's sometimes risk of higher MLR, so just interested in terms of what you're seeing around script trends and just around general performance in the PDP business so far this year."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So first, we're very happy with the position of our government business. Our outlook for the government MCR in 2015 reflects strong results in our Medicare Advantage business and some expected pressure in Part D, as you mentioned. The qua",168,"Scott, it's Tom. So first, we're very happy with the position of our government business. Our outlook for the government MCR in 2015 reflects strong results in our Medicare Advantage business and some expected pressure in Part D, as you mentioned. The quarter-over-quarter increase, specifically in the government MCR, is mainly due to Part D with continuing good Medicare Advantage results. As you pointed out, we reported significant growth in Part D customers in 2015. And as a result, we've had a more pronounced seasonal impact from Part D this quarter. These new customers have a period of time to transition from their previous formulary to our formulary. So as we expected, we saw from additional first quarter cost impact. And all-in, we continue to expect our government MCR to be in the range of 84.5% to 85% for the full year, which we're happy with. As far as the outlook or the utilization outlook, we really didn't see any significant change in MA utilization in the quarter."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, and then just a quick follow-up. Just in terms of the cost trend view reiterating that 5% to 6% for the full year. Just interested if you could give us some flavor in terms of just the first quarter itself and commercial MLR looked quite favorable a",68,"Okay, and then just a quick follow-up. Just in terms of the cost trend view reiterating that 5% to 6% for the full year. Just interested if you could give us some flavor in terms of just the first quarter itself and commercial MLR looked quite favorable again. So just interested if we have a sense of where you were sitting within that range in the first quarter."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes, Scott, well, we're really pleased with our medical trend results. And as we mentioned many times, we delivered a cost trend below 4.5% in 2014, building on a very strong track record we've had for several years with industry-leading results. Our outl",114,"Yes, Scott, well, we're really pleased with our medical trend results. And as we mentioned many times, we delivered a cost trend below 4.5% in 2014, building on a very strong track record we've had for several years with industry-leading results. Our outlook for 2015, medical cost trend, 5% to 6%, does anticipate some uptick in utilization over the course of the year and some expected increase in pharmacy trend due to specialty drug cost. And commenting on the first quarter, we haven't seen the uptick in utilization, but we are seeing some expected pharmacy trend impact. So overall, we're comfortable we're going to again deliver a competitively attractive medical cost trend in 2015."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Matthew Borsch with Goldman Sachs.",10,"The next question comes from Matthew Borsch with Goldman Sachs."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Yes, I was hoping that maybe you could address what you're seeing in the marketplace in terms of middle-market employers and the extent to which there's interest in self-funding, if you've seen that accelerating if you think that's going to continue and m",62,"Yes, I was hoping that maybe you could address what you're seeing in the marketplace in terms of middle-market employers and the extent to which there's interest in self-funding, if you've seen that accelerating if you think that's going to continue and maybe on the larger end of that, what you're getting a taste of in terms of product preferences for 2016."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Matthew, good morning, it's David. As it relates to use the term middle-market, so we'll talk about the regional segment. We define that as employers with 250 to 5,000 employees as well as large single state employers. The broad thing, I would tell you, i",218,"Matthew, good morning, it's David. As it relates to use the term middle-market, so we'll talk about the regional segment. We define that as employers with 250 to 5,000 employees as well as large single state employers. The broad thing, I would tell you, is that the market's appetite and interest in transparent funding and aligned funding, which include ASO, continues to grow. It continues to grow both in the regional segment. That has always been a meaningful portion but not the totality of it, but importantly downmarket into the Select Segment as well. So point one is continued high and accelerating interest in transparent funding because it aligns incentives, it provides transparency and enables better functionality of the incentive alignment programs and the engagement programs we like. The second thing we see is continued elevation and engagement in we typically call them carve-in or specialty programs. We look at them more as a coordination of care programs. Many other examples I cited in our prepared remarks. So those will be the 2 predominant trends we continue to see: elevation in transparent funding and then continued movement in what you might call carve-in, we call them coordination of care programs that are delivering superior medical cost and quality outcomes that Tom made reference to a few moments ago."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, great. Just on a separate angle, if you don't mind. Can I just ask if you have any comments about the outlook for your PBM relationship now that there's a change of control event coming with Catamaran and UNH.",40,"Okay, great. Just on a separate angle, if you don't mind. Can I just ask if you have any comments about the outlook for your PBM relationship now that there's a change of control event coming with Catamaran and UNH."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, Matthew. Just by way of backdrop, important to note that we continue to own and operate a very highly performing PBM for the benefit of our customers and clients, and that high performance is being demonstrated through continued growth in customer l",152,"Sure, Matthew. Just by way of backdrop, important to note that we continue to own and operate a very highly performing PBM for the benefit of our customers and clients, and that high performance is being demonstrated through continued growth in customer lives, strong medical trend in clinical quality performance. As you know, we further strengthened those capabilities about 2 years ago with our expanded relationship with Catamaran seeking several features to strengthen and we're seeing the benefits of those. As we talked about that in the past, while we continue to and own and operate our PBM, we maintain significant optionality and productivity in that structure. And then while we don't typically comment on details of transactions, we view that the PBM marketplace is and will continue to be very dynamic. As such, we ensure that there was some adequate deal protection for us that gives us meaningful flexibility going forward."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Josh Raskin with Barclays.",9,"The next question comes from Josh Raskin with Barclays."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Just getting back to the commercial -- I'm sorry the government MLR. I'm just struggling to understand what caused the 290 basis point impact, like if you hold Medicare Advantage and Medicaid MLRs flat year-over-year, it implies the PDP was up 12 or 13 pe",89,"Just getting back to the commercial -- I'm sorry the government MLR. I'm just struggling to understand what caused the 290 basis point impact, like if you hold Medicare Advantage and Medicaid MLRs flat year-over-year, it implies the PDP was up 12 or 13 percentage points. It's just not big enough in terms of the growth there to make the difference. So when you think strong performance on MA, does that mean the MLR was down? Or just trying to understand a little bit more of the granularity there."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Josh, to answer your last question, the MLR and MA adjusting for reserve development is flattish quarter-over-quarter. And in fact, the impact we're seeing in the government MCR this quarter is largely due to PDP. And again, we're not going to get into th",95,"Josh, to answer your last question, the MLR and MA adjusting for reserve development is flattish quarter-over-quarter. And in fact, the impact we're seeing in the government MCR this quarter is largely due to PDP. And again, we're not going to get into the specifics of the loss ratio, but the PDP MCR is always highest in the first quarter, as you know, because of the benefit design and transition period for new customers. And this quarter in particular for us, given we have a significant new customer growth, the seasonality with higher than normal."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","But I guess, Tom, I mean PDP was up 11%. The overall government revenues were up closer to 17% or 18%. So you have to see -- when you say the seasonality, I guess why is that product changing or are you just saying that the loss ratio and PDP was higher?",52,"But I guess, Tom, I mean PDP was up 11%. The overall government revenues were up closer to 17% or 18%. So you have to see -- when you say the seasonality, I guess why is that product changing or are you just saying that the loss ratio and PDP was higher?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, both the loss ratio and PDP was higher, and again, we have a more significant mix of new customers, which is accountable for the loss ratio impact. Most of the impact is from the larger customer base and the transition period for the new customers.",120,"Well, both the loss ratio and PDP was higher, and again, we have a more significant mix of new customers, which is accountable for the loss ratio impact. Most of the impact is from the larger customer base and the transition period for the new customers. And we do expect to see the normal seasonal pattern with improved results over the balance of the year. We also get some lift from our agreement with Gilead. It was effective April 1 in Part D, and we have anticipated some modest cost pressure, as we mentioned, including last quarter continuing for Part D and our outlook for the full year, but that was as expected and then it's reflected in our outlook."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just switching topics a little bit, the public exchange accounts like the individual businesses running a lot better and more in line with your expectations. Any comments on Reliance on the 3Rs, any change in your estimations for the 3Rs?",43,"Okay. And then just switching topics a little bit, the public exchange accounts like the individual businesses running a lot better and more in line with your expectations. Any comments on Reliance on the 3Rs, any change in your estimations for the 3Rs?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, first, a little bit on the performance in the business, and we're still in the very early stages. Results in the quarter did see some improvement both from the repositioning of our medical mix and the improved customer demographics, and we are seein",152,"Well, first, a little bit on the performance in the business, and we're still in the very early stages. Results in the quarter did see some improvement both from the repositioning of our medical mix and the improved customer demographics, and we are seeing some targeted medical management actions that have lowered lost cost. So over the long term, we're still optimistic that we will see improved results and this will become an effective market segment. As far as the 3Rs are concerned, our accrual for the 3Rs in the first quarter was about $30 million after-tax. The majority of that relates to reinsurance, and we're continuing to accrue in line with the program parameters, and we didn't really make any material change in accruals for the 3Rs related to 2014 business, and we don't really see any significant adjustment to that until we get the final results from the government midyear."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from A.J. Rice with UBS.",10,"The next question comes from A.J. Rice with UBS."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So first of all, maybe just to continue on the Medicare Advantage question. Obviously, we got final rates for 2016. Do you have any comments on that and what that means for you in terms of -- I know there's talk about average update of 1.25%, but each com",67,"So first of all, maybe just to continue on the Medicare Advantage question. Obviously, we got final rates for 2016. Do you have any comments on that and what that means for you in terms of -- I know there's talk about average update of 1.25%, but each company has their own inputs, if you got a sense of where you guys would fall out on that."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","A.J., good morning, it's David. So as we look at 2016, first, we expect to have a base that'll have approximately 60% of our customers in for STAR+PLUS plans, noting a step-up from the prior year. And we expect to [indiscernible] forward beyond '16 to con",206,"A.J., good morning, it's David. So as we look at 2016, first, we expect to have a base that'll have approximately 60% of our customers in for STAR+PLUS plans, noting a step-up from the prior year. And we expect to [indiscernible] forward beyond '16 to continue to step that up. As it relates to the rate setting environment, the net effects for our mix of our portfolio is that the vast majority of our plans are going to have about a flattish rate impact from all the moving parts from CMS. With the exception of 2 of our plans that will have a meaningful reduction based on the risk adjusters and the accounting rebates et cetera, the net result of our portfolio of that is again the vast majority of our business markets flattish, two with meaningful reductions weighted on an all-in base. It's about a 2% reduction. As we look at taking it as a whole, considering our very well-positioned portfolio of coverage services and collaboratives, we feel like our businesses are in good position. Stepping into 2016 and such, we continue to expect to both grow customer base, again stepping into 2016, as well as being able to expand margins stepping into 2016."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, great. And then maybe just a follow-up. I know you recently announced an alliance with scan health plan in California. I wondered if you might give a chance to comment on what you're hoping to do there and what that opportunity it might represent.",45,"Okay, great. And then maybe just a follow-up. I know you recently announced an alliance with scan health plan in California. I wondered if you might give a chance to comment on what you're hoping to do there and what that opportunity it might represent."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, A.J and use the term alliance, which I appreciate. We have a multiple examples of alliances, in some cases traditional competitors, not-for-profit, competitors, for-profit competitors and the like. This most recent relationship with scan aligns our",132,"Sure, A.J and use the term alliance, which I appreciate. We have a multiple examples of alliances, in some cases traditional competitors, not-for-profit, competitors, for-profit competitors and the like. This most recent relationship with scan aligns our very high-performing employer portfolio of businesses in California with their well-performing Medicare capabilities and enables us to deliver an employer-sponsored Medicare Advantage solution to employers that are on target for them but we had distribution reach and lever their capabilities. So it's a wonderful example of playing to both organization strength, enabling us to deliver an expanded set of solutions and capabilities on a more accelerated time frame than we would've been able to do organically and be able to deliver value for our existing clients and expand scan's relationship net [indiscernible] for both organizations."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Kevin Fischbeck with Bank of America.",11,"The next question comes from Kevin Fischbeck with Bank of America."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","I guess a couple of clarification questions. The commentary about the MA rate for 2016, was that including the Star pickup or before the star pickup?",26,"I guess a couple of clarification questions. The commentary about the MA rate for 2016, was that including the Star pickup or before the star pickup?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's net of all the moving parts, Kevin.",9,"It's net of all the moving parts, Kevin."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then on the individual commentary, I guess I don't remember if you said it specifically or not, but it sounded to me like you're still expecting to lose money in 2015 on the public exchanges?",37,"Okay. And then on the individual commentary, I guess I don't remember if you said it specifically or not, but it sounded to me like you're still expecting to lose money in 2015 on the public exchanges?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Net-net, as we've discussed before, Kevin, we look at '14, '15 and '16 as the version 1.0 of the marketplace. We feel that this is planned not around achieving the revenue or EPS significant contributions [indiscernible] of this book of business. As you k",94,"Net-net, as we've discussed before, Kevin, we look at '14, '15 and '16 as the version 1.0 of the marketplace. We feel that this is planned not around achieving the revenue or EPS significant contributions [indiscernible] of this book of business. As you know, we expect to improve the performance of the block of business going from '14 to '15 that is taking place. So on a fully allocated basis, there's a loss in the business, but it's less than 2014, but we'd expect that to improve further as we step into 2016."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just this outlook in the beginning, you talked about the medical management capabilities that you guys are bringing. Some of them, like the preterm births, is really something that comes in pretty usefully in the Medicaid side of the busine",96,"Okay. And then just this outlook in the beginning, you talked about the medical management capabilities that you guys are bringing. Some of them, like the preterm births, is really something that comes in pretty usefully in the Medicaid side of the business. Wanted to see if you feel like you guys are better positioned to participate in that side of business or if you've seen a couple of companies historically been in that market be more aggressive. How do you think about RFPs that seem to be coming up over the next couple of years?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Relative to the Medicaid space, we've been very consistent that we see opportunity in the higher risk or coordinated care dimensions of the Medicaid space, so we can call that the dual space and the various other high-risk portfolios. We have targeted exa",124,"Relative to the Medicaid space, we've been very consistent that we see opportunity in the higher risk or coordinated care dimensions of the Medicaid space, so we can call that the dual space and the various other high-risk portfolios. We have targeted examples of success to date, most notably in counties within Texas where we just -- we're recognized for an award of coordination of care with our behavioral and clinical capabilities. So we do see -- [indiscernible] we do see opportunities. It's highly geographically targeted in our Go Deep markets, and it's within those programs that enable significant coordination of care both engaging the individual and working with the clinical professionals. So we see targeted expansion opportunity over the next several years here."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Ralph Giacobbe with Crdit Suisse.",10,"The next question comes from Ralph Giacobbe with Crdit Suisse."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little bit of sense of why you did grow so much in PDP maybe kind of where it came from, if you could at what percentage was assigned and then just give us a sense of where it all kind of shook out relative to your expectation.",52,"Can you give us a little bit of sense of why you did grow so much in PDP maybe kind of where it came from, if you could at what percentage was assigned and then just give us a sense of where it all kind of shook out relative to your expectation."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Ralph, it's David, at a macro level, the majority of our growth was not auto assigned, so the step function to highly targeted geographically and the significant amount of work was done within the benefit design and configuration to target subsegment of b",108,"Ralph, it's David, at a macro level, the majority of our growth was not auto assigned, so the step function to highly targeted geographically and the significant amount of work was done within the benefit design and configuration to target subsegment of buyers in key geographies. So as Tom noted, meaningful growth, but we expected it. We factored that into our guidance. We talked about it last quarter to acknowledge that there would be -- we recognize there's a transition of care window that largely spans the entire first quarter that transpired but largely not assigned targeted geographies, targeting by segment and design products with that in mind."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, right. That's helpful. And then, can you just update us on where you sit on private exchanges? I know one of your customers recently moved and my understanding is actually that you retained a larger percentage of the book. But can you talk about con",63,"Okay, right. That's helpful. And then, can you just update us on where you sit on private exchanges? I know one of your customers recently moved and my understanding is actually that you retained a larger percentage of the book. But can you talk about conversations you're having with customers and your opportunities there for sort of existing as well as new opportunities?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, relative to the private exchange marketplace, we continue to view this as a potentially attractive long-term market as it unfolds. As such, we've allocated leadership, significant resources to the portfolio of businesses here. We are currently posit",193,"Sure, relative to the private exchange marketplace, we continue to view this as a potentially attractive long-term market as it unfolds. As such, we've allocated leadership, significant resources to the portfolio of businesses here. We are currently position in the vast majority of third-party exchanges that exist in the marketplace up to and including also having our own captive exchange. To date, the performance is generally speaking in line with our expectations which we thought was a slower market transition that maybe some in flag in the grand scheme of things. To date, we've seen some wins and losses in terms of our portfolios we've discussed before. As we stand here today, we have several hundred thousand lives when you span across our core medical and specialty capabilities as well as additional lives in the supplemental space. But it's in the early innings. We're positioned and we're evolving within the marketplace. And as you know, as our existing customers choose to transition, we have a brand positioning and a service proposition that tends to win us a lot of business in the choice marketplace. So performance in line with our expectations thus far."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","That's helpful. Just real quick and a follow-on to that. Just on the transition, if you have an ASO customer and they move to a private exchange and you retain that customer, ASO to ASO, is the profitability essentially the same?",42,"That's helpful. Just real quick and a follow-on to that. Just on the transition, if you have an ASO customer and they move to a private exchange and you retain that customer, ASO to ASO, is the profitability essentially the same?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's varied obviously depending on the configuration, but you should assume that the way we are seeking to position ourselves on the exchanges is to ensure that our offerings enable us to have enough of the, we'll call it, coordination and specialty reach",104,"It's varied obviously depending on the configuration, but you should assume that the way we are seeking to position ourselves on the exchanges is to ensure that our offerings enable us to have enough of the, we'll call it, coordination and specialty reach that I made reference to in my prepared remarks to be able to deliver differentiated value and not move back to I call it TPA administrator answer. So the simple answer is It depends because all the exchanges are not created equal. Our strong operating bias is the integration and coordination because that's where we deliver our step function value."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Christine Arnold with Colin.",9,"The next question comes from Christine Arnold with Colin."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Thanks for your commentary on the government segment. Can you give us the same kind of commentary on your commercial segment? How did you track with respect to stop loss experience rated versus guaranteed cost relative to from a year ago in your expectati",44,"Thanks for your commentary on the government segment. Can you give us the same kind of commentary on your commercial segment? How did you track with respect to stop loss experience rated versus guaranteed cost relative to from a year ago in your expectations?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. So overall, the headline in the commercial segment is the commercial MCR is very consistent with our expectations for the quarter. Again, the headline businesses employee or business continues to perform very well, individual business",110,"Christine, it's Tom. So overall, the headline in the commercial segment is the commercial MCR is very consistent with our expectations for the quarter. Again, the headline businesses employee or business continues to perform very well, individual business continues to improve. Quarter-over-quarter in particular, the MCR was about flat. That reflects the improvement and individual with some offset by business mix impacts. But again, within those businesses the MCRs performing as we'd expected by product line. And I would point out, we would expect some increase or some improvement from the increased health insurance fee, but I would point out that our mix has that impact smaller than most others."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Andy Schenker with Morgan Stanley.",10,"The next question comes from Andy Schenker with Morgan Stanley."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So just first that NASA science can you give us update you previously indicated you have an elevated percentage [indiscernible] based on the procurement cycle. Curious how that's progressing.",29,"So just first that NASA science can you give us update you previously indicated you have an elevated percentage [indiscernible] based on the procurement cycle. Curious how that's progressing."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's David. First just let me redefine our national health as we define it a bit differently than our competition. For us, it's commercial employers with 5,000 and more employees that span multiple states. So we exclude the large single state commercial e",243,"It's David. First just let me redefine our national health as we define it a bit differently than our competition. For us, it's commercial employers with 5,000 and more employees that span multiple states. So we exclude the large single state commercial employers that's part of our regional segment. We have a good recollection. Year-over-year as we look back to last year, our pipeline was about equal to the prior year, but our portion of our book of business that was out to bid was elevated due to procurement cycles. As we look at the current cycle looking forward to 2016 relative to the pipeline of new opportunities, the number of case is about the same. Average case size is somewhat elevated. So on a life basis but more lives to look out but a similar number of cases. As it relates to the percentage of our book of business out to bid, the percent is back down because that procurement cycle that's moving through. So early in the overall sales cycle, a healthy pipeline of opportunities to look out, a reasonable percentage of our book of business is out to bid. We continue to be focused on retaining the right business and earning the right business that has engagement and incentive alignment, expanding our specialty capabilities as indicative of our ability to grow revenue and earnings in the space by delivering value to those clients that are on target for us."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Ana Gupte with leering partners.",10,"The next question comes from Ana Gupte with leering partners."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Wanted to follow up on the question on the commercial loss ratio just as far as individual off-exchange on-exchange, the guaranteed cost and stop loss. So I get it that it's in line with expectations. I think there was a lot of pressure on your off-exchan",89,"Wanted to follow up on the question on the commercial loss ratio just as far as individual off-exchange on-exchange, the guaranteed cost and stop loss. So I get it that it's in line with expectations. I think there was a lot of pressure on your off-exchange book last year. It seems like you've seemed to have traded some of the membership coming from off exchange. And are you seeing the overall individual book negative but that book of business is kind of returning to profitability at this point?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","So it's David. Let me just frame it a little bit relative to the individual. First, as Tom noted in the employer book, the employer book last year this year continues to perform well and in line with our expectations. Within the individual book of busines",170,"So it's David. Let me just frame it a little bit relative to the individual. First, as Tom noted in the employer book, the employer book last year this year continues to perform well and in line with our expectations. Within the individual book of business, as you very well know relative to us, it's small in the grand scheme of things in terms of covered lives. As it relates to the grandfather and some of the transitional block, one of the states where we had a large grandfather block of business is a state where we don't operate on the exchange, specifically California. So we saw attrition relative to the grandfather walk  stepping into 2015, which was in line with our expectations. We still maintain a mix of on exchange and off exchange business. And that, taken as a whole, the loss ratio of our business, and therefore, the underlying performance of individual business steed forward and improved in line with our expectations going from '14 to '15."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then on the guaranteed cost legacy book, have you seen margin expansion? Some of your competitors are very commercially focused. There's some really nice margin expansion. I'm just trying to get on this underlying metric.",36,"And then on the guaranteed cost legacy book, have you seen margin expansion? Some of your competitors are very commercially focused. There's some really nice margin expansion. I'm just trying to get on this underlying metric."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","And Ana, are you referencing individual or group?",8,"And Ana, are you referencing individual or group?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Group, group.",2,"Group, group."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Within our group block of business, as you know, we don't play in the small group employer. So you need to take the under 50 block and removed from the way you think about us. Relative to the over 50 block of business, our performance was strong and remai",55,"Within our group block of business, as you know, we don't play in the small group employer. So you need to take the under 50 block and removed from the way you think about us. Relative to the over 50 block of business, our performance was strong and remains strong in that portfolio of business."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then finally on stop-loss is that trending flat or are margins coming in or expanding? You've seen a nice 19% growth in premiums there.",26,"And then finally on stop-loss is that trending flat or are margins coming in or expanding? You've seen a nice 19% growth in premiums there."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's Tom, margins and stop-loss is just where we'd like them to be. So the performance in the book is good.",22,"It's Tom, margins and stop-loss is just where we'd like them to be. So the performance in the book is good."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Peter Costa with Wells Fargo.",10,"The next question comes from Peter Costa with Wells Fargo."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Question on your strategy around M&A going forward. You're a little bit subscale to some of the national account players. You focus on some geographically concentrated markets as a way to compensate for that. But just the books of business likely to come",144,"Question on your strategy around M&A going forward. You're a little bit subscale to some of the national account players. You focus on some geographically concentrated markets as a way to compensate for that. But just the books of business likely to come up one in particular just the other day is [indiscernible]. It's more of a broad book of individual business and there's some expectation that some of the smaller plans that are focused on certain geographies exchange base business that are going to cut for scale. Do you think some of those folks will be interesting for you guys? And if they are, a lot of why they're up for sale is there will be under pressure. And some of the business is underpriced. How would you react to fixing book of business that you see that are up for sale?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Peter, David. Let me give you a little color on M&A. You factored in many statements and questions there. So first, broadly relative to M&A. M&A continues to be a component of our value creation framework. So it's effective deployment of capital strategic",311,"Peter, David. Let me give you a little color on M&A. You factored in many statements and questions there. So first, broadly relative to M&A. M&A continues to be a component of our value creation framework. So it's effective deployment of capital strategic M&A is a component within there. Our priorities have been consistent in terms of where we see the ability to create step function value, specifically smartly furthering our global footprint; two, expanding our MA and dual capabilities; three, expanding our retail capabilities; and four local tuck-ins, and we've had a successful track record of accomplishing targeted acquisitions over the last 5-plus years in line with our strategy. As it relates to your scale comment, we've chosen to redefine our engagement around scale to ensure that we have appropriate scale to have competitive cost structure from an administrative cost standpoint, which we have. We've been able to prove productivity gain year in year out and free capacity to further ongoing investment back within the franchise. And then you come down to medical cost to your dialogue, and that's a very localized conversation and it's not a localized conversation at state level. It's an MSA level, and increasingly, within our marketplaces, it's coming down to a sub-MSA level. So we're highly focused on key geographies and our ability to win and deliver value for our clients and customers. As related to appetite for future M&A opportunities, we're very aware, engaged and highly focused so long as the transactions are on strategy relative to the items I talked about before. On a final note, I'm not going to speculate on how you would rehabilitate an underperforming book of business, but our organization has demonstrated the ability to deliver high performance within our targeted segments, and again, we see M&A as a forward-looking opportunity to create smart transactions and good shareholder value."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then just on the Part D business, one further question. You talked about some of the higher MLR being from transition issues. Is your guidance going forward making the assumption that those transition issues resolved in Q1? Or do you expect that to co",69,"And then just on the Part D business, one further question. You talked about some of the higher MLR being from transition issues. Is your guidance going forward making the assumption that those transition issues resolved in Q1? Or do you expect that to continue into Q2? And if it isn't transition issues and you're not able to resolve it, will that impact your guidance and by how much?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's Tom. I think about that a little differently. This is the prescribed 90-day period for new members to stay on their old formulary while they transition to our new formulary. So we would expect that to work itself through in the first quarter.",45,"It's Tom. I think about that a little differently. This is the prescribed 90-day period for new members to stay on their old formulary while they transition to our new formulary. So we would expect that to work itself through in the first quarter."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","And the next question comes from Chris Rigg with Susquehanna Financial Group.",12,"And the next question comes from Chris Rigg with Susquehanna Financial Group."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Just wanted to focus on the guidance for a minute, particularly on the Global Health Care segment. You raised by $15 million at the midpoint but you had $25 million of TPD. I'm just wondering why the raise wasn't at least in line with the level of reserve",49,"Just wanted to focus on the guidance for a minute, particularly on the Global Health Care segment. You raised by $15 million at the midpoint but you had $25 million of TPD. I'm just wondering why the raise wasn't at least in line with the level of reserve development."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Chris, it's Tom. We're really pleased that we've been able to increase our outlook this early in the year. Again, we expect to deliver attractive growth and revenue earnings and EPS across the company and in Global Health Care in 2015 just as we have in e",72,"Chris, it's Tom. We're really pleased that we've been able to increase our outlook this early in the year. Again, we expect to deliver attractive growth and revenue earnings and EPS across the company and in Global Health Care in 2015 just as we have in each of the last 5 years. So really I'd see our revised outlook as just reinforcing our confidence that we're on track to delivering those results."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just with regards to the comments in the press release about the investment spending in the quarter in the health care segment, that was expected in the original outlook just to be clear?",36,"Okay. And then just with regards to the comments in the press release about the investment spending in the quarter in the health care segment, that was expected in the original outlook just to be clear?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes.",1,"Yes."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Then next question comes from Dave Windley with Jefferies.",9,"Then next question comes from Dave Windley with Jefferies."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","On the operating expense guidance and ratio, I guess I'm just looking at your starting the year toward the higher end of that range. Your trends tend to rise into the year through the year in historical years, and you're mentioning some favorable impacts",92,"On the operating expense guidance and ratio, I guess I'm just looking at your starting the year toward the higher end of that range. Your trends tend to rise into the year through the year in historical years, and you're mentioning some favorable impacts in I think disability this quarter, excuse me, [indiscernible] this quarter. So I'm guess I'm thinking it should rise this year as well unless you tell me otherwise. How do you see that trending over the balance of the year to hit that range that you have provided?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","David, it's David. So directionally first off, we knew the first quarter was going to have an elevated level of expenses. As such, on the last quarter when we talked about the first quarter pattern, we flagged that and it was called out, as mentioned, in",147,"David, it's David. So directionally first off, we knew the first quarter was going to have an elevated level of expenses. As such, on the last quarter when we talked about the first quarter pattern, we flagged that and it was called out, as mentioned, in the further questions as we look at many of our strategic spend initiatives. Two, as you made reference to, our outlook is to see that our operating expense ratio will show a year-over-year improvement as we have been able to demonstrate for many years as we look back and our organization is tightly aligned relative to that. So the performance of that will transpire a little differently in the 2015 quarters as opposed to the prior quarters. But Q1 was known as an uptick. Our outlook is to see an improved expense ratio and our organization's on track to achieve that."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So if I can clarify just a little further, would you expect the investments that you flagged in 1Q to then exit or evaporate in 2Q and then to drop back down significantly and then turn back out. as it normally does? Or is it just a completely different p",52,"So if I can clarify just a little further, would you expect the investments that you flagged in 1Q to then exit or evaporate in 2Q and then to drop back down significantly and then turn back out. as it normally does? Or is it just a completely different pattern this year?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes, Dave, I wouldn't expect the strategic spending to decline over the balance of the year. I think what I'd expect to see is both a little different pattern of revenue and earnings to get to the result we've talked about.",41,"Yes, Dave, I wouldn't expect the strategic spending to decline over the balance of the year. I think what I'd expect to see is both a little different pattern of revenue and earnings to get to the result we've talked about."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The final question comes from Sarah James with Wedbush securities.",10,"The final question comes from Sarah James with Wedbush securities."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","One of your peers recently indicated their discussions with employers suggest that there could be a step-up in conversions to private exchanges in the next 1 to 2 years. Are you hearing similar from your clients? And then if you could share with us what p",62,"One of your peers recently indicated their discussions with employers suggest that there could be a step-up in conversions to private exchanges in the next 1 to 2 years. Are you hearing similar from your clients? And then if you could share with us what percentage of your private exchange book as self-funded and what percent are new members to Cigna?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's David. First, the dialogue with employers has been active around private exchanges as it has been around consumer-directed engagement programs et cetera. I think the broader picture here is that employers of all sizes are looking for the higher value",290,"It's David. First, the dialogue with employers has been active around private exchanges as it has been around consumer-directed engagement programs et cetera. I think the broader picture here is that employers of all sizes are looking for the higher value creation benefit strategies that are going to be sustainable for them. That's the broader dialogue. And private exchanges represent a tool that many employers are trying to explore. The determinant of that is part of the overall portfolio. What we've seen, and what the market has seen is a relatively modest adoption rate of that toolset, but it's early on, as we've indicated, in the private exchange cycle. Two, what we've seen is a continued elevated performance of self-funded consumer-directed aligned incentive and coordinated integrated offerings. As it relates to our own experience within the private exchanges, to the second part of your question, the vast majority of those employers are in the self-funded space given the profile of what we operate in but we have guaranteed cost lives there as well. We have integrated and nonintegrated lives, but again it's small in the grand scheme of things in terms of what we're seeing. And a portion of the lives we're seeing there are new to Cigna. Greater than 50% of those are transitioning from existing Cigna relationships carried over to the exchanges. But the important part is that it's still a small part about the marketplace as well as our portfolio. Two, we've deployed significant resources to make sure we're in position on the various exchanges, including your own captive and proprietary exchange. And three, we see to be very consultative with our employers to make sure they understand all the choices that are available to them."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And as employers are evaluating their different options, you mentioned, within the high deductible plans private exchanges, can you tell whether or not one is emerging as the more likely way that employers are trending or if there's any difference in how",60,"And as employers are evaluating their different options, you mentioned, within the high deductible plans private exchanges, can you tell whether or not one is emerging as the more likely way that employers are trending or if there's any difference in how they are trending based on employer size, whether they're not going towards the private exchanges versus high deductibles?"
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","I think we can point to both the track record of actions as well as the emerging actions. So the more tangible track record of actions is that employers of a variety of sizes continue to move toward the transparent funding, which includes ASO. That's a co",168,"I think we can point to both the track record of actions as well as the emerging actions. So the more tangible track record of actions is that employers of a variety of sizes continue to move toward the transparent funding, which includes ASO. That's a consistent track. Two, elevation of aligned incentive programs, whether they're consumer-directed full-on CDHP programs or if they're coinsurance programs, coinsurance programs with aligned incentive models, those would be the 2 most tangible pieces I think you could point to. And then over the last couple of years, an emerging trend too, as I mentioned before, carving in or even more adoption of integrated care programs that are coordinated to delivering the value back. But Private exchange, if you will, trend again is still in the early stages and I wouldn't flag it as one where we would see a majority of buying behavior over the next 2 buying cycles. But as we're positioned, we're positioned for in elevation and volume should unfold."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","I will now turn the call back over to David Cordani for closing remarks.",14,"I will now turn the call back over to David Cordani for closing remarks."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thank you. Just to conclude our discussion this morning, I'd like to reiterate just a few important points. First, Cigna's first quarter results represent a strong start to the year and were driven by revenue and earnings contributions across our diversif",168,"Thank you. Just to conclude our discussion this morning, I'd like to reiterate just a few important points. First, Cigna's first quarter results represent a strong start to the year and were driven by revenue and earnings contributions across our diversified portfolio of businesses. Our integrated capabilities are optimizing health, improving medical outcomes and increasing affordability for the individuals we serve. Our more than 37,000 talented colleagues around the world are unified in their commitment to work every day to improve the health, well-being and sense of security of the customers we serve. Our strong first quarter performance and multiple avenues for growth give us confidence that we will achieve our increased full year 2015 outlook. Over the long term, we remain committed to achieving our annual EPS growth of 10% to 13% over the long term and expect to double size of our company's revenue over the next 7 to 8 years. Thank you for joining our call today, and we look forward to furthering our discussions."
172899,290303753,798558,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's first quarter 2015 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this cal",65,"Ladies and gentlemen, this concludes Cigna's first quarter 2015 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 1 (800) 365-2419 or 1 (203) 369-3679. No passcode is required. Thank you for participating. We will now disconnect."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2015 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded.We'll begin by turn",48,"Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2015 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded.
We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",378,"Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks, today, David and Tom will cover a number of topics, including Cigna's first quarter 2015 financial results as well as an update on our financial outlook for 2015.
As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled ""adjusted income from operations"" and ""earnings per share"" on the same basis as our principal measures of financial performance. A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com.
In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC.
Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. As a reminder, beginning in 2015, we have simplified our guidance and disclosures for our Medical Care Ratios or MCRs by reporting them on a basis of total Commercial and total Government. The total Commercial ratio encompasses all of our commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products, provided through guaranteed cost or experience-rated funding arrangements in both the United States and internationally. The total Government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses.
Finally, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or additional prior year development of medical costs.
And with that, I will turn the call over to David."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thanks, Will. Good morning, everyone, and thank you for joining our call today.To begin, I'd like to read the highlights of our financial results for the first quarter. Next, I'll discuss how we are leveraging Cigna's integrated capabilities to engage i",1736,"Thanks, Will. Good morning, everyone, and thank you for joining our call today.
To begin, I'd like to read the highlights of our financial results for the first quarter. Next, I'll discuss how we are leveraging Cigna's integrated capabilities to engage individuals to help them optimize their health and well-being, and how this is translating into value for customers and clients.
Then Tom will provide more detail around our first quarter financial performance and update our full year 2015 outlook. And following your questions, I'll leave you with a few closing remarks.
Let's dive in with some highlights from the quarter. Cigna's first quarter 2015 performance represents a strong start to the year. We are pleased with our results, which extends our track record of attractive financial performance. Once again, our success was driven by the effective and disciplined execution of our strategy, which continuously guide our actions in a dynamic marketplace.
Our first quarter 2015 consolidated revenue increased 11% to $9.5 billion, with strong contributions across our business segments. We reported adjusted income from operations for the first quarter of $513 million or $1.96 per share. Our Global Health Care revenues increased 12%, driven by strong performance in our Commercial and Government businesses. Our Global Supplemental Benefits business, once again drove strong revenue growth in high single-digit after-tax margins, while we continue to make targeted investments in support of future growth, and we achieved 6% revenue growth in our Group Disability and Life business.
Overall, our diversified portfolio of businesses continues to produce significant free cash flow that further enables our financial flexibility with more than $500 million deployed for share repurchase on a year-to-date basis. Our continuous focus and effective strategic execution are generating strong results, enabling ongoing investments in our business portfolio and helping us meet the unique local market needs to the right balance of affordability and personalization of our products and services.
As we've discussed previously, we have a clear framework to drive ongoing future value creation for Cigna. First, our diversified businesses are well positioned to create attractive value for our customers and clients and, as a result, differentiated revenue growth. Second, we are focused on targeted and effective capital deployment to create ongoing shareholder value through investments in our business, strategic M&A and share repurchase. Our businesses generate high levels of free cash flow, which give us financial flexibility and the opportunity to deploy capital to further create value for the benefit of shareholders. And finally, we continue to seek new and emerging opportunities to expand in new distribution marketplaces, new geographies and new buying segments.
Guided by this framework and coupled with effective execution, we continue to expect to deliver average annual revenue growth rate of 8% to 10% over the long term. This framework also positions us to support our focus on enabling health care over financing sick care, which is well aligned with Cigna's efforts to improve the current health care system.
The United States spends $3 trillion a year on health care. Studies consistently show approximately 25% of the total expenditures are wasted through inefficiency or breakage. At the same time, 50% of all adults have at least one chronic disease, conditions which translate to 7 out of the top 10 causes of death in the U.S.
In this dynamic environment, Cigna continues to convene key stakeholders to work toward a sustainable health care system. Health care stakeholders from individuals to corporate employers and government organizations are seeking a common set of core goals. These include maintaining or improving health and productivity, affordable and predictable cost outcomes and greater personalization of solutions and services. To meet these goals, we must continue to accelerate the transition from yesterday's view health insurance as a mechanism for financing the cost of illness to an orientation center around maintaining and improving the health and wellness of individuals. At Cigna, we are and we'll continue to make significant strides toward achieving a more sustainable health care system, by engaging with individuals and physicians through coordinated offerings and alliance incentives.
We have moved beyond the typical multi-product sales and services approach to engaging individuals and coordinate care at a very personal level, as we work to improve health and wellness, all by harnessing information, incenting and supporting individuals and partnering with physicians, the result of which is a service experience for customers that achieves the right balance of personalization and affordability. 
I'd like to share with you a few examples of how we are leveraging the power of integration and coordination, with our broad solution suite, by encouraging maintenance and prevention among the healthy, providing coaching to the healthy at risk, enabling coordinated care for those with chronic conditions and facilitating access to centers of excellence for those with acute conditions.
Our health care professionals engage with customers and clinicians to improve health every day, leveraging the breadth of our clinical capabilities, which spans over 4,000 professionals from doctors and nurses to behavioral professionals, health coaches and pharmacists.
Relative to our behavioral professionals, our capabilities include engaging with a cardiology team when a health event transpires, as we have seen a strong correlation between these types of illness and depression; engaging with our experts in disability programs to improve health and maximize personal productivity; and helping individuals recover from an injury by taking a more holistic view of mind and body. As for result, our customers are empowered by active coordinated care through coaching, support services and incentive programs. And the impact, Cigna clients with integrated offerings have 29% pure mental health and substance abuse related outpatient visits and 8% fewer inpatient events compared with those without integrated offerings.
Another powerful example of our success, with our coordinated approach, is for customers who are expectant moms. In today's health care system, the cost of a premature birth is nearly 11x higher than that of a full-term birth, not to mention the impact on the family stress and, in some cases, lifelong health challenges. CIGNA's Healthy Pregnancies, Healthy Babies program engaged with customers to optimize health during pregnancy, by working with nurses who can assess risks; develop personalized care plans; and continue to support outreach and coordination with OB/GYN teams; and finally, providing coaching on newborn care. Active participation by expected mothers in our integrated program is key. In fact, for those who enroll, there is nearly 50% reduction in premature births versus the U.S. average. This is a huge impact for the family, the child and society overall.
The benefit of integrated and coordinated care is also impactful within Cigna's Specialty Pharmacy programs, where our pharmacists and clinicians engage with customers and health care professionals to improve the effectiveness of drug regimes to drive better overall health outcomes. Our engaged customers have higher medication adherence and lower specialty drug costs, resulting in a 15% lower overall medical cost versus individuals who do not have these coordinated offerings.
Our coordination also works with dental care customers, where there's a high correlation between periodontal health and improved health outcomes. In our dental programs, individuals with diabetes, heart disease or stroke, who have both medical and dental coverage with Cigna has seen higher health quality and lower medical costs. For example, patients with diabetes participating in our coordinated and dental programs saw lower average annual medical costs of approximately 28%, when receiving coordinated care. And for patients with heart disease, costs were lowered by approximately 25%.
As a final example across the U.S., our 4,000 plus clinical professionals continue to engage and help our customers and an increasing numbers through a rapidly growing collaborative care relationships. Today, we have more than 120 of these relationships spanning 29 states. As for impact, more than 90% of Cigna's collaborative care relationships with at least 2 years of experience are seeing success in managing improved medical costs and nearly 80% with at least 1-year of experience are seeing success in total medical cost results or clinical quality measures. Examples of medical results include an improvement in blood pressure, an improvement in BMI and an improvement in total cholesterol levels. These examples reinforce our successful efforts to improve health and quality-of-life while working to remove cost from the system. By leveraging our integrated capabilities and coordinating clinical care resources for each individual through their health journey, we are improving affordability while creating a more sustainable health care system. Over the long term, we believe our approach to health care rather than sick care will promote better health, sustainability and economic vibrancy and lower the cost burden on customers as well as employers.
And this success translates to shareholder value as we leverage our capabilities and meet customer needs with products and services that are enhanced through our highly aligned coordinated offerings. This value is evidenced by our industry-leading medical cost trend over the last several years, high customer retention levels and strong growth in our specialty and integrated services that achieve the personalization of services outcomes that I previously referenced. 
As demonstrated by our discussion this morning, our integration and coordination of care has moved beyond the simple multi-product solution. Today, we are engaging individuals in a very personalized way, leveraging actionable information, partnering with health care professionals and utilizing care resources that both reduce costs and produce superior health outcomes.
Now to summarize my remarks before turning it over to Tom. Cigna's strong start to 2015 continues our long-term track record of financial performance in delivering competitively attractive revenue and earnings and gives us confidence in our increased full year 2015 outlook. The strong free cash flow from a high return on capital and high-margin portfolio of businesses provide ongoing financial flexibility in capital management and deployment. We are effectively executing our strategy and creating value for our customers and clients by leveraging integrated capabilities that promote health care rather than sick care and driving improved personalization and affordability for the benefit of the individuals we serve. We remain committed to our long-term objective, which is to double the size of our business over the next 7 to 8 years, yielding an 8% to 10% annual revenue growth rate on average. And over this time horizon, we expect to continue to deliver competitively attractive long-term EPS growth of 10% to 13% annually on average, all while we continue to invest in our company's business portfolio. And with that, I'd like to turn the call over to Tom."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone. In my remarks today, I will review Cigna's first quarter 2015 results and discuss our outlook for the full year.We've had a good start of the year with strong revenue and earnings contributions across our diversifi",1643,"Thanks, David. Good morning, everyone. In my remarks today, I will review Cigna's first quarter 2015 results and discuss our outlook for the full year.
We've had a good start of the year with strong revenue and earnings contributions across our diversified portfolio of businesses, driven by continued effective execution of our strategy.
The highlights in the quarter include consolidated revenue growth of 11% to $9.5 billion; consolidated earnings of $513 million; quarterly earnings per share of $1.96; and continued strong free cash flow with approximately $515 million returned to shareholders through share repurchase on a year-to-date basis. Overall, the strength of our first quarter performance provides us with solid momentum for the year.
Regarding the segments, I will first comment on our Global Health Care segment. Global Health Care results were solid in the quarter. First quarter premiums and fees grew 12% to $6.7 billion, driven by customer growth in our Commercial and Government businesses as well as specialty contributions and rate actions. We ended first quarter of 2015 with 14.7 million global medical customers, including approximately 200,000 new customers from our QualCare Alliance Networks acquisition. First quarter earnings were $444 million, reflecting medical and specialty business growth, continued effective medical cost management, improving results in our individual business with some offset from increased spending for strategic investments as well as higher seasonal costs in our growing Medicare Part D business.
Turning to medical costs. We continue to deliver medical costs that reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. Our commercial medical trend result continues to be among the lowest in the industry. And given that over 85% of our U.S. Commercial customers are in transparent ASO funding arrangements, our clients directly benefit from these favorable medical costs.
Regarding medical care ratios, our first quarter 2015 total Commercial Medical Care ratio or MCR was 75.2% on a reported basis or 75.9% excluding prior year reserve development.
Overall, we are pleased with the results of our commercial risk businesses in the quarter, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results in our individual business continue to improve from the first quarter and are in-line with our expectations.
In our Government business, our first quarter 2015 total government MCR was 89.4% on a reported basis or 89.9% excluding prior year's reserve development, reflecting continued good performance in our Medicare Advantage business, partially offset by seasonal costs from our growing Medicare Part D business. Across our Commercial and Government risk book of business, our first quarter earnings included favorable prior year reserve development of $25 million after-tax compared to the $30 million after-tax in the first quarter 2014.
Moving to operating expenses, for first quarter 2015, our total Global Health Care operating expense ratio was 21.7%, which reflects an expected increase in spending for strategic investments. Overall, we've had a strong start to 2015 in our Global Health Care business.
Now I will discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability. Premiums and fees grew 8% quarter-over-quarter in global supplemental or 12% on a currency-adjusted basis. First quarter earnings grew 21% or 25% on a currency-adjusted basis to $69 million, reflecting business growth and strong operating expense management as well as some favorable operating expense timing.
For Group Disability and Life, first quarter premium and fees increased 7% over first quarter 2014, reflecting growth across the Disability Life and Accident product lines. First quarter earnings in our group business were $51 million, which include unfavorable claims experienced in our life insurance business as well as an expected increase in operating expenses.
For our Corporate and Other operations, results totaled to an after-tax loss of $51 million in the first quarter of 2015. Overall, as a result of the continued effective execution of our strategy, our first quarter results reflect strong revenue and earnings contributions from our ongoing businesses and significant free cash flow.
Turning to our investment portfolio. In the first quarter, we recognized net realized investment gains of $48 million after-tax, coupled with a strong net investment income result. The high quality and diversification of our investment portfolio continue to drive our overall segment results.
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to deliver affordable and personalized solutions, effectively deploying capital and targeting new and emerging opportunities where we will seek to drive additional value for shareholders. We continue to expect consolidated revenues to grow in the range of 8% to 10% over 2014.
Our outlook for full year 2015 consolidated adjusted income from operations is now in the range of approximately $2.12 billion to $2.21 billion or $8.15 to $8.50 per share. This represents an increase of $0.10 to $0.15 per share over our previous expectations.
I will now discuss the components of our 2015 outlook, starting with Global Health Care. We now expect full year Global Health Care earnings in the range of approximately $1.75 billion  to $1.8 billion, an increase over our prior expectations.
I'll now summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015, starting with our customer base. Regarding global medical customers, we now expect 2015 customer growth of 2% to 4%. This increase over previous expectations primarily reflects customers added through the acquisition of QualCare Alliance Networks, which was completed in the first quarter of 2015.
Turning to medical costs. In our 2015 -- our 2015 outlook continues to assume some increase in medical utilization versus current levels which has been reflected in our pricing. For our total U.S. Commercial book of business, we continue to expect full year medical cost trend to be in the range of 5% to 6%.
Now turning to our medical care ratio outlook. For our total commercial book of business, we continue to expect the 2015 medical care ratio to be in the range of 78% to 79%. For our total government book of business, we continue to expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%.
Regarding operating expenses, we continue to expect our 2015 Global Health Care operating expense ratio to be in the range of 21% to 22%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.75 billion to $1.8 billion.
The other components of our outlook are unchanged. For our Global Supplemental Benefits business, we continue to expect strong top line growth in earnings in the range of $230 million to $250 million. Regarding our Group Disability and Life business, we continue to expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations, that is other operations and corporate, we expect a loss of $180 million for 2015.
So all-in, for full year 2015, we now expect consolidated adjusted income from operations of $2.12 billion to $2.21 billion or $8.15 to $8.50 per share. This represents an increase of $0.10 to $0.15 per share. I would remind you that our outlook continues to exclude the impact of additional prior year reserve development or earning future capital deployment. While we do not anticipate the impact of future capital deployment in our EPS outlook, we continue to expect the additional free cash flow that we generate will be deployed for the benefit of our shareholders either through value-creating acquisitions or share repurchase.
Now moving to our 2015 capital management position and outlook. Overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow to the parent, with a strong return on capital in each of our business segments. Our capital deployment strategy and priorities have not changed. These priorities are: providing the capital necessary to support the growth of our ongoing operations; pursuing M&A activity with a focus on acquiring capabilities and scale to further grow in our targeted areas of focus; and after considering these first 2 items, we'd return capital to shareholders, primarily through share repurchase.
Regarding free cash flow, we ended the quarter with parent company cash of approximately $1.3 billion, which includes approximately $900 million of proceeds from our recent issuance of long-term debt. These proceeds were subsequently used to redeem existing debt in the second quarter of 2015. During the period February 5 through April 29, we repurchased 3.2 million shares of stock for approximately $400 million, bringing our year-to-date share repurchase to 4.3 million shares for approximately $515 million. After considering all sources and uses of parent company cash, we now expect to have approximately $1.3 billion available for capital deployment during the balance of the year. Our free cash flow outlook continues to reflect the industry-leading margins and returns on capital in our businesses and a high level of capital efficiency, particularly from our fee-based businesses. This capital efficiency allows us to fund attractive organic growth while continuing to generate significant free cash flow to be deployed for the benefit of shareholders.
Now to recap. Our first quarter 2015 consolidated results reflect the strength of our diversified portfolio of global businesses and continued effective execution of our focused strategy. The fundamentals of our business remain strong, as evidenced by our first quarter results, which reflected strong revenue and earnings contributions across our diversified portfolio of businesses, industry-leading medical cost trends and high clinical quality and continued strong free cash flow. Based on the strength of these results, we are confident in our ability to achieve our increased full year 2015 earnings outlook.
And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] Our first question comes from Scott Fidel with Deutsche Bank.",12,"[Operator Instructions] Our first question comes from Scott Fidel with Deutsche Bank."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","I was hoping we could just drill into the Government MLR for a little bit and maybe just talk about first just on Medicare Advantage, how utilization trends looked in the quarter, and if you've seen any type of recent indications of any type of inpatient",112,"I was hoping we could just drill into the Government MLR for a little bit and maybe just talk about first just on Medicare Advantage, how utilization trends looked in the quarter, and if you've seen any type of recent indications of any type of inpatient admission acceleration in recent weeks. And then second, just relative to the PDP MLR, just how that tracked relative to your expectations in the quarter. And clearly, given when there's outsized growth in PDP membership there's sometimes risk of higher MLR, so just interested in terms of what you're seeing around script trends and just around general performance in the PDP business so far this year."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So first, we're very happy with the position of our Government business. Our outlook for the Government MCR in 2015 reflects strong results in our Medicare Advantage business and some expected pressure in Part D, as you mentioned. The qua",168,"Scott, it's Tom. So first, we're very happy with the position of our Government business. Our outlook for the Government MCR in 2015 reflects strong results in our Medicare Advantage business and some expected pressure in Part D, as you mentioned. The quarter-over-quarter increase, specifically in the Government MCR, is mainly due to Part D with continuing good Medicare Advantage results. As you pointed out, we reported significant growth in Part D customers in 2015. And as a result, we've had a more pronounced seasonal impact from Part D this quarter. These new customers have a period of time to transition from their previous formulary to our formulary. So as we expected, we saw from additional first quarter cost impacts. And all-in, we continue to expect our government MCR to be in the range of 84.5% to 85.5% for the full year, which we're happy with. As far as the outlook or the utilization outlook, we really didn't see any significant change in MA utilization in the quarter."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, and then just a quick follow-up. Just in terms of the cost trends view reiterating that 5% to 6% for the full year. Just interested if you could give us some flavor in terms of just in the first quarter itself and Commercial MLR looked quite favorab",69,"Okay, and then just a quick follow-up. Just in terms of the cost trends view reiterating that 5% to 6% for the full year. Just interested if you could give us some flavor in terms of just in the first quarter itself and Commercial MLR looked quite favorable again. So just interested, do you have a sense of where you were sitting within that range in the first quarter."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes, Scott, well, we're really pleased with our medical trend results. And as we mentioned many times, we delivered a cost trend below 4.5% in 2014, building on a very strong track record we've had for several years, with industry-leading results. Our out",114,"Yes, Scott, well, we're really pleased with our medical trend results. And as we mentioned many times, we delivered a cost trend below 4.5% in 2014, building on a very strong track record we've had for several years, with industry-leading results. Our outlook for 2015, medical cost trends, 5% to 6%, does anticipate some uptick in utilization over the course of the year and some expected increase in pharmacy trends due to specialty drug costs. And commenting on the first quarter, we haven't seen the uptick in utilization, but we are seeing some expected pharmacy trend impact. So overall, we're comfortable, we're going to again deliver a competitively attractive medical cost trend in 2015."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Matthew Borsch with Goldman Sachs.",10,"The next question comes from Matthew Borsch with Goldman Sachs."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Yes, I was hoping that maybe you could address what you're seeing in the marketplace in terms of middle-market employers and the extent to which there's interest in self-funding, if you've seen that accelerating, if you think that's going to continue and",63,"Yes, I was hoping that maybe you could address what you're seeing in the marketplace in terms of middle-market employers and the extent to which there's interest in self-funding, if you've seen that accelerating, if you think that's going to continue and maybe on the larger end of that, what -- you're getting a taste of in terms of product preferences for 2016."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Matthew, good morning, it's David. As it relates to use the term in our middle-market, so we'll talk about the regional segment. We define that as employers with 250 to 5,000 employees as well as large single-state employers. The broad thing, I would tell",225,"Matthew, good morning, it's David. As it relates to use the term in our middle-market, so we'll talk about the regional segment. We define that as employers with 250 to 5,000 employees as well as large single-state employers. The broad thing, I would tell you, is that the market's appetite and interest in transparent funding and aligned funding, which include ASO, continues to grow. It continues to grow both in the regional segment. That has always been a meaningful portion but not the totality of it, but very importantly, as you move downmarket into the Select Segment as well. So point one is continued high and accelerating interest in transparent funding because it aligns incentives, it provides transparency and enables better functionality of the incentive alignment programs and the engagement programs we like. The second thing we see is continued elevation and engagement in we typically call them carve-in or specialty programs. We look at them more as a coordination of care programs. Many of the examples I cited in our prepared remarks. So those will be the 2 predominant trends we continue to see: elevation in transparent funding and then continued movement in what you might call carve-in, we call them coordination of care programs that are delivering the superior medical costs and quality outcomes that Tom made reference to a few moments ago."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, great. Just on a separate angle, if you don't mind. Can I just ask if you have any comments about the outlook for your PBM relationship, now that there's a change of control event coming with Catamaran and UNH.",40,"Okay, great. Just on a separate angle, if you don't mind. Can I just ask if you have any comments about the outlook for your PBM relationship, now that there's a change of control event coming with Catamaran and UNH."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, Matthew. Just by way of backdrop, important to note that we continue to own and operate a very highly performing PBM for the benefit of our customers and clients, and that high performance is being demonstrated through continued growth in customer l",151,"Sure, Matthew. Just by way of backdrop, important to note that we continue to own and operate a very highly performing PBM for the benefit of our customers and clients, and that high performance is being demonstrated through continued growth in customer lives, strong medical trend in clinical quality performance. As you know, we further strengthened those capabilities about 2 years ago, with our expanded relationship with Catamaran seeking several features to strengthen, and we're seeing the benefit of those. As we've talked about that in the past, while we continue to own and operate our PBM, we maintain significant optionality and flexibility in that structure. And then, while we don't typically comment on details of transactions, we view that the PBM marketplace is and will continue to be very dynamic. As such, we ensure that there is some adequate deal protections for us that gives us meaningful flexibility going forward."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Josh Raskin with Barclays.",9,"The next question comes from Josh Raskin with Barclays."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Just getting back to the commercial -- I'm sorry the Government MLR. I'm just struggling to understand what caused the 290 basis point impact, like if you hold Medicare Advantage and Medicaid MLRs flat year-over-year, it implies the PDP was up 12 or 13 pe",89,"Just getting back to the commercial -- I'm sorry the Government MLR. I'm just struggling to understand what caused the 290 basis point impact, like if you hold Medicare Advantage and Medicaid MLRs flat year-over-year, it implies the PDP was up 12 or 13 percentage points. It's just not big enough in terms of the growth there to make the difference. So when you think strong performance on MA, is that mean the MLR was down? Or just trying to understand a little bit more of the granularity there."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","So, Josh, just to answer your last question, the MLR and MA adjusting for reserve development is flattish quarter-over-quarter. And in fact, the impact we're seeing in the Government MCR this quarter is largely due to PDP. And again, we're not going to ge",97,"So, Josh, just to answer your last question, the MLR and MA adjusting for reserve development is flattish quarter-over-quarter. And in fact, the impact we're seeing in the Government MCR this quarter is largely due to PDP. And again, we're not going to get into the specifics of the loss ratio, but the PDP MCR is always highest in the first quarter, as you know, because of the benefit design and transition period for new customers. And this quarter, in particular, for us, given we have a significant new customer growth, the seasonality with higher than normal."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","But I guess, Tom, I mean PDP was up 11%. The overall Government revenues were up closer to 17% or 18%. So you have to see -- when you say the seasonality, I guess why is that product changing? Or are you just saying that the loss ratio and PDP was higher?",52,"But I guess, Tom, I mean PDP was up 11%. The overall Government revenues were up closer to 17% or 18%. So you have to see -- when you say the seasonality, I guess why is that product changing? Or are you just saying that the loss ratio and PDP was higher?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, both. The loss ratio and PDP was higher, and again, we have a more significant mix of new customers, which is accountable for the loss ratio impact. Most of the impact is from the larger customer base and the transition period for the new customers.",120,"Well, both. The loss ratio and PDP was higher, and again, we have a more significant mix of new customers, which is accountable for the loss ratio impact. Most of the impact is from the larger customer base and the transition period for the new customers. And we do expect to see the normal seasonal pattern with improved results over the balance of the year. We also get some lift from our agreement with Gilead. It was effective April 1 in Part D, and we have anticipated some modest cost pressure, as we've mentioned, including last quarter continuing for Part D and our outlook for the full year, but that was as expected and then it's reflected in our outlook."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just switching topics a little bit, the public exchange accounts, like the individual businesses running a lot better and more in line with your expectations. Any comments on Reliance on the 3Rs, any change in your estimations for the 3Rs?",43,"Okay. And then just switching topics a little bit, the public exchange accounts, like the individual businesses running a lot better and more in line with your expectations. Any comments on Reliance on the 3Rs, any change in your estimations for the 3Rs?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, first, a little bit on the performance in the business, and we're still in the very early stages. Results in the quarter did see some improvement both from the repositioning of our medical mix and the improved customer demographics, and we are seein",152,"Well, first, a little bit on the performance in the business, and we're still in the very early stages. Results in the quarter did see some improvement both from the repositioning of our medical mix and the improved customer demographics, and we are seeing some targeted medical management actions that have lowered lost cost. So over the long term, we're still optimistic that we will see improved results and this will become an effective market segment. As far as the 3Rs are concerned, our accrual for the 3Rs in the first quarter was about $30 million after-tax. The majority of that relates to reinsurance, and we're continuing to accrue in line with the program parameters, and we didn't really make any material change in accruals for the 3Rs related to 2014 business, and we don't really see any significant adjustment to that until we get the final results from the government mid-year."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from A.J. Rice with UBS.",10,"The next question comes from A.J. Rice with UBS."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So first of all, maybe just to continue on the Medicare Advantage question. Obviously, we got final rates for 2016. Do you have any comments on that and also -- and what that means for you in terms of -- I know there's talk about average update of 1.25%,",70,"So first of all, maybe just to continue on the Medicare Advantage question. Obviously, we got final rates for 2016. Do you have any comments on that and also -- and what that means for you in terms of -- I know there's talk about average update of 1.25%, but each company has their own inputs, if you got a sense of where you guys would fall out on that."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","A.J., good morning, it's David. So as we look to 2016, first, we expect to have a base that'll have approximately 60% of our customers in for STAR+PLUS plans, noting a step-up from the prior year. And we expect to think forward beyond '16 to continue to s",206,"A.J., good morning, it's David. So as we look to 2016, first, we expect to have a base that'll have approximately 60% of our customers in for STAR+PLUS plans, noting a step-up from the prior year. And we expect to think forward beyond '16 to continue to step that up. As it relates to the rate setting environment, the net effects for our mix of our portfolio is that the vast majority of our plans are going to have about a flattish rate impact from all the moving parts from CMS. With the exception of 2 of our plans that will have a meaningful reduction based on the risk adjusters and the accounting rebates et cetera. The net result for our portfolio of that is, again, the vast majority of our business markets flattish, 2 with meaningful reductions weighted on an all-in base. It's about a 2% reduction. As we looked at taking it as a whole, considering our very well-positioned portfolio of coverage services and collaboratives, we feel like our businesses are in good position stepping into 2016, as such, we continue to expect to both grow customer base, again, stepping into 2016, as well as being able to expand margins stepping into 2016."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, great. And then maybe just a follow-up. I know you recently announced an alliance with SCAN Health Plan in California. I wondered if you might give a chance to comment on what you're hoping to do there, and what that opportunity might represent.",44,"Okay, great. And then maybe just a follow-up. I know you recently announced an alliance with SCAN Health Plan in California. I wondered if you might give a chance to comment on what you're hoping to do there, and what that opportunity might represent."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, A.J. When -- and you used the term alliance, which I appreciate. We have a multiple examples of alliances with, in some cases, traditional competitors, not-for-profit competitors, for profit competitors and the like. This most recent relationship wi",137,"Sure, A.J. When -- and you used the term alliance, which I appreciate. We have a multiple examples of alliances with, in some cases, traditional competitors, not-for-profit competitors, for profit competitors and the like. This most recent relationship with SCAN aligns our very high-performing employer portfolio of businesses in California with their well-performing Medicare capabilities and enables us to deliver an employer-sponsored Medicare Advantage solution to employers that are on target for them, but we had distribution reach and lever their capabilities. So it's a wonderful example of playing to both organization strength, enabling us to deliver an expanded set of solutions and capabilities on a more accelerated time frames than we would've been able to do organically and be able to deliver value for our existing clients and expand SCAN's relationship net win for both organizations."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Kevin Fischbeck of Bank of America.",11,"The next question comes from Kevin Fischbeck of Bank of America."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","I guess a couple of clarification questions. The commentary about the MA rate for 2016, was that including the Star pickup or before the star pickup?",26,"I guess a couple of clarification questions. The commentary about the MA rate for 2016, was that including the Star pickup or before the star pickup?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's net of all the moving parts, Kevin.",9,"It's net of all the moving parts, Kevin."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then on the individual commentary, I guess I don't remember, if you said it specifically or not, but it sounded to me like you're still expecting to lose money in 2015 on the public exchanges?",37,"Okay. And then on the individual commentary, I guess I don't remember, if you said it specifically or not, but it sounded to me like you're still expecting to lose money in 2015 on the public exchanges?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Net-net, as we've discussed before, Kevin, we look at '14, '15 and '16 as the version 1.0 of the marketplace. We built that business plans not around achieving the revenue or EPS significant contributions made of this book of business. As you know, we exp",93,"Net-net, as we've discussed before, Kevin, we look at '14, '15 and '16 as the version 1.0 of the marketplace. We built that business plans not around achieving the revenue or EPS significant contributions made of this book of business. As you know, we expect it to improve the performance of the block of business going from '14 to '15 that is taking place. So on a fully-allocated basis, there's a loss in the business, but is less than 2014, but we'd expect that to improve further as we step into 2016."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just -- at the beginning, you talked about some of the medical management capabilities that you guys are bringing. Some of them, like the preterm births, is really something that comes in pretty usefully in the Medicaid side of the business",102,"Okay. And then just -- at the beginning, you talked about some of the medical management capabilities that you guys are bringing. Some of them, like the preterm births, is really something that comes in pretty usefully in the Medicaid side of the business. I wonder if you feel like you guys are better positioned to participate in that side of the business, or if you guys have seen a couple of other companies, who haven't historically been in that market get more aggressive. How do you think about RFPs that seem to be coming up over the next couple of years?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Relative to the Medicaid space, we've been very consistent that we see opportunity in the higher risk or coordinated care dimensions of the Medicaid space, so we can call that the dual space and the various other high-risk portfolios. We have targeted exa",123,"Relative to the Medicaid space, we've been very consistent that we see opportunity in the higher risk or coordinated care dimensions of the Medicaid space, so we can call that the dual space and the various other high-risk portfolios. We have targeted examples of success to date, most notably in counties within Texas where we just -- we're recognized for an award of coordination of care with our behavioral and clinical capabilities. So we do see [indiscernible], we do see opportunities. It's highly geographically targeted in our Go Deep markets, and it's within those programs that enable significant coordination of care both engaging the individual and working with the clinical professionals. So we see targeted expansion opportunity over the next several years here."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Ralph Giacobbe with Crdit Suisse.",10,"The next question comes from Ralph Giacobbe with Crdit Suisse."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little bit of sense of why you did grow so much in PDP maybe kind of where it came from, if you could, at what percentage maybe was auto assigned and then just give us a sense of where it all kind of shook out relative to your expectatio",54,"Can you give us a little bit of sense of why you did grow so much in PDP maybe kind of where it came from, if you could, at what percentage maybe was auto assigned and then just give us a sense of where it all kind of shook out relative to your expectation."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Ralph, it's David, at a macro level, the majority of our growth was not auto assigned, so the step function to highly targeted geographically, and the significant amount of work was done within the benefit-design configuration to target subsegment of buye",106,"Ralph, it's David, at a macro level, the majority of our growth was not auto assigned, so the step function to highly targeted geographically, and the significant amount of work was done within the benefit-design configuration to target subsegment of buyers in key geographies. So as Tom noted, meaningful growth, but we expected it. We factored that into our guidance. We talked about it last quarter to acknowledge that there would be -- we recognize there's a transition of care window that largely spans the entire first quarter that transpired, but largely not assigned targeted geographies, targeting by segment and design products with that in mind."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, right. That's helpful. And then, can you just update us on where you sit on private exchanges? I know one of your customers recently moved and my understanding is actually that you retained a larger percentage of the book. But can you talk about con",64,"Okay, right. That's helpful. And then, can you just update us on where you sit on private exchanges? I know one of your customers recently moved and my understanding is actually that you retained a larger percentage of the book. But can you talk about conversations you're having with customers and your opportunities there for sort of the existing as well as new opportunities?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, relative to the private exchange marketplace, we continue to view this as a potentially attractive long-term market as it unfolds. As such, we've allocated leadership, significant resources to the portfolio of businesses here. We are currently posit",193,"Sure, relative to the private exchange marketplace, we continue to view this as a potentially attractive long-term market as it unfolds. As such, we've allocated leadership, significant resources to the portfolio of businesses here. We are currently positioned in the vast majority of third-party exchanges that exist in the marketplace up to and including, also having our own captive exchange. To date, the performance is generally speaking in line with our expectations, which we thought was a slower market transition that maybe some had flagged in the grand scheme of things. To date, we've seen some wins and losses in terms of our portfolios we've discussed before. As we stand here today, we have several hundred thousand lives when you span across our core medical and specialty capabilities as well as additional lives in the supplemental space. But it's in the early innings. We're positioned and we're evolving within the marketplace. And as you know, as our existing customers choose to transition, we have a brand positioning and a service proposition that tends to win us a lot of business in the choice marketplace. So performance in line with our expectations thus far."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","That's helpful. Just real quick and a follow-on to that. Just on the transition, if you have an ASO customer and they move to a private exchange and you retain that customer, ASO to ASO, is the profitability essentially the same?",42,"That's helpful. Just real quick and a follow-on to that. Just on the transition, if you have an ASO customer and they move to a private exchange and you retain that customer, ASO to ASO, is the profitability essentially the same?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's varied, obviously, depending on the configuration, but you should assume that the way we are seeking to position ourselves on the exchanges is to ensure that our offerings enable us to have enough of the, we'll call it, coordination and specialty rea",103,"It's varied, obviously, depending on the configuration, but you should assume that the way we are seeking to position ourselves on the exchanges is to ensure that our offerings enable us to have enough of the, we'll call it, coordination and specialty reach that I made reference to in my prepared remarks to be able to deliver differentiated value and not move back to I call it TPA administrator. So the simple answer is, it depends, because all the exchanges are not created equal. Our strong operating bias is the integration and coordination because that's where we deliver our step function value."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Christine Arnold with Cowen.",9,"The next question comes from Christine Arnold with Cowen."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Thanks for your commentary on the Government segment. Can you give us the same kind of commentary on your Commercial segment? How did you track with respect to stop loss versus experienced rate versus guaranteed cost relative to from a year ago in your ex",45,"Thanks for your commentary on the Government segment. Can you give us the same kind of commentary on your Commercial segment? How did you track with respect to stop loss versus experienced rate versus guaranteed cost relative to from a year ago in your expectations?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. So overall, the headline in the commercial segment is the commercial MCR is very consistent with our expectations for the quarter. Again, the headline messages the employer group business continues to perform very well, individual bus",113,"Christine, it's Tom. So overall, the headline in the commercial segment is the commercial MCR is very consistent with our expectations for the quarter. Again, the headline messages the employer group business continues to perform very well, individual business continues to improve. Quarter-over-quarter, in particular, the MCR is about flat. That reflects the improvement and individual with some offset by business mix impacts. But again, within those businesses the MCR is performing as we'd have expected by product line. Then I would point out, we would expect some increase or some improvement from the increased health insurance fee, but I would point out that our mix has that impact smaller than most others."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Andy Schenker with Morgan Stanley.",10,"The next question comes from Andy Schenker with Morgan Stanley."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So just first, the National Account Science [ph] can you give us some updates and I'll ask for [ph] -- you indicated you had an elevated percentage out for bid this year based on the procurement cycle. So curious how that's progressing.",42,"So just first, the National Account Science [ph] can you give us some updates and I'll ask for [ph] -- you indicated you had an elevated percentage out for bid this year based on the procurement cycle. So curious how that's progressing."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, Andy, it's David. First just let me redefine our national health, as we defined it a bit differently than our competition. For us, it's commercial employers with 5,000 and more employees that span multiple states. So we exclude the large single-stat",243,"Sure, Andy, it's David. First just let me redefine our national health, as we defined it a bit differently than our competition. For us, it's commercial employers with 5,000 and more employees that span multiple states. So we exclude the large single-state commercial employers that's part of our regional segment. We have a new recollection. Year-over-year as we look back to last year, our pipeline was about equal to the prior year, but our -- portion of our book of business that was out to bid was elevated due to procurement cycles. As we look at the current cycle, looking forward to 2016 relative to the pipeline of new opportunities, number of case is about the same. Average case size is somewhat elevated. So on a life-basis, but more lives to look out but then a similar number of cases. As it relates to the percentage of our book of business out to bid, the percent is back down because that procurement cycle that's moving through. So early in the overall sales cycle, a healthy pipeline of opportunities to look out, a reasonable percentage of our book of business is out to bid. We continue to be focused on retaining the right business and earning the right business that has engagement and incentive alignment, expanding our specialty capabilities as indicative of our ability to grow revenue and earnings in the space by delivering value to those clients that are on target for us."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Ana Gupte with Leerink Partners.",10,"The next question comes from Ana Gupte with Leerink Partners."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Wanted to follow up on the question on the commercial loss ratio, just as far as, individual off-exchange on-exchange, the guaranteed cost and the stop loss. So I get it that it's in line with expectations. I think there was a lot of pressure on your off-",92,"Wanted to follow up on the question on the commercial loss ratio, just as far as, individual off-exchange on-exchange, the guaranteed cost and the stop loss. So I get it that it's in line with expectations. I think there was a lot of pressure on your off-exchange book last year. It seems like you've seemed to have traded with some of the membership is that coming from off exchange. And are you seeing the overall individual book negative but that book of business is kind of returning to profitability at this point?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","So it's David. Let me just frame it a little bit relative to the individual. First, as Tom noted in the employer book, the employer book last year, this year continues to perform well and in line with our expectations. Within the individual book of busine",168,"So it's David. Let me just frame it a little bit relative to the individual. First, as Tom noted in the employer book, the employer book last year, this year continues to perform well and in line with our expectations. Within the individual book of business, as you very well know relative to us, it's small in the grand scheme of things in terms of covered lives. As it relates to the grandfathered and some of the transitional block, one of the states where we had a large grandfather block of businesses, a state where we don't operate on the exchange, specifically California. So we saw attrition relative to the grandfathered block stepping into 2015, which was in line with our expectations. We still maintain a mix of on-exchange and off-exchange business in that, taken as a whole, the loss ratio of our business, and therefore, the underlying performance of the individual business steps forward and improved in line with our expectations going from '14 to '15."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then on the guaranteed cost legacy book, have you seen margin expansion? Some of your competitors are very commercially focused. There's some really nice margin expansion. I'm just trying to get to the underlying metric here.",37,"And then on the guaranteed cost legacy book, have you seen margin expansion? Some of your competitors are very commercially focused. There's some really nice margin expansion. I'm just trying to get to the underlying metric here."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","And, Ana, are you referencing individual or group?",8,"And, Ana, are you referencing individual or group?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Group, group.",2,"Group, group."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Within our group block of business, as you know, we don't play in the small group employer. So you need to take the under-50 block and remove that from the way you think about us. Relative to the over-50 block of business, our performance was strong and r",54,"Within our group block of business, as you know, we don't play in the small group employer. So you need to take the under-50 block and remove that from the way you think about us. Relative to the over-50 block of business, our performance was strong and remained strong in that portfolio of business."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then finally on stop-loss, is that trending flat or are margins coming in or expanding? You've seen a nice 19% growth in premiums there.",26,"And then finally on stop-loss, is that trending flat or are margins coming in or expanding? You've seen a nice 19% growth in premiums there."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Ana, it's Tom, margins and stop-loss are just where we'd like them to be. So the result -- the performance in the book is good.",25,"Ana, it's Tom, margins and stop-loss are just where we'd like them to be. So the result -- the performance in the book is good."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Peter Costa with Wells Fargo.",10,"The next question comes from Peter Costa with Wells Fargo."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Question on your strategy around M&A going forward. You're a little bit subscale to some or the other national account players, which you -- now you focus on some geographically concentrated markets as a way to compensate for that. But just some books of",151,"Question on your strategy around M&A going forward. You're a little bit subscale to some or the other national account players, which you -- now you focus on some geographically concentrated markets as a way to compensate for that. But just some books of business likely to come up, one in particular, just the other day is being [indiscernible]. It's more of a broad book of individual business and there's some expectation that some of these smaller plans that are focused on certain geographies exchange base business that are going to cut for scale. Do you think some of those books will be interesting to you guys? And if they are, a lot of why they're up for sale would be that they're under pressure. And so the -- some of the business is underpriced. How would you react to fixing books of business that you see up for sale?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Peter, David. Let me give you a little color on M&A. You factored in many statements and questions there. So first, broadly relative to M&A. M&A continues to be a component of our value creation framework. So it's effective deployment of capital, strategi",313,"Peter, David. Let me give you a little color on M&A. You factored in many statements and questions there. So first, broadly relative to M&A. M&A continues to be a component of our value creation framework. So it's effective deployment of capital, strategic M&A is a component within there. Our priorities have been consistent in terms of where we see the ability to create step-function value, specifically smartly furthering our global footprint; two, expanding our MA and dual capabilities; three, expanding our retail capabilities; and four local tuck-ins. And we've had a successful track record of accomplishing targeted acquisitions over the last 5-plus years in line with our strategy. As it relates to your scale comment, we've chosen to redefine our engagement around scale to ensure that we have appropriate scale to have competitive cost structure from an administrative cost standpoint, which we have. We've been able to prove productivity gains year-in year-out and free capacity to further ongoing investment battle within the franchise. And then you come down to medical cost to your dialogues, and that's a very localized conversation and it's not a localized conversation at the state level. It's an MSA level, and increasingly, within our marketplaces, it's coming down to a sub-MSA level. So we're highly focused on key geographies and our ability to win and deliver value for our clients and customers. As related to appetite for future M&A, I mean, opportunities where we're very aware, engaged and highly focused. So as long as the transactions are on strategy relative to the items I talked about before. On a final note, I'm not going to speculate on how you would rehabilitate an underperforming book of business, but our organization has demonstrated the ability to deliver high performance within our targeted segments, and again, we see M&A as a forward-looking opportunity to create smart transactions and good shareholder value."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then, just it's on the Part D business, one further question. You talked about some of the higher MLR being from transition issues. Is your guidance going forward making the assumption that those transition issues are resolved in Q1? Or do you expect",75,"And then, just it's on the Part D business, one further question. You talked about some of the higher MLR being from transition issues. Is your guidance going forward making the assumption that those transition issues are resolved in Q1? Or do you expect that to continue into Q2? And what if it -- if it isn't transition issues and you're not able to resolve it, will that impact your guidance and by how much?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Peter, it's Tom. I think that a little differently. This is the prescribed 90-day period for new members to stay on their old formulary, while they transition to our new formulary. So we would expect that to work itself during the first quarter.",43,"Peter, it's Tom. I think that a little differently. This is the prescribed 90-day period for new members to stay on their old formulary, while they transition to our new formulary. So we would expect that to work itself during the first quarter."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","And the next question comes from Chris Rigg with Susquehanna Financial Group.",12,"And the next question comes from Chris Rigg with Susquehanna Financial Group."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Just wanted to focus on the guidance for a minute, particularly in a Global Health Care segment. You raised by $15 million at the mid-point, but you had $25 million of TPD. I'm just wondering why the raise wasn't at least in line with the level of desired",49,"Just wanted to focus on the guidance for a minute, particularly in a Global Health Care segment. You raised by $15 million at the mid-point, but you had $25 million of TPD. I'm just wondering why the raise wasn't at least in line with the level of desired development."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Chris, it's Tom. We're really pleased that we've been able to increase our outlook this early in the year. Again, we expect to deliver attractive growth and revenue earnings and EPS across the company and in Global Health Care in 2015, just as we have in",72,"Chris, it's Tom. We're really pleased that we've been able to increase our outlook this early in the year. Again, we expect to deliver attractive growth and revenue earnings and EPS across the company and in Global Health Care in 2015, just as we have in each of the last 5 years. So really I'd see our revised outlook as just reinforcing our confidence that we're on track to deliver those results."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just with regard to the comments in the press release about the investment spending in the quarter, in the health care segment, was that -- that was expected in the original outlook just to be clear?",39,"Okay. And then just with regard to the comments in the press release about the investment spending in the quarter, in the health care segment, was that -- that was expected in the original outlook just to be clear?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes.",1,"Yes."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Dave Windley with Jefferies.",9,"The next question comes from Dave Windley with Jefferies."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","On the operating expense guidance and ratio, I guess I'm just looking at your starting year toward the higher end of that range. Your trends tended to rise, [indiscernible] year rise through the year in historical years, and you're mentioning some favorab",93,"On the operating expense guidance and ratio, I guess I'm just looking at your starting year toward the higher end of that range. Your trends tended to rise, [indiscernible] year rise through the year in historical years, and you're mentioning some favorable impacts in, I think, disability this quarter -- excuse me, sort of this quarter. So I guess, I'm thinking it should rise this year as well unless you tell me otherwise. So how do you see that trending over the balance of the year to hit that range that you provided?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Dave, it's David. So directionally first off, we knew the first quarter was going to have an elevated level of expenses. As such, on the last quarter when we talked about the first quarter pattern, we flagged that and it was called out, as mentioned, in t",146,"Dave, it's David. So directionally first off, we knew the first quarter was going to have an elevated level of expenses. As such, on the last quarter when we talked about the first quarter pattern, we flagged that and it was called out, as mentioned, in the further questions as we looked at many of our strategic spend initiatives. Two, as you made reference to our outlook is to see that our operating expense ratio will show a year-over-year improvement as we have been able to demonstrate for many years as we look back and our organization is tightly aligned relative to that. So the performance of that will transpire a little differently into 2015 quarters as opposed to the prior quarters. But Q1 was known as an uptick. Our outlook is to see an improved expense ratio and organization is on track to achieve that."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So if I can -- if you can clarify just a little further, would you expect the investments that you flagged in 1Q to then exit or evaporate in 2Q and it's a drop back down significantly and then turn back as it normally does? Or is it just a completely dif",55,"So if I can -- if you can clarify just a little further, would you expect the investments that you flagged in 1Q to then exit or evaporate in 2Q and it's a drop back down significantly and then turn back as it normally does? Or is it just a completely different pattern this year?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes, Dave, I wouldn't expect the strategic spending to decline over the balance of the year. I think what I'd expect to see is both a little different pattern of revenue and earnings to get to the result we've talked about.",41,"Yes, Dave, I wouldn't expect the strategic spending to decline over the balance of the year. I think what I'd expect to see is both a little different pattern of revenue and earnings to get to the result we've talked about."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The final question comes from Sarah James with Wedbush Securities.",10,"The final question comes from Sarah James with Wedbush Securities."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","One of your peers recently indicated their discussions with employers suggest that there could be a step-up in conversions to private exchanges in the next 1 to 2 years. Are you hearing similar from your clients? And if you could share with us what percen",61,"One of your peers recently indicated their discussions with employers suggest that there could be a step-up in conversions to private exchanges in the next 1 to 2 years. Are you hearing similar from your clients? And if you could share with us what percentage of your private exchange book is self-funded and what percent are new members to Cigna?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's David. First, the dialogue with employers has been active around private exchanges, as it has been around consumer-directed engagement programs et cetera. I think the broader picture here is that, employers of all sizes are looking for the higher val",291,"It's David. First, the dialogue with employers has been active around private exchanges, as it has been around consumer-directed engagement programs et cetera. I think the broader picture here is that, employers of all sizes are looking for the higher value creation benefit strategies that are going to be sustainable for them. That's the broader dialogue. And private exchanges represent a tool that many employers are trying to explore. The determinant of that is part of the overall portfolio. What we've seen, and what the market has seen is a relatively modest adoption rate of that toolset, but it's early on, as we've indicated, in the private exchange cycle. Two, what we've seen is a continued elevated performance of self-funded consumer-directed aligned incentive and coordinated integrated offerings. As it relates to our own experience within the private exchanges, to the second part of your question, the vast majority of those employers are in the self-funded space given the profile of what we operate in, but we have guaranteed cost lives there as well. We have integrated and nonintegrated lives, but again it's small in the grand scheme of things in terms of what we're seeing. And a portion of the lives we're seeing there are new to Cigna. Greater than 50% of those are transitioning from existing Cigna relationships carried over to the exchanges. But the important part is that it's still a small part of both the marketplace as well as our portfolio. Two, we've deployed significant resources to make sure we're in position on the various exchanges, including our own captive and proprietary exchange. And three, we see to be very consultative with our employers to make sure they understand all the choices that are available to them."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And as employers are evaluating their different options, you mentioned, within the high deductible plans or private exchanges, can you tell whether or not one is emerging as the more likely way that employers are trending, or if there's any difference in",61,"And as employers are evaluating their different options, you mentioned, within the high deductible plans or private exchanges, can you tell whether or not one is emerging as the more likely way that employers are trending, or if there's any difference in how they are trending based on employer size, whether they're not going towards the private exchanges versus high deductibles?"
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, Sarah, I think we could point to both the track record of actions as well as the emerging actions. So the more tangible track record of actions is that, employers of a variety of sizes continue to move toward the transparent funding, which includes",170,"Well, Sarah, I think we could point to both the track record of actions as well as the emerging actions. So the more tangible track record of actions is that, employers of a variety of sizes continue to move toward the transparent funding, which includes ASO. That's a consistent track. Two, elevation of aligned incentive programs, whether they're consumer-directed, full-on CDHP programs or if they're coinsurance programs, coinsurance programs with aligned incentive models, those would be the 2 most tangible pieces I think you could point to. And then over the last couple of years, an emerging trend too, as I referenced before, carving in or even more adoption of integrated care programs that are coordinated to delivering the value back. But private exchange, if you will, trend again is still in the early stages and I wouldn't flag it as one where we would see the majority of buying behavior over the next 2 buying cycles. But as we're positioned, we're positioned for an elevation and volume should unfold."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","I will now turn the call back over to David Cordani for closing remarks.",14,"I will now turn the call back over to David Cordani for closing remarks."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thank you. Just to conclude our discussion this morning, I'd like to reiterate just a few important points. First, Cigna's first quarter results represent a strong start to the year and were driven by revenue and earnings contributions across our diversif",168,"Thank you. Just to conclude our discussion this morning, I'd like to reiterate just a few important points. First, Cigna's first quarter results represent a strong start to the year and were driven by revenue and earnings contributions across our diversified portfolio of businesses. Our integrated capabilities are optimizing health, improving medical outcomes and increasing affordability for the individuals we serve. Our more than 37,000 talented colleagues around the world are unified in their commitment to work every day to improve the health, well-being and sense of security of the customers we serve. Our strong first quarter performance and multiple avenues for growth give us confidence that we will achieve our increased full year 2015 outlook. Over the long term, we remain committed to achieving our annual EPS growth of 10% to 13% over the long term and expect to double size of our company's revenue over the next 7 to 8 years. Thank you for joining our call today, and we look forward to furthering our discussions."
172899,290303753,798950,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's first quarter 2015 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this cal",65,"Ladies and gentlemen, this concludes Cigna's first quarter 2015 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 1 (800) 365-2419 or 1 (203) 369-3679. No passcode is required. Thank you for participating. We will now disconnect."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2015 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded.We'll begin by turn",48,"Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2015 Results Review. [Operator Instructions] As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded.
We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Offic",378,"Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks, today, David and Tom will cover a number of topics, including Cigna's first quarter 2015 financial results as well as an update on our financial outlook for 2015.
As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled ""adjusted income from operations"" and ""earnings per share"" on the same basis as our principal measures of financial performance. A reconciliation of these measures to the most directly comparable GAAP measure is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com.
In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2015 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC.
Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. As a reminder, beginning in 2015, we have simplified our guidance and disclosures for our Medical Care Ratios or MCRs by reporting them on a basis of total Commercial and total Government. The total Commercial ratio encompasses all of our commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products, provided through guaranteed cost or experience-rated funding arrangements in both the United States and internationally. The total Government ratio includes our Medicare Advantage, Medicare Part D and Medicaid businesses.
Finally, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or additional prior year development of medical costs.
And with that, I will turn the call over to David."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thanks, Will. Good morning, everyone, and thank you for joining our call today.To begin, I'd like to read the highlights of our financial results for the first quarter. Next, I'll discuss how we are leveraging Cigna's integrated capabilities to engage i",1735,"Thanks, Will. Good morning, everyone, and thank you for joining our call today.
To begin, I'd like to read the highlights of our financial results for the first quarter. Next, I'll discuss how we are leveraging Cigna's integrated capabilities to engage individuals to help them optimize their health and well-being, and how this is translating into value for customers and clients.
Then Tom will provide more detail around our first quarter financial performance and update our full year 2015 outlook. And following your questions, I'll leave you with a few closing remarks.
Let's dive in with some highlights from the quarter. Cigna's first quarter 2015 performance represents a strong start to the year. We are pleased with our results, which extends our track record of attractive financial performance. Once again, our success was driven by the effective and disciplined execution of our strategy, which continuously guide our actions in a dynamic marketplace.
Our first quarter 2015 consolidated revenue increased 11% to $9.5 billion, with strong contributions across our business segments. We reported adjusted income from operations for the first quarter of $513 million or $1.96 per share. Our Global Health Care revenues increased 12%, driven by strong performance in our Commercial and Government businesses. Our Global Supplemental Benefits business, once again drove strong revenue growth in high single-digit after-tax margins, while we continue to make targeted investments in support of future growth, and we achieved 6% revenue growth in our Group Disability and Life business.
Overall, our diversified portfolio of businesses continues to produce significant free cash flow that further enables our financial flexibility with more than $500 million deployed for share repurchase on a year-to-date basis. Our continued focus and effective strategic execution are generating strong results, enabling ongoing investments in our business portfolio and helping us meet the unique local market needs through the right balance of affordability and personalization of our products and services.
As we've discussed previously, we have a clear framework to drive ongoing future value creation for Cigna. First, our diversified businesses are well positioned to create attractive value for our customers and clients and, as a result, differentiated revenue growth. Second, we are focused on targeted and effective capital deployment to create ongoing shareholder value through investments in our business, strategic M&A and share repurchase. Our businesses generate high levels of free cash flow, which give us financial flexibility and the opportunity to deploy capital to further create value for the benefit of shareholders. And finally, we continue to seek new and emerging opportunities to expand in new distribution marketplaces, new geographies and new buying segments.
Guided by this framework and coupled with effective execution, we continue to expect to deliver average annual revenue growth rate of 8% to 10% over the long term. This framework also positions us to support our focus on enabling health care over financing sick care, which is well aligned with Cigna's efforts to improve the current health care system.
The United States spends $3 trillion a year on health care. Studies consistently show approximately 25% of the total expenditures are wasted through inefficiency or breakage. At the same time, 50% of all adults have at least one chronic disease, conditions which translate to 7 out of the top 10 causes of death in the U.S.
In this dynamic environment, Cigna continues to convene key stakeholders to work toward a sustainable health care system. Health care stakeholders from individuals to corporate employers and government organizations are seeking a common set of core goals. These include maintaining or improving health and productivity, affordable and predictable cost outcomes and greater personalization of solutions and services. To meet these goals, we must continue to accelerate the transition from yesterday's view health insurance as a mechanism for financing the cost of illness to an orientation center around maintaining and improving the health and wellness of individuals. At Cigna, we are and we'll continue to make significant strides toward achieving a more sustainable health care system, by engaging with individuals and physicians through coordinated offerings and alliance incentives.
We have moved beyond the typical multi-product sales and services approach to engaging individuals and coordinate care at a very personal level, as we work to improve health and wellness, all by harnessing information, incenting and supporting individuals and partnering with physicians, the result of which is a service experience for customers that achieves the right balance of personalization and affordability. 
I'd like to share with you a few examples of how we are leveraging the power of integration and coordination, with our broad solution suite, by encouraging maintenance and prevention among the healthy, providing coaching to the healthy at risk, enabling coordinated care for those with chronic conditions and facilitating access to centers of excellence for those with acute conditions.
Our health care professionals engage with customers and clinicians to improve health every day, leveraging the breadth of our clinical capabilities, which spans over 4,000 professionals from doctors and nurses to behavioral health professionals, health coaches and pharmacists.
Relative to our behavioral professionals, our capabilities include engaging with a cardiology team when a health event transpires, as we have seen a strong correlation between these types of illness and depression; engaging with our experts in disability programs to improve health and maximize personal productivity; and helping individuals recover from an injury by taking a more holistic view of mind and body. As for result, our customers are empowered by active coordinated care through coaching, support services and incentive programs. And the impact, Cigna clients with integrated offerings have 29% fewer mental health and substance abuse related outpatient visits and 8% fewer inpatient events compared with those without integrated offerings.
Another powerful example of our success, with our coordinated approach, is for customers who are expectant moms. In today's health care system, the cost of a premature birth is nearly 11x higher than that of a full-term birth, not to mention the impact on the family stress and, in some cases, lifelong health challenges. CIGNA's Healthy Pregnancies, Healthy Babies program engaged with customers to optimize health during pregnancy, by working with nurses who can assess risks; develop personalized care plans; and continue supportive outreach and coordination with OB/GYN teams; and finally, providing coaching on newborn care. Active participation by expected mothers in our integrated program is key. In fact, for those who enroll, there is nearly 50% reduction in premature births versus the U.S. average. This is a huge impact for the family, the child and society overall.
The benefit of integrated and coordinated care is also impactful within Cigna's Specialty Pharmacy programs, where our pharmacists and clinicians engage with customers and health care professionals to improve the effectiveness of drug regimes to drive better overall health outcomes. Our engaged customers have higher medication adherence and lower specialty drug costs, resulting in a 15% lower overall medical cost versus individuals who do not have these coordinated offerings.
Our coordination also works with dental care customers, where there's a high correlation between periodontal health and improved health outcomes. In our dental programs, individuals with diabetes, heart disease or stroke, who have both medical and dental coverage with Cigna have seen higher health quality and lower medical costs. For example, patients with diabetes participating in our coordinated and dental programs saw lower average annual medical costs of approximately 28%, when receiving coordinated care. And for patients with heart disease, costs were low by approximately 25%.
As a final example across the U.S., our 4,000 plus clinical professionals continue to engage and help our customers in increasing numbers through a rapidly growing collaborative care relationships. Today, we have more than 120 of these relationships spanning 29 states. As for impact, more than 90% of Cigna's collaborative care relationships with at least 2 years of experience are seeing success in managing improved medical costs and nearly 80% with at least 1-year of experience are seeing success in total medical cost results or clinical quality measures. Examples of medical results include an improvement in blood pressure, an improvement in BMI and an improvement in total cholesterol levels. These examples reinforce our successful efforts to improve health and quality-of-life while working to remove cost from the system. By leveraging our integrated capabilities and coordinating clinical care resources for each individual through their health journey, we are improving affordability while creating a more sustainable health care system. Over the long term, we believe our approach to health care rather than sick care will promote better health, sustainability and economic vibrancy and lower the cost burden on customers as well as employers.
And this success translates to shareholder value as we leverage our capabilities and meet customer needs with products and services that are enhanced through our highly aligned coordinated offerings. This value is evidenced by our industry-leading medical cost trend over the last several years, high customer retention levels and strong growth in our specialty and integrated services that achieve the personalization of services outcomes that I previously referenced. 
As demonstrated by our discussion this morning, our integration and coordination of care has moved beyond the simple multi-product solution. Today, we are engaging individuals in a very personalized way, leveraging actionable information, partnering with health care professionals and utilizing care resources that both reduce costs and produce superior health outcomes.
Now to summarize my remarks before turning it over to Tom. Cigna's strong start to 2015 continues our long-term track record of financial performance in delivering competitively attractive revenue and earnings and gives us confidence in our increased full year 2015 outlook. The strong free cash flow from a high return on capital and high-margin portfolio of businesses provide ongoing financial flexibility in capital management and deployment. We are effectively executing our strategy and creating value for our customers and clients by leveraging integrated capabilities that promote health care rather than sick care and driving improved personalization and affordability for the benefit of the individuals we serve. We remain committed to our long-term objective, which is to double the size of our business over the next 7 to 8 years, yielding an 8% to 10% annual revenue growth rate on average. And over this time horizon, we expect to continue to deliver competitively attractive long-term EPS growth of 10% to 13% annually on average, all while we continue to invest in our company's business portfolio. And with that, I'd like to turn the call over to Tom."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thanks, David. Good morning, everyone. In my remarks today, I will review Cigna's first quarter 2015 results and discuss our outlook for the full year.We've had a good start of the year with strong revenue and earnings contributions across our diversifi",1643,"Thanks, David. Good morning, everyone. In my remarks today, I will review Cigna's first quarter 2015 results and discuss our outlook for the full year.
We've had a good start of the year with strong revenue and earnings contributions across our diversified portfolio of businesses, driven by continued effective execution of our strategy.
The highlights in the quarter include consolidated revenue growth of 11% to $9.5 billion; consolidated earnings of $513 million; quarterly earnings per share of $1.96; and continued strong free cash flow with approximately $515 million returned to shareholders through share repurchase on a year-to-date basis. Overall, the strength of our first quarter performance provides us with solid momentum for the year.
Regarding the segments, I will first comment on our Global Health Care segment. Global Health Care results were solid in the quarter. First quarter premiums and fees grew 12% to $6.7 billion, driven by customer growth in our Commercial and Government businesses as well as specialty contributions and rate actions. We ended first quarter of 2015 with 14.7 million global medical customers, including approximately 200,000 new customers from our QualCare Alliance Networks acquisition. First quarter earnings were $444 million, reflecting medical and specialty business growth, continued effective medical cost management, improving results in our individual business with some offset from increased spending for strategic investments as well as higher seasonal costs in our growing Medicare Part D business.
Turning to medical costs. We continue to deliver medical costs that reflect better health outcomes and strong clinical excellence for our customers and clients as a result of our deep collaborative relationships with physicians and our focus on personalization of care. Our commercial medical trend result continues to be among the lowest in the industry. And given that over 85% of our U.S. Commercial customers are in transparent ASO funding arrangements, our clients directly benefit from these favorable medical costs.
Regarding medical care ratios, our first quarter 2015 total Commercial Medical Care ratio or MCR was 75.2% on a reported basis or 75.9% excluding prior year reserve development.
Overall, we are pleased with the results of our commercial risk businesses in the quarter, reflecting strong pricing, disciplined underwriting and continued effective medical management and physician engagement. Results in our individual business continue to improve in the first quarter and are in-line with our expectations.
In our Government business, our first quarter 2015 total government MCR was 89.4% on a reported basis or 89.9% excluding prior year's reserve development, reflecting continued good performance in our Medicare Advantage business, partially offset by seasonal costs from our growing Medicare Part D business. Across our Commercial and Government risk books of business, our first quarter earnings included favorable prior year reserve development of $25 million after-tax compared to the $30 million after-tax in the first quarter 2014.
Moving to operating expenses, for first quarter 2015, our total Global Health Care operating expense ratio was 21.7%, which reflects an expected increase in spending for strategic investments. Overall, we've had a strong start to 2015 in our Global Health Care business.
Now I will discuss the results of our Global Supplemental Benefits business, which continues to deliver attractive growth and profitability. Premiums and fees grew 8% quarter-over-quarter in global supplemental or 12% on a currency-adjusted basis. First quarter earnings grew 21% or 25% on a currency-adjusted basis to $69 million, reflecting business growth and strong operating expense management as well as some favorable operating expense timing.
For Group Disability and Life, first quarter premium and fees increased 7% over first quarter 2014, reflecting growth across the Disability Life and Accident product lines. First quarter earnings in our group business were $51 million, which include unfavorable claims experienced in our life insurance business as well as an expected increase in operating expenses.
For our Corporate and Other operations, results totaled to an after-tax loss of $51 million in the first quarter of 2015. Overall, as a result of the continued effective execution of our strategy, our first quarter results reflect strong revenue and earnings contributions from our ongoing businesses and significant free cash flow.
Turning to our investment portfolio. In the first quarter, we recognized net realized investment gains of $48 million after-tax, coupled with a strong net investment income result. The high quality and diversification of our investment portfolio continue to drive our overall investment results.
Now I will discuss our outlook for 2015. In 2015, we expect to continue to deliver strong financial performance for our shareholders by leveraging our differentiated capabilities to deliver affordable and personalized solutions, effectively deploying capital and targeting new and emerging opportunities where we will seek to drive additional value for shareholders. We continue to expect consolidated revenues to grow in the range of 8% to 10% over 2014.
Our outlook for full year 2015 consolidated adjusted income from operations is now in the range of approximately $2.12 billion to $2.21 billion or $8.15 to $8.50 per share. This represents an increase of $0.10 to $0.15 per share over our previous expectations.
I will now discuss the components of our 2015 outlook, starting with Global Health Care. We now expect full year Global Health Care earnings in the range of approximately $1.75 billion to $1.8 billion, an increase over our prior expectations.
I'll now summarize some of the key assumptions reflected in our Global Health Care earnings outlook for 2015, starting with our customer base. Regarding global medical customers, we now expect 2015 customer growth of 2% to 4%. This increase over previous expectations primarily reflects customers added through the acquisition of QualCare Alliance Networks, which was completed in the first quarter of 2015.
Turning to medical costs. In our 2015 -- our 2015 outlook continues to assume some increase in medical utilization versus current levels which has been reflected in our pricing. For our total U.S. Commercial book of business, we continue to expect full year medical cost trend to be in the range of 5% to 6%.
Now turning to our medical care ratio outlook. For our total commercial book of business, we continue to expect the 2015 medical care ratio to be in the range of 78% to 79%. For our total government book of business, we continue to expect the 2015 medical care ratio to be in the range of 84.5% to 85.5%.
Regarding operating expenses, we continue to expect our 2015 Global Health Care operating expense ratio to be in the range of 21% to 22%. Overall, we expect full year 2015 Global Health Care earnings to be approximately $1.75 billion to $1.8 billion.
The other components of our outlook are unchanged. For our Global Supplemental Benefits business, we continue to expect strong top line growth in earnings in the range of $230 million to $250 million. Regarding our Group Disability and Life business, we continue to expect full year 2015 earnings in the range of $320 million to $340 million. Regarding our remaining operations, that is other operations and corporate, we expect a loss of $180 million for 2015.
So all-in, for full year 2015, we now expect consolidated adjusted income from operations of $2.12 billion to $2.21 billion or $8.15 to $8.50 per share. This represents an increase of $0.10 to $0.15 per share. I would remind you that our outlook continues to exclude the impact of additional prior year reserve development or any future capital deployment. While we do not anticipate the impact of future capital deployment in our EPS outlook, we continue to expect the additional free cash flow that we generate will be deployed for the benefit of our shareholders either through value-creating acquisitions or share repurchase.
Now moving to our 2015 capital management position and outlook. Overall, we continue to have excellent financial flexibility. Our subsidiaries remain well capitalized and are generating significant free cash flow to the parent, with a strong return on capital in each of our business segments. Our capital deployment strategy and priorities have not changed. These priorities are: providing the capital necessary to support the growth of our ongoing operations; pursuing M&A activity with a focus on acquiring capabilities and scale to further grow in our target areas of focus; and after considering these first 2 items, we'd return capital to shareholders, primarily through share repurchase.
Regarding free cash flow, we ended the quarter with parent company cash of approximately $1.3 billion, which includes approximately $900 million of proceeds from our recent issuance of long-term debt. These proceeds were subsequently used to redeem existing debt in the second quarter of 2015. During the period February 5 through April 29, we repurchased 3.2 million shares of stock for approximately $400 million, bringing our year-to-date share repurchase to 4.3 million shares for approximately $515 million. After considering all sources and uses of parent company cash, we now expect to have approximately $1.3 billion available for capital deployment during the balance of the year. Our free cash flow outlook continues to reflect the industry-leading margins and returns on capital in our businesses and a high level of capital efficiency, particularly from our fee-based businesses. This capital efficiency allows us to fund attractive organic growth while continuing to generate significant free cash flow to be deployed for the benefit of shareholders.
Now to recap. Our first quarter 2015 consolidated results reflect the strength of our diversified portfolio of global businesses and continued effective execution of our focused strategy. The fundamentals of our business remain strong, as evidenced by our first quarter results, which reflected strong revenue and earnings contributions across our diversified portfolio of businesses, industry-leading medical cost trends and high clinical quality and continued strong free cash flow. Based on the strength of these results, we are confident in our ability to achieve our increased full year 2015 earnings outlook.
And with that, we will turn it over to the operator for the Q&A portion of the call."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","[Operator Instructions] Our first question comes from Scott Fidel with Deutsche Bank.",12,"[Operator Instructions] Our first question comes from Scott Fidel with Deutsche Bank."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","I was hoping we could just drill into the Government MLR for a little bit and maybe just talk about first just on Medicare Advantage, how utilization trends looked in the quarter, and if you've seen any type of recent indications of any type of inpatient",112,"I was hoping we could just drill into the Government MLR for a little bit and maybe just talk about first just on Medicare Advantage, how utilization trends looked in the quarter, and if you've seen any type of recent indications of any type of inpatient admission acceleration in recent weeks. And then second, just relative to the PDP MLR, just how that tracked relative to your expectations in the quarter. And clearly, given when there's outsized growth in PDP membership there's sometimes risk of higher MLR, so just interested in terms of what you're seeing around script trends and just around general performance in the PDP business so far this year."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Scott, it's Tom. So first, we're very happy with the position of our Government business. Our outlook for the Government MCR in 2015 reflects strong results in our Medicare Advantage business and some expected pressure in Part D, as you mentioned. The qua",168,"Scott, it's Tom. So first, we're very happy with the position of our Government business. Our outlook for the Government MCR in 2015 reflects strong results in our Medicare Advantage business and some expected pressure in Part D, as you mentioned. The quarter-over-quarter increase, specifically in the Government MCR, is mainly due to Part D with continuing good Medicare Advantage results. As you pointed out, we reported significant growth in Part D customers in 2015. And as a result, we've had a more pronounced seasonal impact from Part D this quarter. These new customers have a period of time to transition from their previous formulary to our formulary. So as we expected, we saw some additional first quarter cost impacts. And all-in, we continue to expect our government MCR to be in the range of 84.5% to 85.5% for the full year, which we're happy with. As far as the outlook or the utilization outlook, we really didn't see any significant change in MA utilization in the quarter."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, and then just a quick follow-up. Just in terms of the cost trends view reiterating that 5% to 6% for the full year. Just interested if you could give us some flavor in terms of just in the first quarter itself and Commercial MLR looked quite favorab",69,"Okay, and then just a quick follow-up. Just in terms of the cost trends view reiterating that 5% to 6% for the full year. Just interested if you could give us some flavor in terms of just in the first quarter itself and Commercial MLR looked quite favorable again. So just interested, do you have a sense of where you were sitting within that range in the first quarter."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes, Scott, well, we're really pleased with our medical trend results. And as we mentioned many times, we delivered a cost trend below 4.5% in 2014, building on a very strong track record we've had for several years, with industry-leading results. Our out",114,"Yes, Scott, well, we're really pleased with our medical trend results. And as we mentioned many times, we delivered a cost trend below 4.5% in 2014, building on a very strong track record we've had for several years, with industry-leading results. Our outlook for 2015, medical cost trends, 5% to 6%, does anticipate some uptick in utilization over the course of the year and some expected increase in pharmacy trends due to specialty drug costs. And commenting on the first quarter, we haven't seen the uptick in utilization, but we are seeing some expected pharmacy trend impact. So overall, we're comfortable, we're going to again deliver a competitively attractive medical cost trend in 2015."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Matthew Borsch with Goldman Sachs.",10,"The next question comes from Matthew Borsch with Goldman Sachs."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Yes, I was hoping that maybe you could address what you're seeing in the marketplace in terms of middle-market employers and the extent to which there's interest in self-funding, if you've seen that accelerating, if you think that's going to continue and",63,"Yes, I was hoping that maybe you could address what you're seeing in the marketplace in terms of middle-market employers and the extent to which there's interest in self-funding, if you've seen that accelerating, if you think that's going to continue and maybe on the larger end of that, what -- you're getting a taste of in terms of product preferences for 2016."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Matthew, it's David. As it relates to -- you used the term middle-market, so we'll talk about the regional segment. We define that as employers with 250 to 5,000 employees as well as large single-state employers. The broad theme, I would tell you, is that",223,"Matthew, it's David. As it relates to -- you used the term middle-market, so we'll talk about the regional segment. We define that as employers with 250 to 5,000 employees as well as large single-state employers. The broad theme, I would tell you, is that the market's appetite and interest in transparent funding and aligned funding, which include ASO, continues to grow. It continues to grow both in the regional segment. That has always been a meaningful portion but not the totality of it, but very importantly, as you move downmarket into the Select Segment as well. So point one is continued high and accelerating interest in transparent funding because it aligns incentives, it provides transparency and enables better functionality of the incentive alignment programs and the engagement programs we like. The second theme we see is continued elevation and engagement in we typically call them carve-in or specialty programs. We look at them more as a coordination of care programs. Many of the examples I cited in our prepared remarks. So those will be the 2 predominant trends we continue to see: elevation in transparent funding and then continued movement in what you might call carve-in, we call them coordination of care programs that are delivering the superior medical costs and quality outcomes that Tom made reference to a few moments ago."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, great. Just on a separate angle, if you don't mind. Can I just ask if you have any comments about the outlook for your PBM relationship, now that there's a change of control event coming with Catamaran and UNH.",40,"Okay, great. Just on a separate angle, if you don't mind. Can I just ask if you have any comments about the outlook for your PBM relationship, now that there's a change of control event coming with Catamaran and UNH."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, Matthew. Just by way of backdrop, important to note that we continue to own and operate a very highly performing PBM for the benefit of our customers and clients, and that high performance is being demonstrated through continued growth in customer l",150,"Sure, Matthew. Just by way of backdrop, important to note that we continue to own and operate a very highly performing PBM for the benefit of our customers and clients, and that high performance is being demonstrated through continued growth in customer lives, strong medical trend in clinical quality performance. As you know, we further strengthened those capabilities about 2 years ago, with our expanded relationship with Catamaran seeking several features to strengthen, and we're seeing the benefit of those. As we've talked about that in the past, while we continue to own and operate our PBM, we maintain significant optionality and flexibility in that structure. And then, while we don't typically comment on details of transactions, we view that the PBM marketplace is and will continue to be very dynamic. As such, we ensure that there is adequate deal protections for us that gives us meaningful flexibility going forward."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Josh Raskin with Barclays.",9,"The next question comes from Josh Raskin with Barclays."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Just getting back to the commercial -- I'm sorry the Government MLR. I'm just struggling to understand what caused the 290 basis point impact, like if you hold Medicare Advantage and Medicaid MLRs flat year-over-year, it implies the PDP was up 12 or 13 pe",89,"Just getting back to the commercial -- I'm sorry the Government MLR. I'm just struggling to understand what caused the 290 basis point impact, like if you hold Medicare Advantage and Medicaid MLRs flat year-over-year, it implies the PDP was up 12 or 13 percentage points. It's just not big enough in terms of the growth there to make the difference. So when you think strong performance on MA, is that mean the MLR was down? Or just trying to understand a little bit more of the granularity there."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","So, Josh, just to answer your last question, the MLR and MA adjusting for reserve development is flattish quarter-over-quarter. And in fact, the impact we're seeing in the Government MCR this quarter is largely due to PDP. And again, we're not going to ge",97,"So, Josh, just to answer your last question, the MLR and MA adjusting for reserve development is flattish quarter-over-quarter. And in fact, the impact we're seeing in the Government MCR this quarter is largely due to PDP. And again, we're not going to get into the specifics of the loss ratio, but the PDP MCR is always highest in the first quarter, as you know, because of the benefit design and transition period for new customers. And this quarter, in particular, for us, given we have a significant new customer growth, the seasonality was higher than normal."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","But I guess, Tom, I mean PDP was up 11%. The overall Government revenues were up closer to 17% or 18%. So you have to see -- when you say the seasonality, I guess why is that product changing? Or are you just saying that the loss ratio and PDP was higher?",52,"But I guess, Tom, I mean PDP was up 11%. The overall Government revenues were up closer to 17% or 18%. So you have to see -- when you say the seasonality, I guess why is that product changing? Or are you just saying that the loss ratio and PDP was higher?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, both. The loss ratio and PDP was higher, and again, we have a more significant mix of new customers, which is accountable for the loss ratio impact. Most of the impact is from the larger customer base and the transition period for the new customers.",120,"Well, both. The loss ratio and PDP was higher, and again, we have a more significant mix of new customers, which is accountable for the loss ratio impact. Most of the impact is from the larger customer base and the transition period for the new customers. And we do expect to see the normal seasonal pattern with improved results over the balance of the year. We also get some lift from our agreement with Gilead. It was effective April 1 in Part D, and we have anticipated some modest cost pressure, as we've mentioned, including last quarter continuing for Part D in our outlook for the full year, but that was as expected and then it's reflected in our outlook."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just switching topics a little bit, the public exchange accounts, like the individual businesses running a lot better and more in line with your expectations. Any comments on Reliance on the 3Rs, any change in your estimations for the 3Rs?",43,"Okay. And then just switching topics a little bit, the public exchange accounts, like the individual businesses running a lot better and more in line with your expectations. Any comments on Reliance on the 3Rs, any change in your estimations for the 3Rs?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, first, a little bit on the performance in the business, and we're still in the very early stages. Results in the quarter did see some improvement both from the repositioning of our medical mix and the improved customer demographics, and we are seein",152,"Well, first, a little bit on the performance in the business, and we're still in the very early stages. Results in the quarter did see some improvement both from the repositioning of our medical mix and the improved customer demographics, and we are seeing some targeted medical management actions that have lowered lost cost. So over the long term, we're still optimistic that we will see improved results and this will become an effective market segment. As far as the 3Rs are concerned, our accrual for the 3Rs in the first quarter was about $30 million after-tax. The majority of that relates to reinsurance, and we're continuing to accrue in line with the program parameters, and we didn't really make any material change in accruals for the 3Rs related to 2014 business, and we don't really see any significant adjustment to that until we get the final results from the government mid-year."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from A.J. Rice with UBS.",10,"The next question comes from A.J. Rice with UBS."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So first of all, maybe just to continue on the Medicare Advantage question. Obviously, we got final rates for 2016. Do you have any comments on that and also -- and what that means for you in terms of -- I know there's talk about average update of 1.25%,",70,"So first of all, maybe just to continue on the Medicare Advantage question. Obviously, we got final rates for 2016. Do you have any comments on that and also -- and what that means for you in terms of -- I know there's talk about average update of 1.25%, but each company has their own inputs, if you got a sense of where you guys would fall out on that."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","A.J., good morning, it's David. So as we look to 2016, first, we expect to have a base that'll have approximately 60% of our customers in for STAR+PLUS plans, noting a step-up from the prior year. And we expect to think forward beyond '16 to continue to s",206,"A.J., good morning, it's David. So as we look to 2016, first, we expect to have a base that'll have approximately 60% of our customers in for STAR+PLUS plans, noting a step-up from the prior year. And we expect to think forward beyond '16 to continue to step that up. As it relates to the rate setting environment, the net effects for our mix of our portfolio is that the vast majority of our plans are going to have about a flattish rate impact from all the moving parts from CMS. With the exception of 2 of our plans that will have a meaningful reduction based on the risk adjustors and the accounting rebates, et cetera. The net result for our portfolio of that is, again, the vast majority of our business markets flattish, 2 with meaningful reductions weighted on an all-in base. It's about a 2% reduction. As we looked at taking it as a whole, considering our very well-positioned portfolio of coverage services and collaboratives, we feel like our businesses are in good position stepping into 2016, as such, we continue to expect to both grow customer base, again, stepping into 2016, as well as being able to expand margins stepping into 2016."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, great. And then maybe just a follow-up. I know you recently announced an alliance with SCAN Health Plan in California. I wondered if you might give a chance to comment on what you're hoping to do there, and what that opportunity might represent.",44,"Okay, great. And then maybe just a follow-up. I know you recently announced an alliance with SCAN Health Plan in California. I wondered if you might give a chance to comment on what you're hoping to do there, and what that opportunity might represent."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, A.J. When -- and you used the term alliance, which I appreciate. We have a multiple examples of alliances with, in some cases, traditional competitors, not-for-profit competitors, for profit competitors and the like. This most recent relationship wi",137,"Sure, A.J. When -- and you used the term alliance, which I appreciate. We have a multiple examples of alliances with, in some cases, traditional competitors, not-for-profit competitors, for profit competitors and the like. This most recent relationship with SCAN aligns our very high-performing employer portfolio of businesses in California with their well-performing Medicare capabilities and enables us to deliver an employer-sponsored Medicare Advantage solution to employers that are on target for them, but we had distribution reach and lever their capabilities. So it's a wonderful example of playing to both organizations strength, enabling us to deliver an expanded set of solutions and capabilities on a more accelerated time frames than we would've been able to do organically and be able to deliver value for our existing clients and expand SCAN's relationship net win for both organizations."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Kevin Fischbeck of Bank of America.",11,"The next question comes from Kevin Fischbeck of Bank of America."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","I guess a couple of clarification questions. The commentary about the MA rate for 2016, was that including the Star pickup or before the star pickup?",26,"I guess a couple of clarification questions. The commentary about the MA rate for 2016, was that including the Star pickup or before the star pickup?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's net of all the moving parts, Kevin.",9,"It's net of all the moving parts, Kevin."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then on the individual commentary, I guess I don't remember, if you said it specifically or not, but it sounded to me like you're still expecting to lose money in 2015 on the public exchanges?",37,"Okay. And then on the individual commentary, I guess I don't remember, if you said it specifically or not, but it sounded to me like you're still expecting to lose money in 2015 on the public exchanges?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Net-net, as we've discussed before, Kevin, we look at '14, '15 and '16 as the version 1.0 of the marketplace. We built that business plans not around achieving the revenue or EPS significant contributions out of this book of business. As you know, we expe",93,"Net-net, as we've discussed before, Kevin, we look at '14, '15 and '16 as the version 1.0 of the marketplace. We built that business plans not around achieving the revenue or EPS significant contributions out of this book of business. As you know, we expect it to improve the performance of the block of business going from '14 to '15 that is taking place. So on a fully-allocated basis, there's a loss in the business, but is less than 2014, but we'd expect that to improve further as we step into 2016."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just -- at the beginning, you talked about some of the medical management capabilities that you guys are bringing. Some of them, like the preterm births, is really something that comes in pretty usefully in the Medicaid side of the business",100,"Okay. And then just -- at the beginning, you talked about some of the medical management capabilities that you guys are bringing. Some of them, like the preterm births, is really something that comes in pretty usefully in the Medicaid side of the business. I wonder if you feel like you guys are better positioned to participate in that side of the business, RFP-wise I have seen a couple of other companies, who haven't historically been in that market get more aggressive. How do you think about RFPs that seem to be coming up over the next couple of years?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Relative to the Medicaid space, we've been very consistent that we see opportunity in the higher risk or coordinated care dimensions of the Medicaid space, so we can call that the dual space and the various other high-risk portfolios. We have targeted exa",123,"Relative to the Medicaid space, we've been very consistent that we see opportunity in the higher risk or coordinated care dimensions of the Medicaid space, so we can call that the dual space and the various other high-risk portfolios. We have targeted examples of success to date, most notably in counties within Texas where we just -- we're recognized for an award of coordination of care with our behavioral and clinical capabilities. So we do see [indiscernible], we do see opportunities. It's highly geographically targeted in our Go Deep markets, and it's within those programs that enable significant coordination of care both engaging the individual and working with the clinical professionals. So we see targeted expansion opportunity over the next several years here."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Ralph Giacobbe with Crdit Suisse.",10,"The next question comes from Ralph Giacobbe with Crdit Suisse."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Can you give us a little bit of sense of why you did grow so much in PDP maybe kind of where it came from, if you could, at what percentage maybe was auto assigned and then just give us a sense of where it all kind of shook out relative to your expectatio",54,"Can you give us a little bit of sense of why you did grow so much in PDP maybe kind of where it came from, if you could, at what percentage maybe was auto assigned and then just give us a sense of where it all kind of shook out relative to your expectation."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Ralph, it's David, at a macro level, the majority of our growth was not auto assigned, so the step function to highly targeted geographically, and the significant amount of work was done within the benefit-design configuration to target subsegment of buye",106,"Ralph, it's David, at a macro level, the majority of our growth was not auto assigned, so the step function to highly targeted geographically, and the significant amount of work was done within the benefit-design configuration to target subsegment of buyers in key geographies. So as Tom noted, meaningful growth, but we expected it. We factored that into our guidance. We talked about it last quarter to acknowledge that there would be -- we recognize there's a transition of care window that largely spans the entire first quarter that transpired, but largely not assigned targeted geographies, targeting by segment and design products with that in mind."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay, right. That's helpful. And then, can you just update us on where you sit on private exchanges? I know one of your customers recently moved and my understanding is actually that you retained a large percentage of the book. But can you talk about conv",64,"Okay, right. That's helpful. And then, can you just update us on where you sit on private exchanges? I know one of your customers recently moved and my understanding is actually that you retained a large percentage of the book. But can you talk about conversations you're having with customers and your opportunities there for sort of the existing as well as new opportunities?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, relative to the private exchange marketplace, we continue to view this as a potentially attractive long-term market as it unfolds. As such, we've allocated leadership, significant resources to the portfolio of businesses here. We are currently posit",193,"Sure, relative to the private exchange marketplace, we continue to view this as a potentially attractive long-term market as it unfolds. As such, we've allocated leadership, significant resources to the portfolio of businesses here. We are currently positioned in the vast majority of third-party exchanges that exist in the marketplace up to and including, also having our own captive exchange. To date, the performance is generally speaking in line with our expectations, which we thought was a slower market transition than maybe some had flagged in the grand scheme of things. To date, we've seen some wins and losses in terms of our portfolios we've discussed before. As we stand here today, we have several hundred thousand lives when you span across our core medical and specialty capabilities as well as additional lives in the supplemental space. But it's in the early innings. We're positioned and we're evolving within the marketplace. And as you know, as our existing customers choose to transition, we have a brand positioning and a service proposition that tends to win us a lot of business in the choice marketplace. So performance in line with our expectations thus far."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","That's helpful. Just real quick and a follow-on to that. Just on the transition, if you have an ASO customer and they move to a private exchange and you retain that customer, ASO to ASO, is the profitability essentially the same?",42,"That's helpful. Just real quick and a follow-on to that. Just on the transition, if you have an ASO customer and they move to a private exchange and you retain that customer, ASO to ASO, is the profitability essentially the same?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's varied, obviously, depending on the configuration, but you should assume that the way we are seeking to position ourselves on the exchanges is to ensure that our offerings enable us to have enough of the, we'll call it, coordination and specialty rea",103,"It's varied, obviously, depending on the configuration, but you should assume that the way we are seeking to position ourselves on the exchanges is to ensure that our offerings enable us to have enough of the, we'll call it, coordination and specialty reach that I made reference to in my prepared remarks to be able to deliver differentiated value and not move back to I call it TPA administrator. So the simple answer is, it depends, because all the exchanges are not created equal. Our strong operating bias is the integration and coordination because that's where we deliver our step function value."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Christine Arnold with Cowen.",9,"The next question comes from Christine Arnold with Cowen."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Thanks for your commentary on the Government segment. Can you give us the same kind of commentary on your Commercial segment? How did you track with respect to stop loss versus experienced rate versus guaranteed cost relative to from a year ago in your ex",45,"Thanks for your commentary on the Government segment. Can you give us the same kind of commentary on your Commercial segment? How did you track with respect to stop loss versus experienced rate versus guaranteed cost relative to from a year ago in your expectations?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Christine, it's Tom. So overall, the headline in the commercial segment is the commercial MCR is very consistent with our expectations for the quarter. Again, the headline messages the employer group business continues to perform very well, individual bus",113,"Christine, it's Tom. So overall, the headline in the commercial segment is the commercial MCR is very consistent with our expectations for the quarter. Again, the headline messages the employer group business continues to perform very well, individual business continues to improve. Quarter-over-quarter, in particular, the MCR is about flat. That reflects the improvement in individual with some offset by business mix impacts. But again, within those businesses the MCR is performing as we'd have expected by product line. Then I would point out, we would expect some increase or some improvement from the increased health insurance fee, but I would point out that our mix has that impact smaller than most others."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Andy Schenker with Morgan Stanley.",10,"The next question comes from Andy Schenker with Morgan Stanley."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So just first, the National Account selling [ph] can you give us some updates -- on your last call you indicated you had an elevated percentage out for bid this year based on the procurement cycle. So curious how that's progressing.",41,"So just first, the National Account selling [ph] can you give us some updates -- on your last call you indicated you had an elevated percentage out for bid this year based on the procurement cycle. So curious how that's progressing."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Sure, Andy, it's David. First just let me redefine our national health, as we defined it a bit differently than our competition. For us, it's commercial employers with 5,000 and more employees that span multiple states. So we exclude the large single-stat",244,"Sure, Andy, it's David. First just let me redefine our national health, as we defined it a bit differently than our competition. For us, it's commercial employers with 5,000 and more employees that span multiple states. So we exclude the large single-state commercial employers that's part of our regional segment. You have a good recollection. Year-over-year as we look back to last year, our pipeline was about equal to the prior year, but our -- portion of our book of business that was out to bid was elevated due to procurement cycles. As we look at the current cycle, looking forward to 2016 relative to the pipeline of new opportunities, number of cases is about the same. Average case size is somewhat elevated. So on a life-basis, but more lives to look out but then a similar number of cases. As it relates to the percentage of our book of business out to bid, the percent is back down because that procurement cycle that's moving through. So early in the overall sales cycle, a healthy pipeline of opportunities to look at, a reasonable percentage of our book of business is out to bid. We continue to be focused on retaining the right business and earning the right business that has engagement and incentive alignment, expanding our specialty capabilities as indicative of our continued ability to grow revenue and earnings in the space by delivering value to those clients that are on target for us."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Ana Gupte with Leerink Partners.",10,"The next question comes from Ana Gupte with Leerink Partners."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Wanted to follow up on the question on the commercial loss ratio, just as far as, individual off-exchange on-exchange, the guaranteed cost and the stop loss. So I get it that it's in line with expectations. I think there was a lot of pressure on your off-",92,"Wanted to follow up on the question on the commercial loss ratio, just as far as, individual off-exchange on-exchange, the guaranteed cost and the stop loss. So I get it that it's in line with expectations. I think there was a lot of pressure on your off-exchange book last year. It seems like you've seemed to have traded with some of the membership is that coming from off exchange. And are you seeing the overall individual book negative but that book of business is kind of returning to profitability at this point?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","So it's David. Let me just frame it a little bit relative to the individual. First, as Tom noted in the employer book, the employer book last year, this year continues to perform well and in line with our expectations. Within the individual book of busine",168,"So it's David. Let me just frame it a little bit relative to the individual. First, as Tom noted in the employer book, the employer book last year, this year continues to perform well and in line with our expectations. Within the individual book of business, as you very well know relative to us, it's small in the grand scheme of things in terms of covered lives. As it relates to the grandfathered and some of the transitional block, one of the states where we had a large grandfather block of businesses, a state where we don't operate on the exchange, specifically California. So we saw attrition relative to the grandfathered block stepping into 2015, which was in line with our expectations. We still maintain a mix of on-exchange and off-exchange business and that, taken as a whole, the loss ratio of our business, and therefore, the underlying performance of the individual business steps forward and improved in line with our expectations going from '14 to '15."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then on the guaranteed cost legacy book, have you seen margin expansion? Some of your competitors are very commercially focused. There's some really nice margin expansion. I'm just trying to get to the underlying metric here.",37,"And then on the guaranteed cost legacy book, have you seen margin expansion? Some of your competitors are very commercially focused. There's some really nice margin expansion. I'm just trying to get to the underlying metric here."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","And, Ana, are you referencing individual or group?",8,"And, Ana, are you referencing individual or group?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Group, group.",2,"Group, group."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Within our group block of business, as you know, we don't play in the small group employer. So you need to take the under-50 block and remove that from the way you think about us. Relative to the over-50 block of business, our performance was strong and r",54,"Within our group block of business, as you know, we don't play in the small group employer. So you need to take the under-50 block and remove that from the way you think about us. Relative to the over-50 block of business, our performance was strong and remained strong in that portfolio of business."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then finally on stop-loss, is that trending flat or are margins coming in or expanding? You've seen a nice 19% growth in premiums there.",26,"And then finally on stop-loss, is that trending flat or are margins coming in or expanding? You've seen a nice 19% growth in premiums there."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Ana, it's Tom, margins and stop-loss are just where we'd like them to be. So the result -- the performance in the book is good.",25,"Ana, it's Tom, margins and stop-loss are just where we'd like them to be. So the result -- the performance in the book is good."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Peter Costa with Wells Fargo.",10,"The next question comes from Peter Costa with Wells Fargo."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Question on your strategy around M&A going forward. You're a little bit subscale to some of the other national account players, which you -- now you focus on some geographically concentrated markets as a way to compensate for that. But just some books of",152,"Question on your strategy around M&A going forward. You're a little bit subscale to some of the other national account players, which you -- now you focus on some geographically concentrated markets as a way to compensate for that. But just some books of business likely to come up, one in particular, just the other day is being shopped. It's more of a broad book of individual business and there's some expectation that some of these smaller plans that are focused on certain geographies exchange base business that are going to come up for sale. Do you think some of those books will be interesting to you guys? And if they are, a lot of why they're up for sale would be that they're under pressure. And so the -- some of the business is underpriced. How would you react to fixing books of business that you see up for sale?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Peter, David. Let me give you a little color on M&A. You factored in many statements and questions there. So first, broadly relative to M&A. M&A continues to be a component of our value creation framework. So it's effective deployment of capital, strategi",314,"Peter, David. Let me give you a little color on M&A. You factored in many statements and questions there. So first, broadly relative to M&A. M&A continues to be a component of our value creation framework. So it's effective deployment of capital, strategic M&A is a component within there. Our priorities have been consistent in terms of where we see the ability to create step-function value, specifically smartly furthering our global footprint; two, expanding our MA and dual capabilities; three, expanding our retail capabilities; and four local tuck-ins. And we've had a successful track record of accomplishing targeted acquisitions over the last 5-plus years in line with our strategy. As it relates to your scale comment, we've chosen to redefine our orientation around scale to ensure that we have appropriate scale to have competitive cost structure from an administrative cost standpoint, which we have. We've been able to prove productivity gains year-in year-out and free capacity to further ongoing investment back to within the franchise. And then you come down to medical cost to your dialogues, and that's a very localized conversation and it's not a localized conversation at the state level. It's an MSA level, and increasingly, within our marketplaces, it's coming down to a sub-MSA level. So we're highly focused on key geographies and our ability to win and deliver value for our clients and customers. As related to appetite for future M&A, I mean, opportunities where we're very aware, engaged and highly focused. So as long as the transactions are on strategy relative to the items I talked about before. On a final note, I'm not going to speculate on how you would rehabilitate an underperforming book of business, but our organization has demonstrated the ability to deliver high performance within our targeted segments, and again, we see M&A as a forward-looking opportunity to create smart transactions and good shareholder value."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And then, just it's on the Part D business, one further question. You talked about some of the higher MLR being from transition issues. Is your guidance going forward making the assumption that those transition issues are resolved in Q1? Or do you expect",75,"And then, just it's on the Part D business, one further question. You talked about some of the higher MLR being from transition issues. Is your guidance going forward making the assumption that those transition issues are resolved in Q1? Or do you expect that to continue into Q2? And what if it -- if it isn't transition issues and you're not able to resolve it, will that impact your guidance and by how much?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Peter, it's Tom. I think that a little differently. This is the prescribed 90-day period for new members to stay on their old formulary, while they transition to our new formulary. So we would expect that to work itself through during the first quarter.",44,"Peter, it's Tom. I think that a little differently. This is the prescribed 90-day period for new members to stay on their old formulary, while they transition to our new formulary. So we would expect that to work itself through during the first quarter."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","And the next question comes from Chris Rigg with Susquehanna Financial Group.",12,"And the next question comes from Chris Rigg with Susquehanna Financial Group."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Just wanted to focus on the guidance for a minute, particularly in a Global Health Care segment. You raised by $15 million at the mid-point, but you had $25 million of TPD. I'm just wondering why the raise wasn't at least in line with the level of reserve",49,"Just wanted to focus on the guidance for a minute, particularly in a Global Health Care segment. You raised by $15 million at the mid-point, but you had $25 million of TPD. I'm just wondering why the raise wasn't at least in line with the level of reserve development."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Chris, it's Tom. We're really pleased that we've been able to increase our outlook this early in the year. Again, we expect to deliver attractive growth and revenue earnings and EPS across the company and in Global Health Care in 2015, just as we have in",72,"Chris, it's Tom. We're really pleased that we've been able to increase our outlook this early in the year. Again, we expect to deliver attractive growth and revenue earnings and EPS across the company and in Global Health Care in 2015, just as we have in each of the last 5 years. So really I'd see our revised outlook as just reinforcing our confidence that we're on track to deliver those results."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","Okay. And then just with regard to the comments in the press release about the investment spending in the quarter, in the health care segment, was that -- that was expected in the original outlook just to be clear?",39,"Okay. And then just with regard to the comments in the press release about the investment spending in the quarter, in the health care segment, was that -- that was expected in the original outlook just to be clear?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes.",1,"Yes."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The next question comes from Dave Windley with Jefferies.",9,"The next question comes from Dave Windley with Jefferies."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","On the operating expense guidance and ratio, I guess I'm just looking at your starting year toward the higher end of that range. Your trends tended to rise, intra-year, rise through the year in historical years, and you're mentioning some favorable impact",91,"On the operating expense guidance and ratio, I guess I'm just looking at your starting year toward the higher end of that range. Your trends tended to rise, intra-year, rise through the year in historical years, and you're mentioning some favorable impacts in, I think, disability this quarter -- excuse me, sub this quarter. So I guess, I'm thinking it should rise this year as well unless you tell me otherwise. So how do you see that trending over the balance of the year to hit that range that you provided?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Dave, it's David. So directionally first off, we knew the first quarter was going to have an elevated level of expenses. As such, on the last quarter when we talked about the first quarter pattern, we flagged that and it was called out, as mentioned, in t",146,"Dave, it's David. So directionally first off, we knew the first quarter was going to have an elevated level of expenses. As such, on the last quarter when we talked about the first quarter pattern, we flagged that and it was called out, as mentioned, in the further questions as we looked at many of our strategic spend initiatives. Two, as you made reference to our outlook is to see that our operating expense ratio will show a year-over-year improvement as we have been able to demonstrate for many years as we look back and our organization is tightly aligned relative to that. So the performance of that will transpire a little differently into 2015 quarters as opposed to the prior quarters. But Q1 was known as an uptick. Our outlook is to see an improved expense ratio and organization is on track to achieve that."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","So if I can -- if you can clarify just a little further, would you expect the investments that you flagged in 1Q to then exit or evaporate in 2Q and it's a drop back down significantly and then turn back as it normally does? Or is it just a completely dif",55,"So if I can -- if you can clarify just a little further, would you expect the investments that you flagged in 1Q to then exit or evaporate in 2Q and it's a drop back down significantly and then turn back as it normally does? Or is it just a completely different pattern this year?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Yes, Dave, I wouldn't expect the strategic spending to decline over the balance of the year. I think what I'd expect to see is both a little different pattern of revenue and earnings to get to the result we've talked about.",41,"Yes, Dave, I wouldn't expect the strategic spending to decline over the balance of the year. I think what I'd expect to see is both a little different pattern of revenue and earnings to get to the result we've talked about."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","The final question comes from Sarah James with Wedbush Securities.",10,"The final question comes from Sarah James with Wedbush Securities."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","One of your peers recently indicated their discussions with employers suggest that there could be a step-up in conversions to private exchanges in the next 1 to 2 years. Are you hearing similar from your clients? And if you could share with us what percen",61,"One of your peers recently indicated their discussions with employers suggest that there could be a step-up in conversions to private exchanges in the next 1 to 2 years. Are you hearing similar from your clients? And if you could share with us what percentage of your private exchange book is self-funded and what percent are new members to Cigna?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","It's David. First, the dialogue with employers has been active around private exchanges, as it has been around consumer-directed engagement programs, et cetera. I think the broader picture here is that, employers of all sizes are looking for the higher va",293,"It's David. First, the dialogue with employers has been active around private exchanges, as it has been around consumer-directed engagement programs, et cetera. I think the broader picture here is that, employers of all sizes are looking for the higher value creation benefit strategies that are going to be sustainable for them. That's the broader dialogue. And private exchanges represent a tool that many employers are trying to explore to determine whether or not it is part of the overall portfolio. What we've seen, and what the market has seen is a relatively modest adoption rate of that toolset, but it's early on, as we've indicated, in the private exchange cycle. Two, what we've seen is a continued elevated performance of self-funded consumer-directed aligned incentive and coordinated integrated offerings. As it relates to our own experience within the private exchanges, to the second part of your question, the vast majority of those employers are in the self-funded space given the profile of what we operate in, but we have guaranteed cost lives there as well. We have integrated and nonintegrated lives, but again it's small in the grand scheme of things in terms of what we're seeing. And a portion of the lives we're seeing there are new to Cigna. Greater than 50% of those are transitioning from existing Cigna relationships carried over to the exchanges. But the important part is that it's still a small part of both the marketplace as well as our portfolio. Two, we've deployed significant resources to make sure we're in position on the various exchanges, including our own captive and proprietary exchange. And three, we seek to be very consultative with our employers to make sure they understand all the choices that are available to them."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Analysts","And as employers are evaluating their different options, you mentioned, within the high deductible plans or private exchanges, can you tell whether or not one is emerging as the more likely way that employers are trending, or if there's any difference in",61,"And as employers are evaluating their different options, you mentioned, within the high deductible plans or private exchanges, can you tell whether or not one is emerging as the more likely way that employers are trending, or if there's any difference in how they are trending based on employer size, whether they're not going towards the private exchanges versus high deductibles?"
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Well, Sarah, I think we could point to both the track record of actions as well as the emerging actions. So the more tangible track record of actions is that, employers of a variety of sizes continue to move toward the transparent funding, which includes",170,"Well, Sarah, I think we could point to both the track record of actions as well as the emerging actions. So the more tangible track record of actions is that, employers of a variety of sizes continue to move toward the transparent funding, which includes ASO. That's a consistent track. Two, elevation of aligned incentive programs, whether they're consumer-directed, full-on CDHP programs or if they're coinsurance programs, coinsurance programs with aligned incentive models, those would be the 2 most tangible pieces I think you could point to. And then over the last couple of years, an emerging trend too, as I referenced before, carving in or even more adoption of integrated care programs that are coordinated to delivering the value back. But private exchange, if you will, trend again is still in the early stages and I wouldn't flag it as one where we would see the majority of buying behavior over the next 2 buying cycles. But as we're positioned, we're positioned for an elevation and volume should unfold."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","I will now turn the call back over to David Cordani for closing remarks.",14,"I will now turn the call back over to David Cordani for closing remarks."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Executives","Thank you. Just to conclude our discussion this morning, I'd like to reiterate just a few important points. First, Cigna's first quarter results represent a strong start to the year and were driven by revenue and earnings contributions across our diversif",168,"Thank you. Just to conclude our discussion this morning, I'd like to reiterate just a few important points. First, Cigna's first quarter results represent a strong start to the year and were driven by revenue and earnings contributions across our diversified portfolio of businesses. Our integrated capabilities are optimizing health, improving medical outcomes and increasing affordability for the individuals we serve. Our more than 37,000 talented colleagues around the world are unified in their commitment to work every day to improve the health, well-being and sense of security of the customers we serve. Our strong first quarter performance and multiple avenues for growth give us confidence that we will achieve our increased full year 2015 outlook. Over the long term, we remain committed to achieving our annual EPS growth of 10% to 13% over the long term and expect to double size of our company's revenue over the next 7 to 8 years. Thank you for joining our call today, and we look forward to furthering our discussions."
172899,290303753,799158,"Cigna Corp., Q1 2015 Earnings Call, Apr 30, 2015",2015-04-30,"Earnings Calls","The Cigna Group","Operator","Ladies and gentlemen, this concludes Cigna's first quarter 2015 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this cal",65,"Ladies and gentlemen, this concludes Cigna's first quarter 2015 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing 1 (800) 365-2419 or 1 (203) 369-3679. No passcode is required. Thank you for participating. We will now disconnect."
